DDI-MedLine.d78.s1
The DRUGA are a rapidly growing class of DRUGB with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria.
fluoroquinolones	group	antibiotics	group
false

DDI-MedLine.d78.s2
These agents, including DRUGA, DRUGB, DRUGN, DRUGN, and DRUGN, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
norfloxacin	drug	ciprofloxacin	drug
false

DDI-MedLine.d78.s2
These agents, including DRUGA, ciprDRUGB, DRUGB, DRUGN, and DRUGN, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
norfloxacin	drug	ofloxacin	drug
false

DDI-MedLine.d78.s2
These agents, including DRUGA, DRUGN, DRUGN, DRUGB, and DRUGN, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
norfloxacin	drug	enoxacin	drug
false

DDI-MedLine.d78.s2
These agents, including DRUGA, DRUGN, DRUGN, DRUGN, and DRUGB, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
norfloxacin	drug	lomefloxacin	drug
false

DDI-MedLine.d78.s2
These agents, including DRUGN, DRUGA, DRUGB, DRUGN, and DRUGN, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
ciprofloxacin	drug	ofloxacin	drug
false

DDI-MedLine.d78.s2
These agents, including DRUGN, DRUGA, DRUGN, DRUGB, and DRUGN, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
ciprofloxacin	drug	enoxacin	drug
false

DDI-MedLine.d78.s2
These agents, including DRUGN, DRUGA, DRUGN, DRUGN, and DRUGB, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
ciprofloxacin	drug	lomefloxacin	drug
false

DDI-MedLine.d78.s2
These agents, including DRUGN, ciprDRUGA, DRUGA, DRUGB, and DRUGN, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
ofloxacin	drug	enoxacin	drug
false

DDI-MedLine.d78.s2
These agents, including DRUGN, ciprDRUGA, DRUGA, DRUGN, and DRUGB, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
ofloxacin	drug	lomefloxacin	drug
false

DDI-MedLine.d78.s2
These agents, including DRUGN, DRUGN, DRUGN, DRUGA, and DRUGB, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
enoxacin	drug	lomefloxacin	drug
false

DDI-MedLine.d80.s1
In order to provide information for the appropriate package insert labeling of DRUGA (DRUGB) in the US, a comprehensive review was made of DRUGN (0.075 mg) and DRUGN (0.35 mg), with the clinical differences indicated where applicable.
progestin-only oral contraceptives	group	POC	group
false

DDI-MedLine.d80.s1
In order to provide information for the appropriate package insert labeling of DRUGA (DRUGN) in the US, a comprehensive review was made of DRUGB (0.075 mg) and DRUGN (0.35 mg), with the clinical differences indicated where applicable.
progestin-only oral contraceptives	group	norgestrel	drug
false

DDI-MedLine.d80.s1
In order to provide information for the appropriate package insert labeling of DRUGA (DRUGN) in the US, a comprehensive review was made of DRUGN (0.075 mg) and DRUGB (0.35 mg), with the clinical differences indicated where applicable.
progestin-only oral contraceptives	group	norethindrone	drug
false

DDI-MedLine.d80.s1
In order to provide information for the appropriate package insert labeling of DRUGN (DRUGA) in the US, a comprehensive review was made of DRUGB (0.075 mg) and DRUGN (0.35 mg), with the clinical differences indicated where applicable.
POC	group	norgestrel	drug
false

DDI-MedLine.d80.s1
In order to provide information for the appropriate package insert labeling of DRUGN (DRUGA) in the US, a comprehensive review was made of DRUGN (0.075 mg) and DRUGB (0.35 mg), with the clinical differences indicated where applicable.
POC	group	norethindrone	drug
false

DDI-MedLine.d80.s1
In order to provide information for the appropriate package insert labeling of DRUGN (DRUGN) in the US, a comprehensive review was made of DRUGA (0.075 mg) and DRUGB (0.35 mg), with the clinical differences indicated where applicable.
norgestrel	drug	norethindrone	drug
false

DDI-MedLine.d84.s0
Antimicrobial activity of DRUGA alone and in combination with some DRUGB.
Ganoderma lucidum extract	drug_n	antibiotics	group
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGA with four kinds of DRUGB (DRUGN, DRUGN, DRUGN and DRUGN), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
GL	drug_n	antibiotics	group
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGA with four kinds of DRUGN (DRUGB, DRUGN, DRUGN and DRUGN), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
GL	drug_n	ampicillin	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGA with four kinds of DRUGN (DRUGN, DRUGB, DRUGN and DRUGN), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
GL	drug_n	cefazolin	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGA with four kinds of DRUGN (DRUGN, DRUGN, DRUGB and DRUGN), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
GL	drug_n	oxytetracycline	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGA with four kinds of DRUGN (DRUGN, DRUGN, DRUGN and DRUGB), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
GL	drug_n	chloramphenicol	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGN with four kinds of DRUGA (DRUGB, DRUGN, DRUGN and DRUGN), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
antibiotics	group	ampicillin	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGN with four kinds of DRUGA (DRUGN, DRUGB, DRUGN and DRUGN), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
antibiotics	group	cefazolin	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGN with four kinds of DRUGA (DRUGN, DRUGN, DRUGB and DRUGN), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
antibiotics	group	oxytetracycline	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGN with four kinds of DRUGA (DRUGN, DRUGN, DRUGN and DRUGB), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
antibiotics	group	chloramphenicol	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGN with four kinds of DRUGN (DRUGA, DRUGB, DRUGN and DRUGN), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
ampicillin	drug	cefazolin	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGN with four kinds of DRUGN (DRUGA, DRUGN, DRUGB and DRUGN), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
ampicillin	drug	oxytetracycline	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGN with four kinds of DRUGN (DRUGA, DRUGN, DRUGN and DRUGB), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
ampicillin	drug	chloramphenicol	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGN with four kinds of DRUGN (DRUGN, DRUGA, DRUGB and DRUGN), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
cefazolin	drug	oxytetracycline	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGN with four kinds of DRUGN (DRUGN, DRUGA, DRUGN and DRUGB), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
cefazolin	drug	chloramphenicol	drug
false

DDI-MedLine.d84.s3
To investigate the effects of antimicrobial combinations of DRUGN with four kinds of DRUGN (DRUGN, DRUGN, DRUGA and DRUGB), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
oxytetracycline	drug	chloramphenicol	drug
false

DDI-MedLine.d13.s7
On the basis of the estimated number of regular users of intravenous DRUGA in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and DRUGB addicts.
amphetamine	drug	heroin	drug_n
false

DDI-MedLine.d13.s8
However, the absolute number of DRUGA-related deaths is far greater than the number of deaths in DRUGB or DRUGN users.
alcohol	drug	amphetamine	drug
false

DDI-MedLine.d13.s8
However, the absolute number of DRUGA-related deaths is far greater than the number of deaths in DRUGN or DRUGB users.
alcohol	drug	heroin	drug_n
false

DDI-MedLine.d13.s8
However, the absolute number of DRUGN-related deaths is far greater than the number of deaths in DRUGA or DRUGB users.
amphetamine	drug	heroin	drug_n
false

DDI-MedLine.d69.s0
Differential regulation of tyrosine phosphorylation in tumor cells by DRUGA, a homodimeric disintegrin, and monomeric disintegrins DRUGB and DRUGN.
contortrostatin	drug_n	echistatin	drug_n
false

DDI-MedLine.d69.s0
Differential regulation of tyrosine phosphorylation in tumor cells by DRUGA, a homodimeric disintegrin, and monomeric disintegrins DRUGN and DRUGB.
contortrostatin	drug_n	flavoridin	drug_n
false

DDI-MedLine.d69.s0
Differential regulation of tyrosine phosphorylation in tumor cells by DRUGN, a homodimeric disintegrin, and monomeric disintegrins DRUGA and DRUGB.
echistatin	drug_n	flavoridin	drug_n
false

DDI-MedLine.d69.s1
The homodimeric disintegrin DRUGA was compared directly to the monomeric disintegrins DRUGB and DRUGN for the ability to affect protein tyrosine phosphorylation in tumor cells.
contortrostatin	drug_n	echistatin	drug_n
false

DDI-MedLine.d69.s1
The homodimeric disintegrin DRUGA was compared directly to the monomeric disintegrins DRUGN and DRUGB for the ability to affect protein tyrosine phosphorylation in tumor cells.
contortrostatin	drug_n	flavoridin	drug_n
false

DDI-MedLine.d69.s1
The homodimeric disintegrin DRUGN was compared directly to the monomeric disintegrins DRUGA and DRUGB for the ability to affect protein tyrosine phosphorylation in tumor cells.
echistatin	drug_n	flavoridin	drug_n
false

DDI-MedLine.d48.s3
DRUGA, at pH 7.0, was used to chemically modify exposed histidine residues on DRUGB.
Diethyl pyrocarbonate	drug_n	toxin A	drug_n
false

DDI-MedLine.d48.s4
Modification of DRUGA with DRUGB abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel.
toxin A	drug_n	diethyl pyrocarbonate	drug_n
false

DDI-MedLine.d48.s5
Treatment of DRUGA with [(14)C]-DRUGB revealed concentration dependent labelling of histidine residues on the toxin molecules.
toxin A	drug_n	diethyl pyrocarbonate	drug_n
false

DDI-MedLine.d48.s6
The effects of DRUGA could be reversed by DRUGB treatment.
diethyl pyrocarbonate	drug_n	hydroxylamine	drug_n
false

DDI-MedLine.d48.s11
Exposed histidines on DRUGA are available for DRUGB chelation, and these have been exploited in the development of a novel purification protocol for DRUGA using DRUGB-chelating chromatography.
toxin A	drug_n	zinc	drug
false

DDI-MedLine.d48.s11
Exposed histidines on DRUGA are available for DRUGB chelation, and these have been exploited in the development of a novel purification protocol for DRUGA using DRUGB-chelating chromatography.
toxin A	drug_n	zinc	drug
false

DDI-MedLine.d48.s11
Exposed histidines on DRUGB are available for DRUGA chelation, and these have been exploited in the development of a novel purification protocol for DRUGB using DRUGA-chelating chromatography.
zinc	drug	toxin A	drug_n
false

DDI-MedLine.d48.s11
Exposed histidines on DRUGA are available for DRUGB chelation, and these have been exploited in the development of a novel purification protocol for DRUGA using DRUGB-chelating chromatography.
toxin A	drug_n	zinc	drug
false

DDI-MedLine.d18.s0
Note: dissolution of aerosol particles of DRUGA in DRUGB, a model DRUGN.
budesonide	drug	Survanta	brand
false

DDI-MedLine.d18.s0
Note: dissolution of aerosol particles of DRUGA in DRUGN, a model DRUGB.
budesonide	drug	lung surfactant	group
false

DDI-MedLine.d18.s0
Note: dissolution of aerosol particles of DRUGN in DRUGA, a model DRUGB.
Survanta	brand	lung surfactant	group
false

DDI-MedLine.d18.s1
The effect of a DRUGA extract from bovine lung, DRUGB, on the dissolution rate of aerosol particles of DRUGN was determined.
pulmonary surfactant	group	Survanta	brand
false

DDI-MedLine.d18.s1
The effect of a DRUGA extract from bovine lung, DRUGN, on the dissolution rate of aerosol particles of DRUGB was determined.
pulmonary surfactant	group	budesonide	drug
false

DDI-MedLine.d18.s1
The effect of a DRUGN extract from bovine lung, DRUGA, on the dissolution rate of aerosol particles of DRUGB was determined.
Survanta	brand	budesonide	drug
false

DDI-MedLine.d18.s2
Aerosol particles of DRUGA were generated from an DRUGB solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments.
budesonide	drug	ethanol	drug
false

DDI-MedLine.d18.s6
DRUGA increased the extent of dissolution of DRUGB in proportion to the added concentration, which was also verified by equilibrium solubilization studies.
Survanta	brand	budesonide	drug
false

DDI-MedLine.d18.s7
DRUGA also increased rate of dissolution, in a manner similar to DRUGB.
Survanta	brand	sodium dodecyl sulfate	drug_n
false

DDI-MedLine.d18.s8
Analysis of the concentration of DRUGA following ultracentrifugation indicated that there is rapid equilibration of DRUGA between the DRUGB and aqueous phase.
budesonide	drug	Survanta	brand
false

DDI-MedLine.d18.s8
Analysis of the concentration of DRUGA following ultracentrifugation indicated that there is rapid equilibration of DRUGA between the DRUGB and aqueous phase.
budesonide	drug	Survanta	brand
false

DDI-MedLine.d62.s1
As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by DRUGA (DRUGB) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects.
methamphetamine	drug	METH	drug
false

DDI-MedLine.d62.s4
Using in situ hybridization, we observed that DRUGA caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUGN but not by an DRUGB DRUGN.
METH	drug	atypical neuroleptic	group
false

DDI-MedLine.d62.s4
Using in situ hybridization, we observed that DRUGA caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUGN but not by an DRUGN DRUGB.
METH	drug	clozapine	drug
false

DDI-MedLine.d62.s4
Using in situ hybridization, we observed that DRUGN caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUGA but not by an DRUGB DRUGN.
SCH-23390	drug_n	atypical neuroleptic	group
false

DDI-MedLine.d62.s4
Using in situ hybridization, we observed that DRUGN caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUGA but not by an DRUGN DRUGB.
SCH-23390	drug_n	clozapine	drug
false

DDI-MedLine.d62.s4
Using in situ hybridization, we observed that DRUGN caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist DRUGN but not by an DRUGA DRUGB.
atypical neuroleptic	group	clozapine	drug
false

DDI-MedLine.d104.s0
The effects of DRUGA and DRUGB upon DRUGN (DRUGN)-induced locomotion and behavioral changes in mice.
DCG-IV	drug_n	L-CCG-1	drug_n
false

DDI-MedLine.d104.s0
The effects of DRUGA and DRUGN upon DRUGB (DRUGN)-induced locomotion and behavioral changes in mice.
DCG-IV	drug_n	phencyclidine	drug_n
false

DDI-MedLine.d104.s0
The effects of DRUGA and DRUGN upon DRUGN (DRUGB)-induced locomotion and behavioral changes in mice.
DCG-IV	drug_n	PCP	drug_n
false

DDI-MedLine.d104.s0
The effects of DRUGN and DRUGA upon DRUGB (DRUGN)-induced locomotion and behavioral changes in mice.
L-CCG-1	drug_n	phencyclidine	drug_n
false

DDI-MedLine.d104.s0
The effects of DRUGN and DRUGA upon DRUGN (DRUGB)-induced locomotion and behavioral changes in mice.
L-CCG-1	drug_n	PCP	drug_n
false

DDI-MedLine.d104.s0
The effects of DRUGN and DRUGN upon DRUGA (DRUGB)-induced locomotion and behavioral changes in mice.
phencyclidine	drug_n	PCP	drug_n
false

DDI-MedLine.d104.s2
injection of DRUGA (DRUGB) were observed by measuring locomotor activity and stereotyped behavior.
phencyclidine	drug_n	PCP	drug_n
false

DDI-MedLine.d104.s3
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DRUGA and DRUGB, on the above behavioral changes induced by DRUGN were found.
DCG-IV	drug_n	L-CCG-1	drug_n
false

DDI-MedLine.d104.s3
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DRUGA and DRUGN, on the above behavioral changes induced by DRUGB were found.
DCG-IV	drug_n	PCP	drug_n
false

DDI-MedLine.d104.s3
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DRUGN and DRUGA, on the above behavioral changes induced by DRUGB were found.
L-CCG-1	drug_n	PCP	drug_n
false

DDI-MedLine.d104.s8
In order to examine some molecular mechanisms of DRUGA-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with DRUGA, DRUGB, and DRUGN was carried out.
PCP	drug_n	DCG-IV	drug_n
false

DDI-MedLine.d104.s8
In order to examine some molecular mechanisms of DRUGA-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with DRUGA, DRUGN, and DRUGB was carried out.
PCP	drug_n	L-CCG-1	drug_n
false

DDI-MedLine.d104.s8
In order to examine some molecular mechanisms of DRUGN-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with DRUGN, DRUGA, and DRUGB was carried out.
DCG-IV	drug_n	L-CCG-1	drug_n
false

DDI-MedLine.d98.s0
Behavioral responses to repeated DRUGA exposure in mice selectively bred for differential sensitivity to DRUGB.
cocaine	drug	pentobarbital	drug
false

DDI-MedLine.d98.s1
Mice from the 20th generation of three lines divergently selected for response to DRUGA-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study DRUGB-induced behavioral sensitization.
pentobarbital	drug	cocaine	drug
false

DDI-MedLine.d110.s0
DRUGA (DRUGB) and DRUGN: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
18-Methoxycoronaridine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s0
DRUGA (DRUGN) and DRUGB: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
18-Methoxycoronaridine	drug_n	ibogaine	drug_n
false

DDI-MedLine.d110.s0
DRUGN (DRUGA) and DRUGB: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
18-MC	drug_n	ibogaine	drug_n
false

DDI-MedLine.d110.s2
Like DRUGA (40 mg/kg), DRUGB (40 mg/kg) decreases the intravenous self-administration of DRUGN and DRUGN and the oral self-administration of DRUGN and DRUGN in rats;
ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s2
Like DRUGA (40 mg/kg), DRUGN (40 mg/kg) decreases the intravenous self-administration of DRUGB and DRUGN and the oral self-administration of DRUGN and DRUGN in rats;
ibogaine	drug_n	morphine	drug
false

DDI-MedLine.d110.s2
Like DRUGA (40 mg/kg), DRUGN (40 mg/kg) decreases the intravenous self-administration of DRUGN and DRUGB and the oral self-administration of DRUGN and DRUGN in rats;
ibogaine	drug_n	cocaine	drug
false

DDI-MedLine.d110.s2
Like DRUGA (40 mg/kg), DRUGN (40 mg/kg) decreases the intravenous self-administration of DRUGN and DRUGN and the oral self-administration of DRUGB and DRUGN in rats;
ibogaine	drug_n	ethanol	drug
false

DDI-MedLine.d110.s2
Like DRUGA (40 mg/kg), DRUGN (40 mg/kg) decreases the intravenous self-administration of DRUGN and DRUGN and the oral self-administration of DRUGN and DRUGB in rats;
ibogaine	drug_n	nicotine	drug
false

DDI-MedLine.d110.s2
Like DRUGN (40 mg/kg), DRUGA (40 mg/kg) decreases the intravenous self-administration of DRUGB and DRUGN and the oral self-administration of DRUGN and DRUGN in rats;
18-MC	drug_n	morphine	drug
false

DDI-MedLine.d110.s2
Like DRUGN (40 mg/kg), DRUGA (40 mg/kg) decreases the intravenous self-administration of DRUGN and DRUGB and the oral self-administration of DRUGN and DRUGN in rats;
18-MC	drug_n	cocaine	drug
false

DDI-MedLine.d110.s2
Like DRUGN (40 mg/kg), DRUGA (40 mg/kg) decreases the intravenous self-administration of DRUGN and DRUGN and the oral self-administration of DRUGB and DRUGN in rats;
18-MC	drug_n	ethanol	drug
false

DDI-MedLine.d110.s2
Like DRUGN (40 mg/kg), DRUGA (40 mg/kg) decreases the intravenous self-administration of DRUGN and DRUGN and the oral self-administration of DRUGN and DRUGB in rats;
18-MC	drug_n	nicotine	drug
false

DDI-MedLine.d110.s2
Like DRUGN (40 mg/kg), DRUGN (40 mg/kg) decreases the intravenous self-administration of DRUGA and DRUGB and the oral self-administration of DRUGN and DRUGN in rats;
morphine	drug	cocaine	drug
false

DDI-MedLine.d110.s2
Like DRUGN (40 mg/kg), DRUGN (40 mg/kg) decreases the intravenous self-administration of DRUGA and DRUGN and the oral self-administration of DRUGB and DRUGN in rats;
morphine	drug	ethanol	drug
false

DDI-MedLine.d110.s2
Like DRUGN (40 mg/kg), DRUGN (40 mg/kg) decreases the intravenous self-administration of DRUGA and DRUGN and the oral self-administration of DRUGN and DRUGB in rats;
morphine	drug	nicotine	drug
false

DDI-MedLine.d110.s2
Like DRUGN (40 mg/kg), DRUGN (40 mg/kg) decreases the intravenous self-administration of DRUGN and DRUGA and the oral self-administration of DRUGB and DRUGN in rats;
cocaine	drug	ethanol	drug
false

DDI-MedLine.d110.s2
Like DRUGN (40 mg/kg), DRUGN (40 mg/kg) decreases the intravenous self-administration of DRUGN and DRUGA and the oral self-administration of DRUGN and DRUGB in rats;
cocaine	drug	nicotine	drug
false

DDI-MedLine.d110.s2
Like DRUGN (40 mg/kg), DRUGN (40 mg/kg) decreases the intravenous self-administration of DRUGN and DRUGN and the oral self-administration of DRUGA and DRUGB in rats;
ethanol	drug	nicotine	drug
false

DDI-MedLine.d110.s3
unlike DRUGA, DRUGB does not affect responding for a nondrug reinforcer (water).
ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s4
Both DRUGA and DRUGB ameliorate DRUGN withdrawal signs.
ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s4
Both DRUGA and DRUGN ameliorate DRUGB withdrawal signs.
ibogaine	drug_n	opioid	group
false

DDI-MedLine.d110.s4
Both DRUGN and DRUGA ameliorate DRUGB withdrawal signs.
18-MC	drug_n	opioid	group
false

DDI-MedLine.d110.s5
Both DRUGA and DRUGB decrease extracellular levels of dopamine in the nucleus accumbens, but only DRUGA increases extracellular levels of serotonin in the nucleus accumbens.
ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s5
Both DRUGB and DRUGA decrease extracellular levels of dopamine in the nucleus accumbens, but only DRUGB increases extracellular levels of serotonin in the nucleus accumbens.
18-MC	drug_n	ibogaine	drug_n
false

DDI-MedLine.d110.s6
Both DRUGA and DRUGB block DRUGN-induced and DRUGN-induced dopamine release in the nucleus accumbens;
ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s6
Both DRUGN and DRUGN block DRUGA-induced and DRUGB-induced dopamine release in the nucleus accumbens;
morphine	drug	nicotine	drug
false

DDI-MedLine.d110.s8
Both DRUGA and DRUGB enhance the locomotor and/or stereotypic effects of stimulants.
ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s9
DRUGA attenuates, but DRUGB potentiates, the acute locomotor effects of DRUGN;
Ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s13
DRUGA, but not DRUGB, decreases heart rate at high doses.
Ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s14
While DRUGA and DRUGB have similar affinities for kappa opioid and possibly nicotinic receptors, DRUGA has much lower affinities than DRUGB for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.
18-MC	drug_n	ibogaine	drug_n
false

DDI-MedLine.d110.s14
While DRUGA and DRUGB have similar affinities for kappa opioid and possibly nicotinic receptors, DRUGA has much lower affinities than DRUGB for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.
18-MC	drug_n	ibogaine	drug_n
false

DDI-MedLine.d110.s14
While DRUGB and DRUGA have similar affinities for kappa opioid and possibly nicotinic receptors, DRUGB has much lower affinities than DRUGA for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.
ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s14
While DRUGA and DRUGB have similar affinities for kappa opioid and possibly nicotinic receptors, DRUGA has much lower affinities than DRUGB for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.
18-MC	drug_n	ibogaine	drug_n
false

DDI-MedLine.d110.s15
Both DRUGA and DRUGB are sequestered in fat and, like DRUGB, DRUGA probably has an active metabolite.
18-MC	drug_n	ibogaine	drug_n
false

DDI-MedLine.d110.s15
Both DRUGA and DRUGB are sequestered in fat and, like DRUGB, DRUGA probably has an active metabolite.
18-MC	drug_n	ibogaine	drug_n
false

DDI-MedLine.d110.s15
Both DRUGB and DRUGA are sequestered in fat and, like DRUGA, DRUGB probably has an active metabolite.
ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s15
Both DRUGB and DRUGA are sequestered in fat and, like DRUGA, DRUGB probably has an active metabolite.
ibogaine	drug_n	18-MC	drug_n
false

DDI-MedLine.d110.s16
The data suggest that DRUGA has a narrower spectrum of actions and will have a substantially greater therapeutic index than DRUGB.
18-MC	drug_n	ibogaine	drug_n
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGA interference by DRUGB, DRUGN, DRUGN, DRUGN and DRUGN were systematically investigated in 16 patients receiving DRUGN therapy.
anticoagulant	group	phenobarbital	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGA interference by DRUGN, DRUGB, DRUGN, DRUGN and DRUGN were systematically investigated in 16 patients receiving DRUGN therapy.
anticoagulant	group	secobarbital	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGA interference by DRUGN, DRUGN, DRUGB, DRUGN and DRUGN were systematically investigated in 16 patients receiving DRUGN therapy.
anticoagulant	group	glutethimide	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGA interference by DRUGN, DRUGN, DRUGN, DRUGB and DRUGN were systematically investigated in 16 patients receiving DRUGN therapy.
anticoagulant	group	chloral hydrate	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGA interference by DRUGN, DRUGN, DRUGN, DRUGN and DRUGB were systematically investigated in 16 patients receiving DRUGN therapy.
anticoagulant	group	methaqualone	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGA interference by DRUGN, DRUGN, DRUGN, DRUGN and DRUGN were systematically investigated in 16 patients receiving DRUGB therapy.
anticoagulant	group	coumarin	group
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGA, DRUGB, DRUGN, DRUGN and DRUGN were systematically investigated in 16 patients receiving DRUGN therapy.
phenobarbital	drug	secobarbital	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGA, DRUGN, DRUGB, DRUGN and DRUGN were systematically investigated in 16 patients receiving DRUGN therapy.
phenobarbital	drug	glutethimide	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGA, DRUGN, DRUGN, DRUGB and DRUGN were systematically investigated in 16 patients receiving DRUGN therapy.
phenobarbital	drug	chloral hydrate	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGA, DRUGN, DRUGN, DRUGN and DRUGB were systematically investigated in 16 patients receiving DRUGN therapy.
phenobarbital	drug	methaqualone	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGA, DRUGN, DRUGN, DRUGN and DRUGN were systematically investigated in 16 patients receiving DRUGB therapy.
phenobarbital	drug	coumarin	group
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGN, DRUGA, DRUGB, DRUGN and DRUGN were systematically investigated in 16 patients receiving DRUGN therapy.
secobarbital	drug	glutethimide	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGN, DRUGA, DRUGN, DRUGB and DRUGN were systematically investigated in 16 patients receiving DRUGN therapy.
secobarbital	drug	chloral hydrate	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGN, DRUGA, DRUGN, DRUGN and DRUGB were systematically investigated in 16 patients receiving DRUGN therapy.
secobarbital	drug	methaqualone	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGN, DRUGA, DRUGN, DRUGN and DRUGN were systematically investigated in 16 patients receiving DRUGB therapy.
secobarbital	drug	coumarin	group
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGN, DRUGN, DRUGA, DRUGB and DRUGN were systematically investigated in 16 patients receiving DRUGN therapy.
glutethimide	drug	chloral hydrate	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGN, DRUGN, DRUGA, DRUGN and DRUGB were systematically investigated in 16 patients receiving DRUGN therapy.
glutethimide	drug	methaqualone	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGN, DRUGN, DRUGA, DRUGN and DRUGN were systematically investigated in 16 patients receiving DRUGB therapy.
glutethimide	drug	coumarin	group
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGN, DRUGN, DRUGN, DRUGA and DRUGB were systematically investigated in 16 patients receiving DRUGN therapy.
chloral hydrate	drug	methaqualone	drug
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGN, DRUGN, DRUGN, DRUGA and DRUGN were systematically investigated in 16 patients receiving DRUGB therapy.
chloral hydrate	drug	coumarin	group
false

DDI-MedLine.d106.s1
The intensity, uniformity and time course of DRUGN interference by DRUGN, DRUGN, DRUGN, DRUGN and DRUGA were systematically investigated in 16 patients receiving DRUGB therapy.
methaqualone	drug	coumarin	group
false

DDI-MedLine.d106.s4
Anticoagulant inhibition was observed during the administration of DRUGA, DRUGB and DRUGN;
phenobarbital	drug	secobarbital	drug
false

DDI-MedLine.d106.s4
Anticoagulant inhibition was observed during the administration of DRUGA, DRUGN and DRUGB;
phenobarbital	drug	glutethimide	drug
false

DDI-MedLine.d106.s4
Anticoagulant inhibition was observed during the administration of DRUGN, DRUGA and DRUGB;
secobarbital	drug	glutethimide	drug
false

DDI-MedLine.d106.s5
there was no significant change in prothrombin test results during the trials of DRUGA and DRUGB.
chloral hydrate	drug	methaqualone	drug
false

DDI-MedLine.d106.s6
DRUGA and DRUGB should not be administered to patients receiving DRUGN.
Barbiturates	group	glutethimide	drug
false

DDI-MedLine.d106.s8
DRUGA and DRUGB interact pharmacologically with orally administered DRUGN, but the effect is not clinically significant.
Chloral hydrate	drug	methaqualone	drug
false

DDI-MedLine.d106.s9
It is concluded that DRUGA and DRUGB may be administered safely without additional caution in prothrombin test monitoring during oral DRUGN therapy.
chloral hydrate	drug	methaqualone	drug
false

DDI-MedLine.d106.s9
It is concluded that DRUGA and DRUGN may be administered safely without additional caution in prothrombin test monitoring during oral DRUGB therapy.
chloral hydrate	drug	anticoagulant	group
false

DDI-MedLine.d106.s9
It is concluded that DRUGN and DRUGA may be administered safely without additional caution in prothrombin test monitoring during oral DRUGB therapy.
methaqualone	drug	anticoagulant	group
false

DDI-MedLine.d127.s6
Concomitantly given DRUGA did not interfere with the absorption of a tablet of DRUGB.
thiazide diuretics	group	digoxin	drug
false

DDI-MedLine.d135.s0
Combinations of DRUGA and DRUGB: effects on drug discrimination and behavioral inhibition in rats.
clozapine	drug	phencyclidine	drug_n
false

DDI-MedLine.d135.s1
DRUGA (DRUGB) produces psychotomimetic effects in humans that resemble schizophrenia symptoms.
Phencyclidine	drug_n	PCP	drug_n
false

DDI-MedLine.d135.s3
In the present study, the DRUGA DRUGB was tested in combination with an active dose of DRUGN in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.
atypical antipsychotic	group	clozapine	drug
false

DDI-MedLine.d135.s3
In the present study, the DRUGA DRUGN was tested in combination with an active dose of DRUGB in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.
atypical antipsychotic	group	PCP	drug_n
false

DDI-MedLine.d135.s3
In the present study, the DRUGN DRUGA was tested in combination with an active dose of DRUGB in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.
clozapine	drug	PCP	drug_n
false

DDI-MedLine.d135.s5
Acute dosing with DRUGA failed to alter the behavioral effects of DRUGB in either procedure even when tested up to doses that produced pharmacological effects alone.
clozapine	drug	PCP	drug_n
false

DDI-MedLine.d135.s6
These results suggest that acute dosing with DRUGA would not affect behaviors most closely associated with DRUGB intoxication.
clozapine	drug	PCP	drug_n
false

DDI-MedLine.d135.s8
Since chronic dosing is required for therapeutic efficacy of DRUGA, future studies should focus on investigation of chronic dosing effects of these drugs in combination with DRUGB.
antipsychotics	group	PCP	drug_n
false

DDI-MedLine.d95.s4
DRUGA (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with DRUGB (8 micromol/l) or DRUGN (125 mmol/l) from both lean and dietary-obese rats.
Resveratrol	drug_n	noradrenaline	drug
false

DDI-MedLine.d95.s4
DRUGA (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with DRUGN (8 micromol/l) or DRUGB (125 mmol/l) from both lean and dietary-obese rats.
Resveratrol	drug_n	KCl	drug
false

DDI-MedLine.d95.s4
DRUGN (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with DRUGA (8 micromol/l) or DRUGB (125 mmol/l) from both lean and dietary-obese rats.
noradrenaline	drug	KCl	drug
false

DDI-MedLine.d95.s6
However, DRUGA (100 and 300 micromol/l) did not alter the effects of DRUGB on arteries from dietary-obese rats, giving superimposed concentration-responses curves.
L-NAME	drug_n	reseveratrol	drug_n
false

DDI-MedLine.d95.s7
DRUGA was also ineffective in altering DRUGB activity in arteries from both lean and dietary-obese rats.
Indomethacin	drug	resveratrol	drug_n
false

DDI-MedLine.d95.s8
In DRUGA-precontracted arteries from dietary-obese rats, responses to DRUGB were not attenuated by endothelial denudation, indicating an action independent of the endothelium.
noradrenaline	drug	resveratrol	drug_n
false

DDI-MedLine.d79.s0
If taken 1 hour before DRUGA (DRUGB), DRUGN does not affect DRUGB exposure, despite persistent buffering effects.
indinavir	drug	IDV	drug
false

DDI-MedLine.d79.s0
If taken 1 hour before DRUGA (DRUGN), DRUGB does not affect DRUGN exposure, despite persistent buffering effects.
indinavir	drug	didanosine	drug
false

DDI-MedLine.d79.s0
If taken 1 hour before DRUGA (DRUGB), DRUGN does not affect DRUGB exposure, despite persistent buffering effects.
indinavir	drug	IDV	drug
false

DDI-MedLine.d79.s0
If taken 1 hour before DRUGN (DRUGA), DRUGB does not affect DRUGA exposure, despite persistent buffering effects.
IDV	drug	didanosine	drug
false

DDI-MedLine.d79.s0
If taken 1 hour before DRUGN (DRUGB), DRUGA does not affect DRUGB exposure, despite persistent buffering effects.
didanosine	drug	IDV	drug
false

DDI-MedLine.d79.s1
Concurrent administration of DRUGA and DRUGB significantly reduces the level of exposure to DRUGA, but it is unclear how soon after DRUGB administration DRUGA may be given safely.
indinavir	drug	didanosine	drug
false

DDI-MedLine.d79.s1
Concurrent administration of DRUGB and DRUGA significantly reduces the level of exposure to DRUGB, but it is unclear how soon after DRUGA administration DRUGB may be given safely.
didanosine	drug	indinavir	drug
false

DDI-MedLine.d79.s1
Concurrent administration of DRUGB and DRUGA significantly reduces the level of exposure to DRUGB, but it is unclear how soon after DRUGA administration DRUGB may be given safely.
didanosine	drug	indinavir	drug
false

DDI-MedLine.d79.s1
Concurrent administration of DRUGA and DRUGB significantly reduces the level of exposure to DRUGA, but it is unclear how soon after DRUGB administration DRUGA may be given safely.
indinavir	drug	didanosine	drug
false

DDI-MedLine.d79.s1
Concurrent administration of DRUGB and DRUGA significantly reduces the level of exposure to DRUGB, but it is unclear how soon after DRUGA administration DRUGB may be given safely.
didanosine	drug	indinavir	drug
false

DDI-MedLine.d79.s2
We compared DRUGA pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of DRUGA alone versus 800 mg of DRUGA administered 1 h after DRUGB administration.
indinavir	drug	didanosine	drug
false

DDI-MedLine.d79.s2
We compared DRUGA pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of DRUGA alone versus 800 mg of DRUGA administered 1 h after DRUGB administration.
indinavir	drug	didanosine	drug
false

DDI-MedLine.d79.s2
We compared DRUGA pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of DRUGA alone versus 800 mg of DRUGA administered 1 h after DRUGB administration.
indinavir	drug	didanosine	drug
false

DDI-MedLine.d75.s3
The percentage of neurons hyperpolarized by DRUGA, DRUGB, and DRUGN was significantly reduced when 1% but not <
mu-selective opioids	group	delta(1)-selective opioids	group
false

DDI-MedLine.d75.s3
The percentage of neurons hyperpolarized by DRUGA, DRUGN, and DRUGB was significantly reduced when 1% but not <
mu-selective opioids	group	kappa-selective opioids	group
false

DDI-MedLine.d75.s3
The percentage of neurons hyperpolarized by DRUGN, DRUGA, and DRUGB was significantly reduced when 1% but not <
delta(1)-selective opioids	group	kappa-selective opioids	group
false

DDI-MedLine.d133.s0
Suppression by DRUGA of DRUGN-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by DRUGB in wistar rats.
verapamil	drug	azoxymethane	drug_n
false

DDI-MedLine.d133.s0
Suppression by DRUGN of DRUGA-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by DRUGB in wistar rats.
bombesin	drug_n	azoxymethane	drug_n
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGA and DRUGB (DRUGN), a DRUGN, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGN (DRUGN) and the labeling index of intestinal cancers were investigated in male Wistar rats.
bombesin	drug_n	verapamil hydrochloride	drug
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGA and DRUGB hydrochloride (DRUGB), a DRUGN, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGN (DRUGN) and the labeling index of intestinal cancers were investigated in male Wistar rats.
bombesin	drug_n	verapamil	drug
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGA and DRUGN (DRUGN), a DRUGB, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGN (DRUGN) and the labeling index of intestinal cancers were investigated in male Wistar rats.
bombesin	drug_n	calcium channel blocker	group
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGA and DRUGN (DRUGN), a DRUGN, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGB (DRUGN) and the labeling index of intestinal cancers were investigated in male Wistar rats.
bombesin	drug_n	azoxymethane	drug_n
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGA and DRUGN (DRUGN), a DRUGN, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGN (DRUGB) and the labeling index of intestinal cancers were investigated in male Wistar rats.
bombesin	drug_n	AOM	drug_n
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGN and DRUGA (DRUGB), a DRUGN, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGN (DRUGN) and the labeling index of intestinal cancers were investigated in male Wistar rats.
verapamil hydrochloride	drug	verapamil	drug
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGN and DRUGA (DRUGN), a DRUGB, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGN (DRUGN) and the labeling index of intestinal cancers were investigated in male Wistar rats.
verapamil hydrochloride	drug	calcium channel blocker	group
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGN and DRUGA (DRUGN), a DRUGN, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGB (DRUGN) and the labeling index of intestinal cancers were investigated in male Wistar rats.
verapamil hydrochloride	drug	azoxymethane	drug_n
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGN and DRUGA (DRUGN), a DRUGN, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGN (DRUGB) and the labeling index of intestinal cancers were investigated in male Wistar rats.
verapamil hydrochloride	drug	AOM	drug_n
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGN and DRUGA hydrochloride (DRUGA), a DRUGB, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGN (DRUGN) and the labeling index of intestinal cancers were investigated in male Wistar rats.
verapamil	drug	calcium channel blocker	group
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGN and DRUGA hydrochloride (DRUGA), a DRUGN, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGB (DRUGN) and the labeling index of intestinal cancers were investigated in male Wistar rats.
verapamil	drug	azoxymethane	drug_n
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGN and DRUGA hydrochloride (DRUGA), a DRUGN, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGN (DRUGB) and the labeling index of intestinal cancers were investigated in male Wistar rats.
verapamil	drug	AOM	drug_n
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGN and DRUGN (DRUGN), a DRUGA, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGB (DRUGN) and the labeling index of intestinal cancers were investigated in male Wistar rats.
calcium channel blocker	group	azoxymethane	drug_n
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGN and DRUGN (DRUGN), a DRUGA, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGN (DRUGB) and the labeling index of intestinal cancers were investigated in male Wistar rats.
calcium channel blocker	group	AOM	drug_n
false

DDI-MedLine.d133.s1
BACKGROUND: The effects of combined administration of DRUGN and DRUGN (DRUGN), a DRUGN, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by DRUGA (DRUGB) and the labeling index of intestinal cancers were investigated in male Wistar rats.
azoxymethane	drug_n	AOM	drug_n
false

DDI-MedLine.d133.s2
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of DRUGA (7.4 mg/kg body weight) and subcutaneous injections of DRUGB (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of DRUGN (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.
AOM	drug_n	bombesin	drug_n
false

DDI-MedLine.d133.s2
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of DRUGA (7.4 mg/kg body weight) and subcutaneous injections of DRUGN (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of DRUGB (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.
AOM	drug_n	verapamil	drug
false

DDI-MedLine.d133.s2
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of DRUGN (7.4 mg/kg body weight) and subcutaneous injections of DRUGA (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of DRUGB (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.
bombesin	drug_n	verapamil	drug
false

DDI-MedLine.d133.s4
Although DRUGA administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by DRUGB or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis.
verapamil	drug	bombesin	drug_n
false

DDI-MedLine.d17.s1
The interaction of DRUGA and synthetic DRUGB on placental vessels was studied in vitro.
prostaglandin F2alpha	drug	oxytocin	drug
false

DDI-MedLine.d17.s3
In seven experiments reactions to DRUGA and DRUGB were DRUGN.
norepinephrine	drug	oxytocin	drug
false

DDI-MedLine.d17.s3
In seven experiments reactions to DRUGA and DRUGN were DRUGB.
norepinephrine	drug	PGF2alpha	drug
false

DDI-MedLine.d17.s3
In seven experiments reactions to DRUGN and DRUGA were DRUGB.
oxytocin	drug	PGF2alpha	drug
false

DDI-MedLine.d36.s0
DRUGA overdose recognized by a DRUGB assay.
Carbamazepine	drug	tricyclic antidepressant	group
false

DDI-MedLine.d36.s2
We report the case of an adolescent with altered consciousness caused by DRUGA overdose with a positive DRUGN level to alert clinicians to the cross-reactivity of DRUGA with a toxicology screen for DRUGB.
carbamazepine	drug	tricyclic antidepressants	group
false

DDI-MedLine.d36.s2
We report the case of an adolescent with altered consciousness caused by DRUGB overdose with a positive DRUGA level to alert clinicians to the cross-reactivity of DRUGB with a toxicology screen for DRUGAs.
tricyclic antidepressant	group	carbamazepine	drug
false

DDI-MedLine.d36.s2
We report the case of an adolescent with altered consciousness caused by DRUGN overdose with a positive DRUGA level to alert clinicians to the cross-reactivity of DRUGN with a toxicology screen for DRUGAs.
tricyclic antidepressant	group	tricyclic antidepressants	group
false

DDI-MedLine.d126.s0
DRUGN-induced oxidative stress in rat brain and liver is prevented by DRUGA or DRUGB.
vitamin E	drug	allopurinol	drug
false

DDI-MedLine.d126.s1
Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by DRUGA, a DRUGB.
cypermethrin	drug	Type II pyrethroid	drug_n
false

DDI-MedLine.d126.s6
Pretreatment of rats with DRUGA (100 mg/kg, ip) or DRUGB (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral DRUGN administration within 4 h.
allopurinol	drug	Vitamin E	drug
false

DDI-MedLine.d126.s7
Thus, the results suggest that DRUGN exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by DRUGA and DRUGB.
allopurinol	drug	Vitamin E	drug
false

DDI-MedLine.d58.s3
In this study we investigated the effect of DRUGA on high threshold voltage-dependent Ca(2+) channel subtypes using their DRUGB DRUGN (L-type), DRUGN (N-type), or DRUGN (P-type) in bovine chromaffin cells.
ginsenosides	drug_n	selective Ca(2+) channel blockers	group
false

DDI-MedLine.d58.s3
In this study we investigated the effect of DRUGA on high threshold voltage-dependent Ca(2+) channel subtypes using their DRUGN DRUGB (L-type), DRUGN (N-type), or DRUGN (P-type) in bovine chromaffin cells.
ginsenosides	drug_n	nimodipine	drug
false

DDI-MedLine.d58.s3
In this study we investigated the effect of DRUGA on high threshold voltage-dependent Ca(2+) channel subtypes using their DRUGN DRUGN (L-type), DRUGB (N-type), or DRUGN (P-type) in bovine chromaffin cells.
ginsenosides	drug_n	omega-conotoxin GVIA	drug_n
false

DDI-MedLine.d58.s3
In this study we investigated the effect of DRUGA on high threshold voltage-dependent Ca(2+) channel subtypes using their DRUGN DRUGN (L-type), DRUGN (N-type), or DRUGB (P-type) in bovine chromaffin cells.
ginsenosides	drug_n	omega-agatoxin IVA	drug_n
false

DDI-MedLine.d58.s3
In this study we investigated the effect of DRUGN on high threshold voltage-dependent Ca(2+) channel subtypes using their DRUGA DRUGB (L-type), DRUGN (N-type), or DRUGN (P-type) in bovine chromaffin cells.
selective Ca(2+) channel blockers	group	nimodipine	drug
false

DDI-MedLine.d58.s3
In this study we investigated the effect of DRUGN on high threshold voltage-dependent Ca(2+) channel subtypes using their DRUGA DRUGN (L-type), DRUGB (N-type), or DRUGN (P-type) in bovine chromaffin cells.
selective Ca(2+) channel blockers	group	omega-conotoxin GVIA	drug_n
false

DDI-MedLine.d58.s3
In this study we investigated the effect of DRUGN on high threshold voltage-dependent Ca(2+) channel subtypes using their DRUGA DRUGN (L-type), DRUGN (N-type), or DRUGB (P-type) in bovine chromaffin cells.
selective Ca(2+) channel blockers	group	omega-agatoxin IVA	drug_n
false

DDI-MedLine.d58.s3
In this study we investigated the effect of DRUGN on high threshold voltage-dependent Ca(2+) channel subtypes using their DRUGN DRUGA (L-type), DRUGB (N-type), or DRUGN (P-type) in bovine chromaffin cells.
nimodipine	drug	omega-conotoxin GVIA	drug_n
false

DDI-MedLine.d58.s3
In this study we investigated the effect of DRUGN on high threshold voltage-dependent Ca(2+) channel subtypes using their DRUGN DRUGA (L-type), DRUGN (N-type), or DRUGB (P-type) in bovine chromaffin cells.
nimodipine	drug	omega-agatoxin IVA	drug_n
false

DDI-MedLine.d58.s3
In this study we investigated the effect of DRUGN on high threshold voltage-dependent Ca(2+) channel subtypes using their DRUGN DRUGN (L-type), DRUGA (N-type), or DRUGB (P-type) in bovine chromaffin cells.
omega-conotoxin GVIA	drug_n	omega-agatoxin IVA	drug_n
false

DDI-MedLine.d58.s6
DRUGA had no effect on DRUGB response.
Nimodipine	drug	ginsenosides	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGA are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGB-sensitive (N-type) channel, an DRUGN-sensitive (P-type) channel and DRUGN/DRUGB/DRUGN-resistant (presumptive Q-type) channel.
ginsenosides	drug_n	omega-conotoxin GVIA	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGA are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGN-sensitive (N-type) channel, an DRUGB-sensitive (P-type) channel and DRUGN/DRUGN/DRUGN-resistant (presumptive Q-type) channel.
ginsenosides	drug_n	omega-agatoxin IVA	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGA are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGN-sensitive (N-type) channel, an DRUGN-sensitive (P-type) channel and DRUGB/DRUGN/DRUGN-resistant (presumptive Q-type) channel.
ginsenosides	drug_n	nimodipine	drug
false

DDI-MedLine.d58.s7
These data suggest that DRUGA are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGB-sensitive (N-type) channel, an DRUGN-sensitive (P-type) channel and DRUGN/DRUGB/DRUGN-resistant (presumptive Q-type) channel.
ginsenosides	drug_n	omega-conotoxin GVIA	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGA are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGN-sensitive (N-type) channel, an DRUGN-sensitive (P-type) channel and DRUGN/DRUGN/DRUGB-resistant (presumptive Q-type) channel.
ginsenosides	drug_n	omega-agatoxin VIA	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGN are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGA-sensitive (N-type) channel, an DRUGB-sensitive (P-type) channel and DRUGN/DRUGA/DRUGN-resistant (presumptive Q-type) channel.
omega-conotoxin GVIA	drug_n	omega-agatoxin IVA	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGN are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGA-sensitive (N-type) channel, an DRUGN-sensitive (P-type) channel and DRUGB/DRUGA/DRUGN-resistant (presumptive Q-type) channel.
omega-conotoxin GVIA	drug_n	nimodipine	drug
false

DDI-MedLine.d58.s7
These data suggest that DRUGN are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGA-sensitive (N-type) channel, an DRUGN-sensitive (P-type) channel and DRUGN/DRUGA/DRUGB-resistant (presumptive Q-type) channel.
omega-conotoxin GVIA	drug_n	omega-agatoxin VIA	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGN are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGN-sensitive (N-type) channel, an DRUGA-sensitive (P-type) channel and DRUGB/DRUGN/DRUGN-resistant (presumptive Q-type) channel.
omega-agatoxin IVA	drug_n	nimodipine	drug
false

DDI-MedLine.d58.s7
These data suggest that DRUGN are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGB-sensitive (N-type) channel, an DRUGA-sensitive (P-type) channel and DRUGN/DRUGB/DRUGN-resistant (presumptive Q-type) channel.
omega-agatoxin IVA	drug_n	omega-conotoxin GVIA	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGN are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGN-sensitive (N-type) channel, an DRUGA-sensitive (P-type) channel and DRUGN/DRUGN/DRUGB-resistant (presumptive Q-type) channel.
omega-agatoxin IVA	drug_n	omega-agatoxin VIA	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGN are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGB-sensitive (N-type) channel, an DRUGN-sensitive (P-type) channel and DRUGA/DRUGB/DRUGN-resistant (presumptive Q-type) channel.
nimodipine	drug	omega-conotoxin GVIA	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGN are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGN-sensitive (N-type) channel, an DRUGN-sensitive (P-type) channel and DRUGA/DRUGN/DRUGB-resistant (presumptive Q-type) channel.
nimodipine	drug	omega-agatoxin VIA	drug_n
false

DDI-MedLine.d58.s7
These data suggest that DRUGN are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an DRUGA-sensitive (N-type) channel, an DRUGN-sensitive (P-type) channel and DRUGN/DRUGA/DRUGB-resistant (presumptive Q-type) channel.
omega-conotoxin GVIA	drug_n	omega-agatoxin VIA	drug_n
false

DDI-MedLine.d58.s8
Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by DRUGA in bovine chromaffin cell could be the cellular basis of antistress effects induced by DRUGB.
ginsenosides	drug_n	ginseng	drug
false

DDI-MedLine.d8.s0
In vitro activity of DRUGA, either singly or in combination with DRUGB, against Mycobacterium ulcerans.
KRM-1648	drug_n	ofloxacin	drug
false

DDI-MedLine.d8.s1
The antimicrobial effect of a DRUGA, DRUGB, either alone or in combination with DRUGN, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans.
benzoxazinorifamycin	drug_n	KRM-1648	drug_n
false

DDI-MedLine.d8.s1
The antimicrobial effect of a DRUGA, DRUGN, either alone or in combination with DRUGB, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans.
benzoxazinorifamycin	drug_n	ofloxacin	drug
false

DDI-MedLine.d8.s1
The antimicrobial effect of a DRUGN, DRUGA, either alone or in combination with DRUGB, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans.
KRM-1648	drug_n	ofloxacin	drug
false

DDI-MedLine.d8.s5
ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for DRUGA and DRUGB were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively.
rifampicin	drug	rifabutin	drug
false

DDI-MedLine.d8.s6
When combined with DRUGA, DRUGN exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGB (or DRUGN) and DRUGA.
ofloxacin	drug	rifampicin	drug
false

DDI-MedLine.d8.s6
When combined with DRUGA, DRUGN exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGN (or DRUGB) and DRUGA.
ofloxacin	drug	rifabutin	drug
false

DDI-MedLine.d8.s6
When combined with DRUGN, DRUGA exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGB (or DRUGN) and DRUGN.
KRM-1648	drug_n	rifampicin	drug
false

DDI-MedLine.d8.s6
When combined with DRUGN, DRUGA exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGN (or DRUGB) and DRUGN.
KRM-1648	drug_n	rifabutin	drug
false

DDI-MedLine.d8.s6
When combined with DRUGB, DRUGA exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGN (or DRUGN) and DRUGB.
KRM-1648	drug_n	ofloxacin	drug
false

DDI-MedLine.d8.s6
When combined with DRUGN, DRUGN exhibited strong synergistic activity while only additive effects were observed with the combination of DRUGA (or DRUGB) and DRUGN.
rifampicin	drug	rifabutin	drug
false

DDI-MedLine.d114.s1
The effects of DRUGA (DRUGB) on DRUGN (DRUGN)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
ruthenium red	drug_n	RR	drug_n
false

DDI-MedLine.d114.s1
The effects of DRUGA (DRUGN) on DRUGB (DRUGN)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
ruthenium red	drug_n	inositol 1,4,5-trisphosphate	drug_n
false

DDI-MedLine.d114.s1
The effects of DRUGA (DRUGN) on DRUGN (DRUGB)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
ruthenium red	drug_n	InsP(3)	drug_n
false

DDI-MedLine.d114.s1
The effects of DRUGN (DRUGA) on DRUGB (DRUGN)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
RR	drug_n	inositol 1,4,5-trisphosphate	drug_n
false

DDI-MedLine.d114.s1
The effects of DRUGN (DRUGA) on DRUGN (DRUGB)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
RR	drug_n	InsP(3)	drug_n
false

DDI-MedLine.d114.s1
The effects of DRUGN (DRUGN) on DRUGA (DRUGB)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
inositol 1,4,5-trisphosphate	drug_n	InsP(3)	drug_n
false

DDI-MedLine.d114.s6
In contrast, in isolated single pancreatic acinar cells, DRUGA had no effect on DRUGB-induced responses.
RR	drug_n	InsP(3)	drug_n
false

DDI-MedLine.d114.s8
In addition, we have shown that DRUGA is a useful pharmacological tool with which to examine the DRUGB-mediated responses of megakaryocytes.
RR	drug_n	InsP(3)	drug_n
false

DDI-MedLine.d109.s0
Effect of DRUGA on the pharmacokinetics of DRUGB in healthy volunteers.
rofecoxib	drug	digoxin	drug
false

DDI-MedLine.d109.s1
The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, DRUGA, at steady state on the pharmacokinetics of DRUGB following a single dose in healthy subjects.
rofecoxib	drug	digoxin	drug
false

DDI-MedLine.d109.s7
For DRUGA AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (DRUGB + DRUGA/placebo + DRUGA) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively.
digoxin	drug	rofecoxib	drug
false

DDI-MedLine.d109.s7
For DRUGB AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (DRUGA + DRUGB/placebo + DRUGB) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively.
rofecoxib	drug	digoxin	drug
false

DDI-MedLine.d109.s7
For DRUGB AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (DRUGA + DRUGB/placebo + DRUGB) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively.
rofecoxib	drug	digoxin	drug
false

DDI-MedLine.d109.s9
The harmonic mean elimination half-life was 45.7 and 43.4 hours for DRUGA + DRUGB and placebo + DRUGB treatments, respectively.
rofecoxib	drug	digoxin	drug
false

DDI-MedLine.d109.s9
The harmonic mean elimination half-life was 45.7 and 43.4 hours for DRUGA + DRUGB and placebo + DRUGB treatments, respectively.
rofecoxib	drug	digoxin	drug
false

DDI-MedLine.d109.s11
The mean (SD) cumulative urinary excretion of immunoreactive DRUGA after concurrent treatment with DRUGB or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively.
digoxin	drug	rofecoxib	drug
false

DDI-MedLine.d109.s13
DRUGA did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of DRUGB.
Rofecoxib	drug	digoxin	drug
false

DDI-MedLine.d115.s0
Concomitant DRUGA, DRUGB, DRUGN, and DRUGN chemotherapy plus DRUGN therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
cyclophosphamide	drug	doxorubicin	drug
false

DDI-MedLine.d115.s0
Concomitant DRUGA, DRUGN, DRUGB, and DRUGN chemotherapy plus DRUGN therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
cyclophosphamide	drug	vincristine	drug
false

DDI-MedLine.d115.s0
Concomitant DRUGA, DRUGN, DRUGN, and DRUGB chemotherapy plus DRUGN therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
cyclophosphamide	drug	prednisone	drug
false

DDI-MedLine.d115.s0
Concomitant DRUGA, DRUGN, DRUGN, and DRUGN chemotherapy plus DRUGB therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
cyclophosphamide	drug	highly active antiretroviral	group
false

DDI-MedLine.d115.s0
Concomitant DRUGN, DRUGA, DRUGB, and DRUGN chemotherapy plus DRUGN therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
doxorubicin	drug	vincristine	drug
false

DDI-MedLine.d115.s0
Concomitant DRUGN, DRUGA, DRUGN, and DRUGB chemotherapy plus DRUGN therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
doxorubicin	drug	prednisone	drug
false

DDI-MedLine.d115.s0
Concomitant DRUGN, DRUGA, DRUGN, and DRUGN chemotherapy plus DRUGB therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
doxorubicin	drug	highly active antiretroviral	group
false

DDI-MedLine.d115.s0
Concomitant DRUGN, DRUGN, DRUGA, and DRUGB chemotherapy plus DRUGN therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
vincristine	drug	prednisone	drug
false

DDI-MedLine.d115.s0
Concomitant DRUGN, DRUGN, DRUGA, and DRUGN chemotherapy plus DRUGB therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
vincristine	drug	highly active antiretroviral	group
false

DDI-MedLine.d115.s0
Concomitant DRUGN, DRUGN, DRUGN, and DRUGA chemotherapy plus DRUGB therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
prednisone	drug	highly active antiretroviral	group
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGB, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGB, DRUGN, and DRUGN with DRUGN plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	doxorubicin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGB, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGN, and DRUGN with DRUGB plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	vincristine	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGN, and DRUGB (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGN, and DRUGB with DRUGN plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	prednisone	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGB, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGB, DRUGN, and DRUGN with DRUGN plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	doxorubicin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGB, and DRUGN with DRUGN plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	teniposide	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGN, and DRUGB (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGN, and DRUGB with DRUGN plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	prednisone	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGB, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGN, and DRUGN with DRUGB plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	vincristine	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGN, and DRUGN with DRUGN plus DRUGB) without receiving DRUGN therapy.
cyclophosphamide	drug	bleomycin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGN, and DRUGN with DRUGN plus DRUGN) without receiving DRUGB therapy.
cyclophosphamide	drug	antiretroviral	group
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGB, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGN, and DRUGN with DRUGB plus DRUGN) without receiving DRUGN therapy.
doxorubicin	drug	vincristine	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGN, and DRUGB (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGN, and DRUGB with DRUGN plus DRUGN) without receiving DRUGN therapy.
doxorubicin	drug	prednisone	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGB, DRUGA, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGB, DRUGA, DRUGN, and DRUGN with DRUGN plus DRUGN) without receiving DRUGN therapy.
doxorubicin	drug	cyclophosphamide	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGB, and DRUGN with DRUGN plus DRUGN) without receiving DRUGN therapy.
doxorubicin	drug	teniposide	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGN, and DRUGB (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGN, and DRUGB with DRUGN plus DRUGN) without receiving DRUGN therapy.
doxorubicin	drug	prednisone	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGB, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGN, and DRUGN with DRUGB plus DRUGN) without receiving DRUGN therapy.
doxorubicin	drug	vincristine	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGN, and DRUGN with DRUGN plus DRUGB) without receiving DRUGN therapy.
doxorubicin	drug	bleomycin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGN, and DRUGN with DRUGN plus DRUGN) without receiving DRUGB therapy.
doxorubicin	drug	antiretroviral	group
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGA, and DRUGB (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGB with DRUGA plus DRUGN) without receiving DRUGN therapy.
vincristine	drug	prednisone	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGB, DRUGN, DRUGA, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGB, DRUGN, DRUGN, and DRUGN with DRUGA plus DRUGN) without receiving DRUGN therapy.
vincristine	drug	cyclophosphamide	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGB, DRUGA, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGB, DRUGN, and DRUGN with DRUGA plus DRUGN) without receiving DRUGN therapy.
vincristine	drug	doxorubicin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGA, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGB, and DRUGN with DRUGA plus DRUGN) without receiving DRUGN therapy.
vincristine	drug	teniposide	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGA, and DRUGB (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGB with DRUGA plus DRUGN) without receiving DRUGN therapy.
vincristine	drug	prednisone	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGA, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGN with DRUGA plus DRUGB) without receiving DRUGN therapy.
vincristine	drug	bleomycin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGA, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGN with DRUGA plus DRUGN) without receiving DRUGB therapy.
vincristine	drug	antiretroviral	group
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGB, DRUGN, DRUGN, and DRUGA (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGB, DRUGN, DRUGN, and DRUGA with DRUGN plus DRUGN) without receiving DRUGN therapy.
prednisone	drug	cyclophosphamide	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGB, DRUGN, and DRUGA (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGB, DRUGN, and DRUGA with DRUGN plus DRUGN) without receiving DRUGN therapy.
prednisone	drug	doxorubicin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGN, and DRUGA (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGB, and DRUGA with DRUGN plus DRUGN) without receiving DRUGN therapy.
prednisone	drug	teniposide	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGB, and DRUGA (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGA with DRUGB plus DRUGN) without receiving DRUGN therapy.
prednisone	drug	vincristine	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGN, and DRUGA (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGA with DRUGN plus DRUGB) without receiving DRUGN therapy.
prednisone	drug	bleomycin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGN, and DRUGA (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGA with DRUGN plus DRUGN) without receiving DRUGB therapy.
prednisone	drug	antiretroviral	group
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGB, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGB, DRUGN, and DRUGN with DRUGN plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	doxorubicin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGB, and DRUGN with DRUGN plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	teniposide	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGN, and DRUGB (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGN, and DRUGB with DRUGN plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	prednisone	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGB, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGN, and DRUGN with DRUGB plus DRUGN) without receiving DRUGN therapy.
cyclophosphamide	drug	vincristine	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGN, and DRUGN with DRUGN plus DRUGB) without receiving DRUGN therapy.
cyclophosphamide	drug	bleomycin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGA, DRUGN, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGA, DRUGN, DRUGN, and DRUGN with DRUGN plus DRUGN) without receiving DRUGB therapy.
cyclophosphamide	drug	antiretroviral	group
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGB, and DRUGN with DRUGN plus DRUGN) without receiving DRUGN therapy.
doxorubicin	drug	teniposide	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGN, and DRUGB (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGN, and DRUGB with DRUGN plus DRUGN) without receiving DRUGN therapy.
doxorubicin	drug	prednisone	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGB, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGN, and DRUGN with DRUGB plus DRUGN) without receiving DRUGN therapy.
doxorubicin	drug	vincristine	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGN, and DRUGN with DRUGN plus DRUGB) without receiving DRUGN therapy.
doxorubicin	drug	bleomycin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGA, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGA, DRUGN, and DRUGN with DRUGN plus DRUGN) without receiving DRUGB therapy.
doxorubicin	drug	antiretroviral	group
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGN, and DRUGB (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGA, and DRUGB with DRUGN plus DRUGN) without receiving DRUGN therapy.
teniposide	drug	prednisone	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGB, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGA, and DRUGN with DRUGB plus DRUGN) without receiving DRUGN therapy.
teniposide	drug	vincristine	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGA, and DRUGN with DRUGN plus DRUGB) without receiving DRUGN therapy.
teniposide	drug	bleomycin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGA, and DRUGN with DRUGN plus DRUGN) without receiving DRUGB therapy.
teniposide	drug	antiretroviral	group
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGB, and DRUGA (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGA with DRUGB plus DRUGN) without receiving DRUGN therapy.
prednisone	drug	vincristine	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGN, and DRUGA (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGA with DRUGN plus DRUGB) without receiving DRUGN therapy.
prednisone	drug	bleomycin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGN, and DRUGA (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGA with DRUGN plus DRUGN) without receiving DRUGB therapy.
prednisone	drug	antiretroviral	group
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGA, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGN with DRUGA plus DRUGB) without receiving DRUGN therapy.
vincristine	drug	bleomycin	drug
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGA, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGN with DRUGA plus DRUGN) without receiving DRUGB therapy.
vincristine	drug	antiretroviral	group
false

DDI-MedLine.d115.s2
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUGN, DRUGN, DRUGN, and DRUGN (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUGN, DRUGN, DRUGN, and DRUGN with DRUGN plus DRUGA) without receiving DRUGB therapy.
bleomycin	drug	antiretroviral	group
false

DDI-MedLine.d115.s5
DRUGA regimens consisted of two DRUGB and one DRUGN.
Antiretroviral	group	reverse transcriptase inhibitors	group
false

DDI-MedLine.d115.s5
DRUGA regimens consisted of two DRUGN and one DRUGB.
Antiretroviral	group	protease inhibitor	group
false

DDI-MedLine.d115.s5
DRUGN regimens consisted of two DRUGA and one DRUGB.
reverse transcriptase inhibitors	group	protease inhibitor	group
false

DDI-MedLine.d21.s6
DRUGA (5 mg/kg), DRUGB (30 mg/kg), DRUGN (0.25 mg/kg), DRUGN (20 mg/kg) DRUGN (30 mg/kg) or vehicle was administered.
Imipramine	drug	moclobemide	drug
false

DDI-MedLine.d21.s6
DRUGA (5 mg/kg), DRUGN (30 mg/kg), DRUGB (0.25 mg/kg), DRUGN (20 mg/kg) DRUGN (30 mg/kg) or vehicle was administered.
Imipramine	drug	clonazepam	drug
false

DDI-MedLine.d21.s6
DRUGA (5 mg/kg), DRUGN (30 mg/kg), DRUGN (0.25 mg/kg), DRUGB (20 mg/kg) DRUGN (30 mg/kg) or vehicle was administered.
Imipramine	drug	fluoxetine	drug
false

DDI-MedLine.d21.s6
DRUGA (5 mg/kg), DRUGN (30 mg/kg), DRUGN (0.25 mg/kg), DRUGN (20 mg/kg) DRUGB (30 mg/kg) or vehicle was administered.
Imipramine	drug	sertraline	drug
false

DDI-MedLine.d21.s6
DRUGN (5 mg/kg), DRUGA (30 mg/kg), DRUGB (0.25 mg/kg), DRUGN (20 mg/kg) DRUGN (30 mg/kg) or vehicle was administered.
moclobemide	drug	clonazepam	drug
false

DDI-MedLine.d21.s6
DRUGN (5 mg/kg), DRUGA (30 mg/kg), DRUGN (0.25 mg/kg), DRUGB (20 mg/kg) DRUGN (30 mg/kg) or vehicle was administered.
moclobemide	drug	fluoxetine	drug
false

DDI-MedLine.d21.s6
DRUGN (5 mg/kg), DRUGA (30 mg/kg), DRUGN (0.25 mg/kg), DRUGN (20 mg/kg) DRUGB (30 mg/kg) or vehicle was administered.
moclobemide	drug	sertraline	drug
false

DDI-MedLine.d21.s6
DRUGN (5 mg/kg), DRUGN (30 mg/kg), DRUGA (0.25 mg/kg), DRUGB (20 mg/kg) DRUGN (30 mg/kg) or vehicle was administered.
clonazepam	drug	fluoxetine	drug
false

DDI-MedLine.d21.s6
DRUGN (5 mg/kg), DRUGN (30 mg/kg), DRUGA (0.25 mg/kg), DRUGN (20 mg/kg) DRUGB (30 mg/kg) or vehicle was administered.
clonazepam	drug	sertraline	drug
false

DDI-MedLine.d21.s6
DRUGN (5 mg/kg), DRUGN (30 mg/kg), DRUGN (0.25 mg/kg), DRUGA (20 mg/kg) DRUGB (30 mg/kg) or vehicle was administered.
fluoxetine	drug	sertraline	drug
false

DDI-MedLine.d21.s9
DRUGA and DRUGB did not change fasting or overload glycemia.
Imipramine	drug	clonazepam	drug
false

DDI-MedLine.d21.s10
DRUGA and DRUGB increased blood DRUGN at different times after the DRUGN overload.
Fluoxetine	drug	moclobemide	drug
false

DDI-MedLine.d21.s10
DRUGA and DRUGN increased blood DRUGB at different times after the DRUGB overload.
Fluoxetine	drug	glucose	drug
false

DDI-MedLine.d21.s10
DRUGN and DRUGA increased blood DRUGB at different times after the DRUGB overload.
moclobemide	drug	glucose	drug
false

DDI-MedLine.d21.s11
DRUGA neutralized the increase of glycemia induced by oral DRUGB overload.
Sertraline	drug	glucose	drug
false

DDI-MedLine.d21.s13
Again, DRUGA neutralized the increase in glycemia after DRUGB overload both in diabetic and non-diabetic rats.
sertraline	drug	glucose	drug
false

DDI-MedLine.d47.s0
Activity of DRUGA alone and in combination with DRUGB and DRUGN against Cryptosporidium parvum in cell culture.
buforin II	drug_n	azithromycin	drug
false

DDI-MedLine.d47.s0
Activity of DRUGA alone and in combination with DRUGN and DRUGB against Cryptosporidium parvum in cell culture.
buforin II	drug_n	minocycline	drug
false

DDI-MedLine.d47.s0
Activity of DRUGN alone and in combination with DRUGA and DRUGB against Cryptosporidium parvum in cell culture.
azithromycin	drug	minocycline	drug
false

DDI-MedLine.d47.s1
The in vitro anti-cryptosporidial activity of DRUGA alone and in combination with DRUGB and DRUGN was investigated.
buforin II	drug_n	azithromycin	drug
false

DDI-MedLine.d47.s1
The in vitro anti-cryptosporidial activity of DRUGA alone and in combination with DRUGN and DRUGB was investigated.
buforin II	drug_n	minocycline	drug
false

DDI-MedLine.d47.s1
The in vitro anti-cryptosporidial activity of DRUGN alone and in combination with DRUGA and DRUGB was investigated.
azithromycin	drug	minocycline	drug
false

DDI-MedLine.d47.s3
Moreover, its activity was enhanced when it was combined with either DRUGA or DRUGB with 90% parasite reduction at the highest concentration tested.
azithromycin	drug	minocycline	drug
false

DDI-MedLine.d47.s4
DRUGN may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either DRUGA or DRUGB.
azithromycin	drug	minocycline	drug
false

DDI-MedLine.d112.s0
Effect of DRUGA on the pharmacokinetics of DRUGB.
dofetillide	drug	digoxin	drug
false

DDI-MedLine.d112.s1
The effect of DRUGA on the steady-state pharmacokinetics of DRUGB was evaluated in a randomized, double-blind study.
dofetilide	drug	digoxin	drug
false

DDI-MedLine.d112.s2
Five days of DRUGA treatment did not significantly affect steady-state pharmacokinetic variables of DRUGB compared with placebo;
dofetilide	drug	digoxin	drug
false

DDI-MedLine.d112.s3
therefore, the use of DRUGA does not necessitate an adjustment in DRUGB dose to maintain therapeutic DRUGB levels.
dofetilide	drug	digoxin	drug
false

DDI-MedLine.d19.s4
Numerous drug interactions are possible with some DRUGA, such as DRUGB and DRUGN, which affect hepatic microsomal enzyme systems.
anticonvulsant agents	group	phenobarbitone	drug
false

DDI-MedLine.d19.s4
Numerous drug interactions are possible with some DRUGA, such as DRUGN and DRUGB, which affect hepatic microsomal enzyme systems.
anticonvulsant agents	group	phenytoin	drug
false

DDI-MedLine.d19.s4
Numerous drug interactions are possible with some DRUGN, such as DRUGA and DRUGB, which affect hepatic microsomal enzyme systems.
phenobarbitone	drug	phenytoin	drug
false

DDI-MedLine.d16.s1
The interaction of intramuscularly injected DRUGA and its N-demethylated metabolite (metabolite I) with DRUGB was evaluated in rats.
ketamine	drug	halothane	drug
false

DDI-MedLine.d16.s5
The half-life of DRUGB in plasma and brain was longer in the presence of DRUGA than when DRUGB was given alone.
halothane	drug	ketamine	drug
false

DDI-MedLine.d116.s3
The concomitant administration of DRUGA and DRUGB resulted in the need for an unusually high maintenance dose of DRUGB (20 mg per day) in order to produce a therapeutic effect.
rifampin	drug	warfarin	drug
false

DDI-MedLine.d116.s6
The effect of DRUGB on the DRUGA requirement of our patient appeared to be maximal 5 to 7 days after the initiation of DRUGB and extended a similar length of time after DRUGB withdrawal.
warfarin	drug	rifampin	drug
false

DDI-MedLine.d116.s6
The effect of DRUGB on the DRUGA requirement of our patient appeared to be maximal 5 to 7 days after the initiation of DRUGB and extended a similar length of time after DRUGB withdrawal.
warfarin	drug	rifampin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGA (DRUGB) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGN and DRUGN.
sodium carboxymethylcellulose	drug_n	NaCMC	drug_n
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGA (DRUGN) and DRUGB (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGN and DRUGN.
sodium carboxymethylcellulose	drug_n	carboxymethylcellulose-cysteine	drug_n
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGA (DRUGN) and DRUGN (DRUGB) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGN and DRUGN.
sodium carboxymethylcellulose	drug_n	CMC-Cys	drug_n
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGA (DRUGN) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGB (DRUGN) and model peptide drugs, DRUGN and DRUGN.
sodium carboxymethylcellulose	drug_n	sodium fluorescein	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGA (DRUGN) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGB) and model peptide drugs, DRUGN and DRUGN.
sodium carboxymethylcellulose	drug_n	NaFlu	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGA (DRUGN) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGB and DRUGN.
sodium carboxymethylcellulose	drug_n	bacitracin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGA (DRUGN) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGN and DRUGB.
sodium carboxymethylcellulose	drug_n	insulin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGA) and DRUGB (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGN and DRUGN.
NaCMC	drug_n	carboxymethylcellulose-cysteine	drug_n
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGA) and DRUGN (DRUGB) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGN and DRUGN.
NaCMC	drug_n	CMC-Cys	drug_n
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGA) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGB (DRUGN) and model peptide drugs, DRUGN and DRUGN.
NaCMC	drug_n	sodium fluorescein	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGA) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGB) and model peptide drugs, DRUGN and DRUGN.
NaCMC	drug_n	NaFlu	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGA) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGB and DRUGN.
NaCMC	drug_n	bacitracin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGA) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGN and DRUGB.
NaCMC	drug_n	insulin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGA (DRUGB) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGN and DRUGN.
carboxymethylcellulose-cysteine	drug_n	CMC-Cys	drug_n
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGA (DRUGN) conjugates on the intestinal permeation of DRUGB (DRUGN) and model peptide drugs, DRUGN and DRUGN.
carboxymethylcellulose-cysteine	drug_n	sodium fluorescein	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGA (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGB) and model peptide drugs, DRUGN and DRUGN.
carboxymethylcellulose-cysteine	drug_n	NaFlu	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGA (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGB and DRUGN.
carboxymethylcellulose-cysteine	drug_n	bacitracin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGA (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGN and DRUGB.
carboxymethylcellulose-cysteine	drug_n	insulin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGN (DRUGA) conjugates on the intestinal permeation of DRUGB (DRUGN) and model peptide drugs, DRUGN and DRUGN.
CMC-Cys	drug_n	sodium fluorescein	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGN (DRUGA) conjugates on the intestinal permeation of DRUGN (DRUGB) and model peptide drugs, DRUGN and DRUGN.
CMC-Cys	drug_n	NaFlu	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGN (DRUGA) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGB and DRUGN.
CMC-Cys	drug_n	bacitracin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGN (DRUGA) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGN and DRUGB.
CMC-Cys	drug_n	insulin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGA (DRUGB) and model peptide drugs, DRUGN and DRUGN.
sodium fluorescein	drug	NaFlu	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGA (DRUGN) and model peptide drugs, DRUGB and DRUGN.
sodium fluorescein	drug	bacitracin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGA (DRUGN) and model peptide drugs, DRUGN and DRUGB.
sodium fluorescein	drug	insulin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGA) and model peptide drugs, DRUGB and DRUGN.
NaFlu	drug	bacitracin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGA) and model peptide drugs, DRUGN and DRUGB.
NaFlu	drug	insulin	drug
false

DDI-MedLine.d76.s1
The purpose of this study was to evaluate the effect of DRUGN (DRUGN) and DRUGN (DRUGN) conjugates on the intestinal permeation of DRUGN (DRUGN) and model peptide drugs, DRUGA and DRUGB.
bacitracin	drug	insulin	drug
false

DDI-MedLine.d76.s2
DRUGA was covalently linked to carbodiimide activated DRUGB.
Cysteine	drug	NaCMC	drug_n
false

DDI-MedLine.d76.s5
Unmodified DRUGA (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of DRUGB to 1.3 and 1% (m/v) DRUGA conjugated with DRUGN further enhanced the permeation.
NaCMC	drug_n	NaFlu	drug
false

DDI-MedLine.d76.s5
Unmodified DRUGA (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of DRUGN to 1.3 and 1% (m/v) DRUGA conjugated with DRUGB further enhanced the permeation.
NaCMC	drug_n	cysteine	drug
false

DDI-MedLine.d76.s5
Unmodified DRUGB (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of DRUGA to 1.3 and 1% (m/v) DRUGB conjugated with DRUGN further enhanced the permeation.
NaFlu	drug	NaCMC	drug_n
false

DDI-MedLine.d76.s5
Unmodified DRUGN (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of DRUGA to 1.3 and 1% (m/v) DRUGN conjugated with DRUGB further enhanced the permeation.
NaFlu	drug	cysteine	drug
false

DDI-MedLine.d76.s5
Unmodified DRUGA (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of DRUGN to 1.3 and 1% (m/v) DRUGA conjugated with DRUGB further enhanced the permeation.
NaCMC	drug_n	cysteine	drug
false

DDI-MedLine.d76.s7
Decreasing the concentration of DRUGA, exhibiting 7.3% (m/m) of immobilised DRUGB (DRUGA7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of DRUGN from 1.8 to 1.2.
CMC-Cys	drug_n	cysteine	drug
false

DDI-MedLine.d76.s7
Decreasing the concentration of DRUGA, exhibiting 7.3% (m/m) of immobilised DRUGN (DRUGA7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of DRUGB from 1.8 to 1.2.
CMC-Cys	drug_n	NaFlu	drug
false

DDI-MedLine.d76.s7
Decreasing the concentration of DRUGN, exhibiting 7.3% (m/m) of immobilised DRUGA (DRUGN7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of DRUGB from 1.8 to 1.2.
cysteine	drug	NaFlu	drug
false

DDI-MedLine.d76.s8
DRUGA at 1% (m/v) in the presence of free DRUGB had no significant effect on the R-value of DRUGN compared to DRUGA alone.
NaCMC	drug_n	cysteine	drug
false

DDI-MedLine.d76.s8
DRUGA at 1% (m/v) in the presence of free DRUGN had no significant effect on the R-value of DRUGB compared to DRUGA alone.
NaCMC	drug_n	NaFlu	drug
false

DDI-MedLine.d76.s8
DRUGN at 1% (m/v) in the presence of free DRUGA had no significant effect on the R-value of DRUGB compared to DRUGN alone.
cysteine	drug	NaFlu	drug
false

DDI-MedLine.d76.s8
DRUGB at 1% (m/v) in the presence of free DRUGA had no significant effect on the R-value of DRUGN compared to DRUGB alone.
cysteine	drug	NaCMC	drug_n
false

DDI-MedLine.d76.s8
DRUGB at 1% (m/v) in the presence of free DRUGN had no significant effect on the R-value of DRUGA compared to DRUGB alone.
NaFlu	drug	NaCMC	drug_n
false

DDI-MedLine.d76.s9
Formulation of fluorescence labelled DRUGA and DRUGB in unconjugated DRUGN (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) DRUGN7.3 a significantly improved permeation was observed (R= 1.3).
bacitracin	drug	insulin	drug
false

DDI-MedLine.d76.s9
Formulation of fluorescence labelled DRUGA and DRUGN in unconjugated DRUGB (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) DRUGN7.3 a significantly improved permeation was observed (R= 1.3).
bacitracin	drug	NaCMC	drug_n
false

DDI-MedLine.d76.s9
Formulation of fluorescence labelled DRUGA and DRUGN in unconjugated DRUGN (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) DRUGB7.3 a significantly improved permeation was observed (R= 1.3).
bacitracin	drug	CMC-Cys	drug_n
false

DDI-MedLine.d76.s9
Formulation of fluorescence labelled DRUGN and DRUGA in unconjugated DRUGB (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) DRUGN7.3 a significantly improved permeation was observed (R= 1.3).
insulin	drug	NaCMC	drug_n
false

DDI-MedLine.d76.s9
Formulation of fluorescence labelled DRUGN and DRUGA in unconjugated DRUGN (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) DRUGB7.3 a significantly improved permeation was observed (R= 1.3).
insulin	drug	CMC-Cys	drug_n
false

DDI-MedLine.d76.s9
Formulation of fluorescence labelled DRUGN and DRUGN in unconjugated DRUGA (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) DRUGB7.3 a significantly improved permeation was observed (R= 1.3).
NaCMC	drug_n	CMC-Cys	drug_n
false

DDI-MedLine.d76.s10
Conjugation at DRUGA with DRUGB moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGN and the model peptide drugs DRUGN and DRUGN in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
NaCMC	drug_n	cysteine	drug
false

DDI-MedLine.d76.s10
Conjugation at DRUGA with DRUGN moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGB and the model peptide drugs DRUGN and DRUGN in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
NaCMC	drug_n	NaFlu	drug
false

DDI-MedLine.d76.s10
Conjugation at DRUGA with DRUGN moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGN and the model peptide drugs DRUGB and DRUGN in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
NaCMC	drug_n	bacitracin	drug
false

DDI-MedLine.d76.s10
Conjugation at DRUGA with DRUGN moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGN and the model peptide drugs DRUGN and DRUGB in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
NaCMC	drug_n	insulin	drug
false

DDI-MedLine.d76.s10
Conjugation at DRUGN with DRUGA moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGB and the model peptide drugs DRUGN and DRUGN in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
cysteine	drug	NaFlu	drug
false

DDI-MedLine.d76.s10
Conjugation at DRUGN with DRUGA moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGN and the model peptide drugs DRUGB and DRUGN in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
cysteine	drug	bacitracin	drug
false

DDI-MedLine.d76.s10
Conjugation at DRUGN with DRUGA moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGN and the model peptide drugs DRUGN and DRUGB in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
cysteine	drug	insulin	drug
false

DDI-MedLine.d76.s10
Conjugation at DRUGN with DRUGN moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGA and the model peptide drugs DRUGB and DRUGN in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
NaFlu	drug	bacitracin	drug
false

DDI-MedLine.d76.s10
Conjugation at DRUGN with DRUGN moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGA and the model peptide drugs DRUGN and DRUGB in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
NaFlu	drug	insulin	drug
false

DDI-MedLine.d76.s10
Conjugation at DRUGN with DRUGN moieties significantly improves the intestinal permeation of the hydrophilic molecule DRUGN and the model peptide drugs DRUGA and DRUGB in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
bacitracin	drug	insulin	drug
false

DDI-MedLine.d3.s0
Pharmacokinetic Interaction between DRUGA and DRUGB or DRUGN in healthy males.
amprenavir	drug	rifabutin	drug
false

DDI-MedLine.d3.s0
Pharmacokinetic Interaction between DRUGA and DRUGN or DRUGB in healthy males.
amprenavir	drug	rifampin	drug
false

DDI-MedLine.d3.s0
Pharmacokinetic Interaction between DRUGN and DRUGA or DRUGB in healthy males.
rifabutin	drug	rifampin	drug
false

DDI-MedLine.d3.s1
The objective of this study was to determine if there is a pharmacokinetic interaction when DRUGA is given with DRUGB or DRUGN and to determine the effects of these drugs on the erythromycin breath test (ERMBT).
amprenavir	drug	rifabutin	drug
false

DDI-MedLine.d3.s1
The objective of this study was to determine if there is a pharmacokinetic interaction when DRUGA is given with DRUGN or DRUGB and to determine the effects of these drugs on the erythromycin breath test (ERMBT).
amprenavir	drug	rifampin	drug
false

DDI-MedLine.d3.s1
The objective of this study was to determine if there is a pharmacokinetic interaction when DRUGN is given with DRUGA or DRUGB and to determine the effects of these drugs on the erythromycin breath test (ERMBT).
rifabutin	drug	rifampin	drug
false

DDI-MedLine.d3.s3
All subjects received DRUGA (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either DRUGB (300 mg once a day [QD]) (cohort 1) or DRUGN (600 mg QD) (cohort 2) for 14 days.
amprenavir	drug	rifabutin	drug
false

DDI-MedLine.d3.s3
All subjects received DRUGA (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either DRUGN (300 mg once a day [QD]) (cohort 1) or DRUGB (600 mg QD) (cohort 2) for 14 days.
amprenavir	drug	rifampin	drug
false

DDI-MedLine.d3.s3
All subjects received DRUGN (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either DRUGA (300 mg once a day [QD]) (cohort 1) or DRUGB (600 mg QD) (cohort 2) for 14 days.
rifabutin	drug	rifampin	drug
false

DDI-MedLine.d3.s4
Cohort 1 then received DRUGA plus DRUGB for 10 days, and cohort 2 received DRUGA plus DRUGN for 4 days.
amprenavir	drug	rifabutin	drug
false

DDI-MedLine.d3.s4
Cohort 1 then received DRUGA plus DRUGN for 10 days, and cohort 2 received DRUGA plus DRUGB for 4 days.
amprenavir	drug	rifampin	drug
false

DDI-MedLine.d3.s4
Cohort 1 then received DRUGB plus DRUGA for 10 days, and cohort 2 received DRUGB plus DRUGN for 4 days.
rifabutin	drug	amprenavir	drug
false

DDI-MedLine.d3.s4
Cohort 1 then received DRUGN plus DRUGA for 10 days, and cohort 2 received DRUGN plus DRUGB for 4 days.
rifabutin	drug	rifampin	drug
false

DDI-MedLine.d3.s4
Cohort 1 then received DRUGA plus DRUGN for 10 days, and cohort 2 received DRUGA plus DRUGB for 4 days.
amprenavir	drug	rifampin	drug
false

DDI-MedLine.d3.s5
Serial plasma and urine samples for measurement of DRUGA, DRUGB, and DRUGN and their DRUGN, were measured by high-performance liquid chromatography.
amprenavir	drug	rifabutin	drug
false

DDI-MedLine.d3.s5
Serial plasma and urine samples for measurement of DRUGA, DRUGN, and DRUGB and their DRUGN, were measured by high-performance liquid chromatography.
amprenavir	drug	rifampin	drug
false

DDI-MedLine.d3.s5
Serial plasma and urine samples for measurement of DRUGA, DRUGN, and DRUGN and their DRUGB, were measured by high-performance liquid chromatography.
amprenavir	drug	25-O-desacetyl metabolites	drug_n
false

DDI-MedLine.d3.s5
Serial plasma and urine samples for measurement of DRUGN, DRUGA, and DRUGB and their DRUGN, were measured by high-performance liquid chromatography.
rifabutin	drug	rifampin	drug
false

DDI-MedLine.d3.s5
Serial plasma and urine samples for measurement of DRUGN, DRUGA, and DRUGN and their DRUGB, were measured by high-performance liquid chromatography.
rifabutin	drug	25-O-desacetyl metabolites	drug_n
false

DDI-MedLine.d3.s5
Serial plasma and urine samples for measurement of DRUGN, DRUGN, and DRUGA and their DRUGB, were measured by high-performance liquid chromatography.
rifampin	drug	25-O-desacetyl metabolites	drug_n
false

DDI-MedLine.d3.s6
DRUGA did not significantly affect DRUGB's pharmacokinetics.
Rifabutin	drug	amprenavir	drug
false

DDI-MedLine.d3.s7
DRUGN significantly increased the area under the curve at steady state (AUC(ss)) of DRUGA by 2.93-fold and the AUC(ss) of 25-O-desacetylDRUGA by 13.3-fold.
rifabutin	drug	25-O-desacetylrifabutin	drug_n
false

DDI-MedLine.d3.s8
DRUGA significantly decreased the AUC(ss) of DRUGB by 82%, but DRUGB had no effect on DRUGN pharmacokinetics.
Rifampin	drug	amprenavir	drug
false

DDI-MedLine.d3.s8
DRUGA significantly decreased the AUC(ss) of DRUGN by 82%, but DRUGN had no effect on DRUGB pharmacokinetics.
Rifampin	drug	rifampin	drug
false

DDI-MedLine.d3.s8
DRUGN significantly decreased the AUC(ss) of DRUGA by 82%, but DRUGA had no effect on DRUGB pharmacokinetics.
amprenavir	drug	rifampin	drug
false

DDI-MedLine.d3.s8
DRUGN significantly decreased the AUC(ss) of DRUGA by 82%, but DRUGA had no effect on DRUGB pharmacokinetics.
amprenavir	drug	rifampin	drug
false

DDI-MedLine.d3.s10
The results of the ERMBT after 2 weeks of DRUGA and DRUGB therapy were increased 187 and 156%, respectively.
rifabutin	drug	rifampin	drug
false

DDI-MedLine.d3.s11
DRUGA plus DRUGB was well tolerated.
Amprenavir	drug	rifampin	drug
false

DDI-MedLine.d3.s14
DRUGN significantly decreases clearance of DRUGA and 25-O-desacetylDRUGA, and the combination is poorly tolerated.
rifabutin	drug	25-O-desacetylrifabutin	drug_n
false

DDI-MedLine.d3.s15
DRUGA inhibits the ERMBT, and DRUGB and DRUGN are equipotent inducers of the ERMBT.
Amprenavir	drug	rifampin	drug
false

DDI-MedLine.d3.s15
DRUGA inhibits the ERMBT, and DRUGN and DRUGB are equipotent inducers of the ERMBT.
Amprenavir	drug	rifabutin	drug
false

DDI-MedLine.d3.s15
DRUGN inhibits the ERMBT, and DRUGA and DRUGB are equipotent inducers of the ERMBT.
rifampin	drug	rifabutin	drug
false

DDI-MedLine.d28.s7
The DRUGA (DRUGB and DRUGN), a new class of oral DRUGN, are "insulin sensitizers"
thiazolidinediones	group	rosiglitazone	drug
false

DDI-MedLine.d28.s7
The DRUGA (DRUGN and DRUGB), a new class of oral DRUGN, are "insulin sensitizers"
thiazolidinediones	group	pioglitazone	drug
false

DDI-MedLine.d28.s7
The DRUGA (DRUGN and DRUGN), a new class of oral DRUGB, are "insulin sensitizers"
thiazolidinediones	group	antidiabetic agents	group
false

DDI-MedLine.d28.s7
The DRUGN (DRUGA and DRUGB), a new class of oral DRUGN, are "insulin sensitizers"
rosiglitazone	drug	pioglitazone	drug
false

DDI-MedLine.d28.s7
The DRUGN (DRUGA and DRUGN), a new class of oral DRUGB, are "insulin sensitizers"
rosiglitazone	drug	antidiabetic agents	group
false

DDI-MedLine.d28.s7
The DRUGN (DRUGN and DRUGA), a new class of oral DRUGB, are "insulin sensitizers"
pioglitazone	drug	antidiabetic agents	group
false

DDI-MedLine.d74.s2
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of DRUGA (20mM), DRUGB (100 or 150 mg. per 100 ml.), and DRUGN (10 mM).
arginine	drug	glucose	drug
false

DDI-MedLine.d74.s2
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of DRUGA (20mM), DRUGN (100 or 150 mg. per 100 ml.), and DRUGB (10 mM).
arginine	drug	theophylline	drug
false

DDI-MedLine.d74.s2
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of DRUGN (20mM), DRUGA (100 or 150 mg. per 100 ml.), and DRUGB (10 mM).
glucose	drug	theophylline	drug
false

DDI-MedLine.d74.s4
DRUGA, alone and in the presence of DRUGB, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals.
Glucose	drug	theophylline	drug
false

DDI-MedLine.d74.s5
DRUGA, in the presence of DRUGB and DRUGN, caused excessive glucagon release but nearly normal insulin release in the diabetics.
Arginine	drug	glucose	drug
false

DDI-MedLine.d74.s5
DRUGA, in the presence of DRUGN and DRUGB, caused excessive glucagon release but nearly normal insulin release in the diabetics.
Arginine	drug	theophylline	drug
false

DDI-MedLine.d74.s5
DRUGN, in the presence of DRUGA and DRUGB, caused excessive glucagon release but nearly normal insulin release in the diabetics.
glucose	drug	theophylline	drug
false

DDI-MedLine.d74.s6
DRUGA, in the absence of DRUGB or DRUGN, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals.
Arginine	drug	glucose	drug
false

DDI-MedLine.d74.s6
DRUGA, in the absence of DRUGN or DRUGB, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals.
Arginine	drug	theophylline	drug
false

DDI-MedLine.d74.s6
DRUGN, in the absence of DRUGA or DRUGB, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals.
glucose	drug	theophylline	drug
false

DDI-MedLine.d74.s11
Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to DRUGA, but are relatively insensitive to DRUGB.
theophylline	drug	glucose	drug
false

DDI-MedLine.d125.s0
The mode of toxic action of the pesticide DRUGA: the metabolism of DRUGB to DRUGN.
gliftor	drug_n	1,3-difluoroacetone	drug_n
false

DDI-MedLine.d125.s0
The mode of toxic action of the pesticide DRUGA: the metabolism of DRUGN to DRUGB.
gliftor	drug_n	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s0
The mode of toxic action of the pesticide DRUGN: the metabolism of DRUGA to DRUGB.
1,3-difluoroacetone	drug_n	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s1
The biochemical toxicology of DRUGA, a known metabolite of the major ingredient of the pesticide DRUGB (DRUGN), was investigated in vivo and in vitro.
1,3-difluoroacetone	drug_n	Gliftor	drug_n
false

DDI-MedLine.d125.s1
The biochemical toxicology of DRUGA, a known metabolite of the major ingredient of the pesticide DRUGN (DRUGB), was investigated in vivo and in vitro.
1,3-difluoroacetone	drug_n	1,3-difluoro-2-propanol	drug_n
false

DDI-MedLine.d125.s1
The biochemical toxicology of DRUGN, a known metabolite of the major ingredient of the pesticide DRUGA (DRUGB), was investigated in vivo and in vitro.
Gliftor	drug_n	1,3-difluoro-2-propanol	drug_n
false

DDI-MedLine.d125.s2
Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted DRUGA to DRUGB in vitro.
1,3-difluoroacetone	drug_n	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s3
Administration of DRUGA (100 mg kg(-1) body weight) to rats in vivo resulted in DRUGB synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation.
1,3-difluoroacetone	drug_n	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s4
Animals dosed with DRUGA did not display the 2-3 hour lag phase in either DRUGB synthesis or in citrate and fluoride accumulation characteristic of animals dosed with DRUGN.
1,3-difluoroacetone	drug_n	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s4
Animals dosed with DRUGA did not display the 2-3 hour lag phase in either DRUGN synthesis or in citrate and fluoride accumulation characteristic of animals dosed with DRUGB.
1,3-difluoroacetone	drug_n	1,3-difluoro-2-propanol	drug_n
false

DDI-MedLine.d125.s4
Animals dosed with DRUGN did not display the 2-3 hour lag phase in either DRUGA synthesis or in citrate and fluoride accumulation characteristic of animals dosed with DRUGB.
(-)-erythro-fluorocitrate	drug_n	1,3-difluoro-2-propanol	drug_n
false

DDI-MedLine.d125.s5
We demonstrate that the conversion of DRUGA to DRUGB by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, DRUGN from DRUGA.
1,3-difluoro-2-propanol	drug_n	1,3-difluoroacetone	drug_n
false

DDI-MedLine.d125.s5
We demonstrate that the conversion of DRUGA to DRUGN by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, DRUGB from DRUGA.
1,3-difluoro-2-propanol	drug_n	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s5
We demonstrate that the conversion of DRUGN to DRUGA by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, DRUGB from DRUGN.
1,3-difluoroacetone	drug_n	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s5
We demonstrate that the conversion of DRUGB to DRUGA by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, DRUGN from DRUGB.
1,3-difluoroacetone	drug_n	1,3-difluoro-2-propanol	drug_n
false

DDI-MedLine.d125.s5
We demonstrate that the conversion of DRUGB to DRUGN by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, DRUGA from DRUGB.
(-)-erythro-fluorocitrate	drug_n	1,3-difluoro-2-propanol	drug_n
false

DDI-MedLine.d125.s6
Prior administration of DRUGA (90 mg kg(-1) body weight) was shown to prevent the conversion of DRUGN (100 mg kg(-1) body weight) to DRUGB in vivo and to eliminate the fluoride and citrate elevations seen in DRUGN-intoxicated animals.
4-methylpyrazole	drug	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s6
Prior administration of DRUGA (90 mg kg(-1) body weight) was shown to prevent the conversion of DRUGB (100 mg kg(-1) body weight) to DRUGN in vivo and to eliminate the fluoride and citrate elevations seen in DRUGB-intoxicated animals.
4-methylpyrazole	drug	1,3-difluoro-2-propanol	drug_n
false

DDI-MedLine.d125.s6
Prior administration of DRUGN (90 mg kg(-1) body weight) was shown to prevent the conversion of DRUGA (100 mg kg(-1) body weight) to DRUGB in vivo and to eliminate the fluoride and citrate elevations seen in DRUGA-intoxicated animals.
1,3-difluoro-2-propanol	drug_n	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s6
Prior administration of DRUGN (90 mg kg(-1) body weight) was shown to prevent the conversion of DRUGB (100 mg kg(-1) body weight) to DRUGA in vivo and to eliminate the fluoride and citrate elevations seen in DRUGB-intoxicated animals.
(-)-erythro-fluorocitrate	drug_n	1,3-difluoro-2-propanol	drug_n
false

DDI-MedLine.d125.s7
However, administration of DRUGA (90 mg kg(-1) body weight) to rats 2 hours prior to DRUGB (100 mg kg(-1) body weight) was ineffective in preventing DRUGN synthesis and did not diminish fluoride or citrate accumulation in vivo.
4-methylpyrazole	drug	1,3-difluoroacetone	drug_n
false

DDI-MedLine.d125.s7
However, administration of DRUGA (90 mg kg(-1) body weight) to rats 2 hours prior to DRUGN (100 mg kg(-1) body weight) was ineffective in preventing DRUGB synthesis and did not diminish fluoride or citrate accumulation in vivo.
4-methylpyrazole	drug	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s7
However, administration of DRUGN (90 mg kg(-1) body weight) to rats 2 hours prior to DRUGA (100 mg kg(-1) body weight) was ineffective in preventing DRUGB synthesis and did not diminish fluoride or citrate accumulation in vivo.
1,3-difluoroacetone	drug_n	(-)-erythro-fluorocitrate	drug_n
false

DDI-MedLine.d125.s8
We conclude that the prophylactic and antidotal properties of DRUGA seen in animals treated with DRUGB derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting DRUGB to DRUGN in the committed step of the toxic pathway.
4-methylpyrazole	drug	1,3-difluoro-2-propanol	drug_n
false

DDI-MedLine.d125.s8
We conclude that the prophylactic and antidotal properties of DRUGA seen in animals treated with DRUGN derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting DRUGN to DRUGB in the committed step of the toxic pathway.
4-methylpyrazole	drug	1,3-difluoroacetone	drug_n
false

DDI-MedLine.d125.s8
We conclude that the prophylactic and antidotal properties of DRUGN seen in animals treated with DRUGA derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting DRUGA to DRUGB in the committed step of the toxic pathway.
1,3-difluoro-2-propanol	drug_n	1,3-difluoroacetone	drug_n
false

DDI-MedLine.d125.s8
We conclude that the prophylactic and antidotal properties of DRUGN seen in animals treated with DRUGA derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting DRUGA to DRUGB in the committed step of the toxic pathway.
1,3-difluoro-2-propanol	drug_n	1,3-difluoroacetone	drug_n
false

DDI-MedLine.d129.s0
DRUGA as potent DRUGB of glucocorticoid-induced mouse mammary tumor virus gene expression.
Green tea polyphenols	drug	enhancers	drug
false

DDI-MedLine.d129.s3
DRUGA showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude DRUGB.
n-dodecyl gallate	drug	tannic acid	drug
false

DDI-MedLine.d86.s1
AIM AND BACKGROUND: The pharmacokinetic interaction between DRUGA, a DRUGB metabolized by CYP3A4, and the DRUGN DRUGN was studied in 18 healthy subjects.
sirolimus	drug	macrolide immunosuppressant	group
false

DDI-MedLine.d86.s1
AIM AND BACKGROUND: The pharmacokinetic interaction between DRUGA, a DRUGN metabolized by CYP3A4, and the DRUGB DRUGN was studied in 18 healthy subjects.
sirolimus	drug	calcium channel blocker	group
false

DDI-MedLine.d86.s1
AIM AND BACKGROUND: The pharmacokinetic interaction between DRUGA, a DRUGN metabolized by CYP3A4, and the DRUGN DRUGB was studied in 18 healthy subjects.
sirolimus	drug	diltiazem	drug
false

DDI-MedLine.d86.s1
AIM AND BACKGROUND: The pharmacokinetic interaction between DRUGN, a DRUGA metabolized by CYP3A4, and the DRUGB DRUGN was studied in 18 healthy subjects.
macrolide immunosuppressant	group	calcium channel blocker	group
false

DDI-MedLine.d86.s1
AIM AND BACKGROUND: The pharmacokinetic interaction between DRUGN, a DRUGA metabolized by CYP3A4, and the DRUGN DRUGB was studied in 18 healthy subjects.
macrolide immunosuppressant	group	diltiazem	drug
false

DDI-MedLine.d86.s1
AIM AND BACKGROUND: The pharmacokinetic interaction between DRUGN, a DRUGN metabolized by CYP3A4, and the DRUGA DRUGB was studied in 18 healthy subjects.
calcium channel blocker	group	diltiazem	drug
false

DDI-MedLine.d86.s2
Several clinically important interactions have previously been reported for other DRUGA that are metabolized by the same enzyme and for DRUGB.
immunosuppressive drugs	group	calcium antagonists	group
false

DDI-MedLine.d86.s3
METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of DRUGA, a single oral 120-mg dose of DRUGB, and the two drugs given together.
sirolimus	drug	diltiazem	drug
false

DDI-MedLine.d86.s5
RESULTS: The geometric mean (90% confidence interval) whole blood DRUGB area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with DRUGA coadministration, whereas the mean elimination half-life of DRUGB decreased slightly, from 79 to 67 hours.
diltiazem	drug	sirolimus	drug
false

DDI-MedLine.d86.s6
Apparent oral clearance and volume of distribution of DRUGA decreased with 38% and 45%, respectively, when DRUGA was given with DRUGB.
sirolimus	drug	diltiazem	drug
false

DDI-MedLine.d86.s7
The plasma maximum concentration and area under the plasma concentration-time curve of DRUGA, desacetylDRUGA, and desmethylDRUGA were unchanged after coadministration of DRUGN, and no potentiation of the effects of DRUGA on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
diltiazem	drug	desacetyldiltiazem	drug_n
false

DDI-MedLine.d86.s7
The plasma maximum concentration and area under the plasma concentration-time curve of DRUGA, desacetylDRUGA, and desmethylDRUGA were unchanged after coadministration of DRUGN, and no potentiation of the effects of DRUGA on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
diltiazem	drug	desmethyldiltiazem	drug_n
false

DDI-MedLine.d86.s7
The plasma maximum concentration and area under the plasma concentration-time curve of DRUGA, desacetylDRUGA, and desmethylDRUGA were unchanged after coadministration of DRUGB, and no potentiation of the effects of DRUGA on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
diltiazem	drug	sirolimus	drug
false

DDI-MedLine.d86.s7
The plasma maximum concentration and area under the plasma concentration-time curve of DRUGN, DRUGA, and DRUGB were unchanged after coadministration of DRUGN, and no potentiation of the effects of DRUGN on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
desacetyldiltiazem	drug_n	desmethyldiltiazem	drug_n
false

DDI-MedLine.d86.s7
The plasma maximum concentration and area under the plasma concentration-time curve of DRUGN, DRUGA, and desmethylDRUGN were unchanged after coadministration of DRUGB, and no potentiation of the effects of DRUGN on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
desacetyldiltiazem	drug_n	sirolimus	drug
false

DDI-MedLine.d86.s7
The plasma maximum concentration and area under the plasma concentration-time curve of DRUGB, DRUGA, and desmethylDRUGB were unchanged after coadministration of DRUGN, and no potentiation of the effects of DRUGB on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
desacetyldiltiazem	drug_n	diltiazem	drug
false

DDI-MedLine.d86.s7
The plasma maximum concentration and area under the plasma concentration-time curve of DRUGN, desacetylDRUGN, and DRUGA were unchanged after coadministration of DRUGB, and no potentiation of the effects of DRUGN on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
desmethyldiltiazem	drug_n	sirolimus	drug
false

DDI-MedLine.d86.s7
The plasma maximum concentration and area under the plasma concentration-time curve of DRUGB, desacetylDRUGB, and DRUGA were unchanged after coadministration of DRUGN, and no potentiation of the effects of DRUGB on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
desmethyldiltiazem	drug_n	diltiazem	drug
false

DDI-MedLine.d86.s7
The plasma maximum concentration and area under the plasma concentration-time curve of DRUGB, desacetylDRUGB, and desmethylDRUGB were unchanged after coadministration of DRUGA, and no potentiation of the effects of DRUGB on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
sirolimus	drug	diltiazem	drug
false

DDI-MedLine.d86.s8
CONCLUSIONS: Single-dose DRUGA coadministration leads to higher DRUGB exposure, presumably by inhibition of the first-pass metabolism of DRUGB.
diltiazem	drug	sirolimus	drug
false

DDI-MedLine.d86.s9
Because of the pronounced intersubject variability in the extent of the DRUGB-DRUGA interaction, whole blood DRUGB concentrations should be monitored closely in patients treated with the two drugs.
diltiazem	drug	sirolimus	drug
false

DDI-MedLine.d99.s1
OBJECTIVE: Our objective was to examine the interaction between DRUGA and DRUGB to confirm that DRUGA inhibits CYP2C9.
fluvoxamine	drug	tolbutamide	drug
false

DDI-MedLine.d99.s1
OBJECTIVE: Our objective was to examine the interaction between DRUGB and DRUGA to confirm that DRUGB inhibits CYP2C9.
tolbutamide	drug	fluvoxamine	drug
false

DDI-MedLine.d99.s8
Plasma was analyzed for DRUGA, and urine was analyzed for DRUGA and its two metabolites, 4-hydroxyDRUGA and carboxyDRUGA by means of HPLC.
tolbutamide	drug	4-hydroxytolbutamide	drug_n
false

DDI-MedLine.d99.s8
Plasma was analyzed for DRUGA, and urine was analyzed for DRUGA and its two metabolites, 4-hydroxyDRUGA and carboxyDRUGA by means of HPLC.
tolbutamide	drug	carboxytolbutamide	drug_n
false

DDI-MedLine.d99.s8
Plasma was analyzed for DRUGA, and urine was analyzed for DRUGA and its two metabolites, 4-hydroxyDRUGA and carboxyDRUGA by means of HPLC.
tolbutamide	drug	4-hydroxytolbutamide	drug_n
false

DDI-MedLine.d99.s8
Plasma was analyzed for DRUGA, and urine was analyzed for DRUGA and its two metabolites, 4-hydroxyDRUGA and carboxyDRUGA by means of HPLC.
tolbutamide	drug	carboxytolbutamide	drug_n
false

DDI-MedLine.d99.s8
Plasma was analyzed for DRUGN, and urine was analyzed for DRUGN and its two metabolites, DRUGA and DRUGB by means of HPLC.
4-hydroxytolbutamide	drug_n	carboxytolbutamide	drug_n
false

DDI-MedLine.d99.s11
The clearance by means of DRUGA and DRUGB was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of DRUGN per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of DRUGN per day).
4-hydroxytolbutamide	drug_n	carboxytolbutamide	drug_n
false

DDI-MedLine.d99.s11
The clearance by means of DRUGA and carboxyDRUGB was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of DRUGB per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of DRUGB per day).
4-hydroxytolbutamide	drug_n	tolbutamide	drug
false

DDI-MedLine.d99.s11
The clearance by means of DRUGA and carboxyDRUGB was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of DRUGB per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of DRUGB per day).
4-hydroxytolbutamide	drug_n	tolbutamide	drug
false

DDI-MedLine.d99.s11
The clearance by means of 4-hydroxyDRUGB and DRUGA was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of DRUGB per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of DRUGB per day).
carboxytolbutamide	drug_n	tolbutamide	drug
false

DDI-MedLine.d99.s11
The clearance by means of 4-hydroxyDRUGB and DRUGA was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of DRUGB per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of DRUGB per day).
carboxytolbutamide	drug_n	tolbutamide	drug
false

DDI-MedLine.d140.s0
Longitudinal assessment of DRUGA in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on DRUGB.
everolimus	drug	cyclosporine	drug
false

DDI-MedLine.d140.s1
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of DRUGA and DRUGB (INN, DRUGN) when coadministered in de novo kidney allograft recipients during the first year after transplantation.
everolimus	drug	cyclosporine	drug
false

DDI-MedLine.d140.s1
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of DRUGA and DRUGN (INN, DRUGB) when coadministered in de novo kidney allograft recipients during the first year after transplantation.
everolimus	drug	ciclosporin	drug
false

DDI-MedLine.d140.s1
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of DRUGN and DRUGA (INN, DRUGB) when coadministered in de novo kidney allograft recipients during the first year after transplantation.
cyclosporine	drug	ciclosporin	drug
false

DDI-MedLine.d140.s2
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive DRUGA tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with DRUGB and DRUGN.
everolimus	drug	cyclosporine	drug
false

DDI-MedLine.d140.s2
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive DRUGA tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with DRUGN and DRUGB.
everolimus	drug	prednisone	drug
false

DDI-MedLine.d140.s2
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive DRUGN tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with DRUGA and DRUGB.
cyclosporine	drug	prednisone	drug
false

DDI-MedLine.d140.s3
Blood sampling for the pharmacokinetics of DRUGA and DRUGB was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12.
everolimus	drug	cyclosporine	drug
false

DDI-MedLine.d140.s6
Potential differences in DRUGA dosing and pharmacokinetics at different levels of DRUGB exposure were assessed in the context of ANOVA.
cyclosporine	drug	everolimus	drug
false

DDI-MedLine.d140.s13
DRUGA doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered DRUGB dose level (P = .13, .82, and .76, respectively).
Cyclosporine	drug	everolimus	drug
false

DDI-MedLine.d140.s15
For a 4-fold range of DRUGA doses there were no differential effects on DRUGB dosing or pharmacokinetics.
everolimus	drug	cyclosporine	drug
false

DDI-MedLine.d87.s1
DRUGA is a novel DRUGB that may selectively prevent DRUGN-induced gastrointestinal effects without reversing analgesia.
ADL-8-2698	drug	peripherally restricted opioid antagonist	group
false

DDI-MedLine.d87.s1
DRUGN is a novel DRUGA that may selectively prevent DRUGB-induced gastrointestinal effects without reversing analgesia.
peripherally restricted opioid antagonist	group	opioid	group
false

DDI-MedLine.d87.s2
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous DRUGA (0.05 mg x kg(-1)), and oral DRUGB (4 mg) and intravenous DRUGA (0.05 mg x kg(-1)) in a double blind, cross-over study.
morphine	drug	ADL 8-2698	drug
false

DDI-MedLine.d87.s2
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous DRUGB (0.05 mg x kg(-1)), and oral DRUGA (4 mg) and intravenous DRUGB (0.05 mg x kg(-1)) in a double blind, cross-over study.
ADL 8-2698	drug	morphine	drug
false

DDI-MedLine.d87.s5
Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive DRUGA (4 mg) or placebo and intravenous DRUGB (0.15 mg/kg) or to receive oral and intravenous placebo.
ADL 8-2698	drug	morphine	drug
false

DDI-MedLine.d87.s7
DRUGA analgesia and pupil constriction were unaffected by DRUGB and differed from placebo (P < .002).
Morphine	drug	ADL 8-2698	drug
false

DDI-MedLine.d25.s1
OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of DRUGA and DRUGB.
clarithromycin	drug	simvastatin	drug
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGA inhibit the metabolism of DRUGB that are metabolized by CYP3A4 (i.e., DRUGN, DRUGN, DRUGN, DRUGN).
Macrolide antibiotics	group	HMG-CoA reductase inhibitors	group
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGN inhibit the metabolism of DRUGA that are metabolized by CYP3A4 (i.e., DRUGB, DRUGN, DRUGN, DRUGN).
HMG-CoA reductase inhibitors	group	atorvastatin	drug
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGN inhibit the metabolism of DRUGA that are metabolized by CYP3A4 (i.e., DRUGN, DRUGB, DRUGN, DRUGN).
HMG-CoA reductase inhibitors	group	cerivastatin	drug
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGN inhibit the metabolism of DRUGA that are metabolized by CYP3A4 (i.e., DRUGN, DRUGN, DRUGB, DRUGN).
HMG-CoA reductase inhibitors	group	lovastatin	drug
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGN inhibit the metabolism of DRUGA that are metabolized by CYP3A4 (i.e., DRUGN, DRUGN, DRUGN, DRUGB).
HMG-CoA reductase inhibitors	group	simvastatin	drug
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGN inhibit the metabolism of DRUGN that are metabolized by CYP3A4 (i.e., DRUGA, DRUGB, DRUGN, DRUGN).
atorvastatin	drug	cerivastatin	drug
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGN inhibit the metabolism of DRUGN that are metabolized by CYP3A4 (i.e., DRUGA, DRUGN, DRUGB, DRUGN).
atorvastatin	drug	lovastatin	drug
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGN inhibit the metabolism of DRUGN that are metabolized by CYP3A4 (i.e., DRUGA, DRUGN, DRUGN, DRUGB).
atorvastatin	drug	simvastatin	drug
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGN inhibit the metabolism of DRUGN that are metabolized by CYP3A4 (i.e., DRUGN, DRUGA, DRUGB, DRUGN).
cerivastatin	drug	lovastatin	drug
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGN inhibit the metabolism of DRUGN that are metabolized by CYP3A4 (i.e., DRUGN, DRUGA, DRUGN, DRUGB).
cerivastatin	drug	simvastatin	drug
false

DDI-MedLine.d25.s12
CONCLUSIONS: DRUGN inhibit the metabolism of DRUGN that are metabolized by CYP3A4 (i.e., DRUGN, DRUGN, DRUGA, DRUGB).
lovastatin	drug	simvastatin	drug
false

DDI-MedLine.d0.s0
The effects of concomitant DRUGA administration on the steady-state pharmacokinetics of DRUGB.
phenytoin	drug	quetiapine	drug
false

DDI-MedLine.d0.s1
DRUGA ('DRUGB') is a newly introduced DRUGN with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.
Quetiapine fumarate	drug	Seroquel	brand
false

DDI-MedLine.d0.s1
DRUGA ('DRUGN') is a newly introduced DRUGB with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.
Quetiapine fumarate	drug	atypical antipsychotic	group
false

DDI-MedLine.d0.s1
DRUGN ('DRUGA') is a newly introduced DRUGB with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.
Seroquel	brand	atypical antipsychotic	group
false

DDI-MedLine.d111.s2
DRUGA, DRUGB, DRUGN, DRUGN, DRUGN, and DRUGN were added to pooled human serum at therapeutic concentrations.
Acetaminophen	drug	lidocaine	drug
false

DDI-MedLine.d111.s2
DRUGA, DRUGN, DRUGB, DRUGN, DRUGN, and DRUGN were added to pooled human serum at therapeutic concentrations.
Acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d111.s2
DRUGA, DRUGN, DRUGN, DRUGB, DRUGN, and DRUGN were added to pooled human serum at therapeutic concentrations.
Acetaminophen	drug	quinidine	drug
false

DDI-MedLine.d111.s2
DRUGA, DRUGN, DRUGN, DRUGN, DRUGB, and DRUGN were added to pooled human serum at therapeutic concentrations.
Acetaminophen	drug	theophylline	drug
false

DDI-MedLine.d111.s2
DRUGA, DRUGN, DRUGN, DRUGN, DRUGN, and DRUGB were added to pooled human serum at therapeutic concentrations.
Acetaminophen	drug	valproic acid	drug
false

DDI-MedLine.d111.s2
DRUGN, DRUGA, DRUGB, DRUGN, DRUGN, and DRUGN were added to pooled human serum at therapeutic concentrations.
lidocaine	drug	phenobarbital	drug
false

DDI-MedLine.d111.s2
DRUGN, DRUGA, DRUGN, DRUGB, DRUGN, and DRUGN were added to pooled human serum at therapeutic concentrations.
lidocaine	drug	quinidine	drug
false

DDI-MedLine.d111.s2
DRUGN, DRUGA, DRUGN, DRUGN, DRUGB, and DRUGN were added to pooled human serum at therapeutic concentrations.
lidocaine	drug	theophylline	drug
false

DDI-MedLine.d111.s2
DRUGN, DRUGA, DRUGN, DRUGN, DRUGN, and DRUGB were added to pooled human serum at therapeutic concentrations.
lidocaine	drug	valproic acid	drug
false

DDI-MedLine.d111.s2
DRUGN, DRUGN, DRUGA, DRUGB, DRUGN, and DRUGN were added to pooled human serum at therapeutic concentrations.
phenobarbital	drug	quinidine	drug
false

DDI-MedLine.d111.s2
DRUGN, DRUGN, DRUGA, DRUGN, DRUGB, and DRUGN were added to pooled human serum at therapeutic concentrations.
phenobarbital	drug	theophylline	drug
false

DDI-MedLine.d111.s2
DRUGN, DRUGN, DRUGA, DRUGN, DRUGN, and DRUGB were added to pooled human serum at therapeutic concentrations.
phenobarbital	drug	valproic acid	drug
false

DDI-MedLine.d111.s2
DRUGN, DRUGN, DRUGN, DRUGA, DRUGB, and DRUGN were added to pooled human serum at therapeutic concentrations.
quinidine	drug	theophylline	drug
false

DDI-MedLine.d111.s2
DRUGN, DRUGN, DRUGN, DRUGA, DRUGN, and DRUGB were added to pooled human serum at therapeutic concentrations.
quinidine	drug	valproic acid	drug
false

DDI-MedLine.d111.s2
DRUGN, DRUGN, DRUGN, DRUGN, DRUGA, and DRUGB were added to pooled human serum at therapeutic concentrations.
theophylline	drug	valproic acid	drug
false

DDI-MedLine.d111.s4
The following eight target drug/added drug combinations were studied: DRUGA/DRUGB.
acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, and DRUGN/DRUGN.
acetaminophen	drug	theophylline	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGB/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGA, and DRUGN/DRUGN.
acetaminophen	drug	lidocaine	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGB, DRUGN/DRUGA, DRUGN/DRUGN, DRUGB/DRUGN, DRUGN/DRUGA, and DRUGN/DRUGN.
acetaminophen	drug	quinidine	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, DRUGB/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGN/DRUGB.
acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, DRUGB/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGN/DRUGB.
acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGB/DRUGN.
acetaminophen	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGB, DRUGN/DRUGA, DRUGN/DRUGN, DRUGB/DRUGN, DRUGN/DRUGA, and DRUGN/DRUGN.
acetaminophen	drug	quinidine	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGB/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGA, and DRUGN/DRUGN.
acetaminophen	drug	lidocaine	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, and DRUGN/DRUGN.
acetaminophen	drug	theophylline	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGB/DRUGN.
acetaminophen	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, DRUGB/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGN/DRUGB.
acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGB/DRUGN, DRUGN/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, DRUGA/DRUGN, and DRUGN/DRUGN.
theophylline	drug	lidocaine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, DRUGB/DRUGN, DRUGA/DRUGN, and DRUGN/DRUGN.
theophylline	drug	quinidine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGN/DRUGN, DRUGB/DRUGN, DRUGB/DRUGN, DRUGN/DRUGN, DRUGA/DRUGN, and DRUGN/DRUGB.
theophylline	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGA, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGB, and DRUGN/DRUGN.
theophylline	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGN/DRUGN, DRUGB/DRUGN, DRUGB/DRUGN, DRUGN/DRUGN, DRUGA/DRUGN, and DRUGN/DRUGB.
theophylline	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, DRUGA/DRUGN, and DRUGB/DRUGN.
theophylline	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, DRUGB/DRUGN, DRUGA/DRUGN, and DRUGN/DRUGN.
theophylline	drug	quinidine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGB/DRUGN, DRUGN/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, DRUGA/DRUGN, and DRUGN/DRUGN.
theophylline	drug	lidocaine	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGA, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGB, and DRUGN/DRUGN.
theophylline	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, DRUGA/DRUGN, and DRUGB/DRUGN.
theophylline	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGN/DRUGN, DRUGB/DRUGN, DRUGB/DRUGN, DRUGN/DRUGN, DRUGA/DRUGN, and DRUGN/DRUGB.
theophylline	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGA/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, DRUGN/DRUGN, and DRUGN/DRUGN.
lidocaine	drug	quinidine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGA/DRUGN, DRUGB/DRUGN, DRUGB/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, and DRUGN/DRUGB.
lidocaine	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGN, DRUGA/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, and DRUGN/DRUGN.
lidocaine	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGA/DRUGN, DRUGB/DRUGN, DRUGB/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, and DRUGN/DRUGB.
lidocaine	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGA, DRUGN/DRUGN, and DRUGB/DRUGN.
lidocaine	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGA/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, DRUGN/DRUGN, and DRUGN/DRUGN.
lidocaine	drug	quinidine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGB, DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, DRUGB/DRUGN, and DRUGN/DRUGN.
lidocaine	drug	theophylline	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGN, DRUGA/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, and DRUGN/DRUGN.
lidocaine	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGA, DRUGN/DRUGN, and DRUGB/DRUGN.
lidocaine	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGA/DRUGN, DRUGB/DRUGN, DRUGB/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, and DRUGN/DRUGB.
lidocaine	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGA, DRUGB/DRUGN, DRUGB/DRUGN, DRUGA/DRUGN, DRUGN/DRUGN, and DRUGN/DRUGB.
quinidine	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, DRUGA/DRUGN, DRUGN/DRUGB, and DRUGN/DRUGN.
quinidine	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGA, DRUGB/DRUGN, DRUGB/DRUGN, DRUGA/DRUGN, DRUGN/DRUGN, and DRUGN/DRUGB.
quinidine	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGB, DRUGA/DRUGN, DRUGN/DRUGN, and DRUGB/DRUGN.
quinidine	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGB/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGB, DRUGN/DRUGN, and DRUGN/DRUGN.
quinidine	drug	lidocaine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGB, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGN, DRUGB/DRUGN, and DRUGN/DRUGN.
quinidine	drug	theophylline	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, DRUGA/DRUGN, DRUGN/DRUGB, and DRUGN/DRUGN.
quinidine	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGB, DRUGA/DRUGN, DRUGN/DRUGN, and DRUGB/DRUGN.
quinidine	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGA, DRUGB/DRUGN, DRUGB/DRUGN, DRUGA/DRUGN, DRUGN/DRUGN, and DRUGN/DRUGB.
quinidine	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGN, DRUGN/DRUGN, DRUGA/DRUGB, DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, and DRUGN/DRUGA.
phenobarbital	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGN, DRUGA/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, and DRUGB/DRUGA.
phenobarbital	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGB, DRUGA/DRUGN, DRUGA/DRUGN, DRUGB/DRUGN, DRUGN/DRUGN, and DRUGN/DRUGA.
phenobarbital	drug	quinidine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGB/DRUGN, DRUGA/DRUGN, DRUGA/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, and DRUGN/DRUGA.
phenobarbital	drug	lidocaine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGB, DRUGN/DRUGN, DRUGA/DRUGN, DRUGA/DRUGN, DRUGN/DRUGN, DRUGB/DRUGN, and DRUGN/DRUGA.
phenobarbital	drug	theophylline	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGN, DRUGN/DRUGN, DRUGA/DRUGB, DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, and DRUGN/DRUGA.
phenobarbital	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGN, DRUGA/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, and DRUGB/DRUGA.
phenobarbital	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, DRUGB/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGN/DRUGB.
acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGB/DRUGN.
acetaminophen	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGB, DRUGN/DRUGA, DRUGN/DRUGN, DRUGB/DRUGN, DRUGN/DRUGA, and DRUGN/DRUGN.
acetaminophen	drug	quinidine	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGB/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGA, and DRUGN/DRUGN.
acetaminophen	drug	lidocaine	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, and DRUGN/DRUGN.
acetaminophen	drug	theophylline	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGB/DRUGN.
acetaminophen	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, DRUGB/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGN/DRUGB.
acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGN, DRUGA/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, and DRUGB/DRUGA.
phenobarbital	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGB, DRUGA/DRUGN, DRUGA/DRUGN, DRUGB/DRUGN, DRUGN/DRUGN, and DRUGN/DRUGA.
phenobarbital	drug	quinidine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGB/DRUGN, DRUGA/DRUGN, DRUGA/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, and DRUGN/DRUGA.
phenobarbital	drug	lidocaine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGB, DRUGN/DRUGN, DRUGA/DRUGN, DRUGA/DRUGN, DRUGN/DRUGN, DRUGB/DRUGN, and DRUGN/DRUGA.
phenobarbital	drug	theophylline	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGN, DRUGN/DRUGN, DRUGA/DRUGB, DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, and DRUGN/DRUGA.
phenobarbital	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGN, DRUGA/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, and DRUGB/DRUGA.
phenobarbital	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, DRUGB/DRUGN, DRUGN/DRUGN, and DRUGA/DRUGN.
valproic acid	drug	quinidine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGB/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, and DRUGA/DRUGN.
valproic acid	drug	lidocaine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, DRUGB/DRUGN, and DRUGA/DRUGN.
valproic acid	drug	theophylline	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGB, and DRUGA/DRUGN.
valproic acid	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGN, DRUGB/DRUGN, DRUGB/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, and DRUGA/DRUGB.
valproic acid	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGB/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGB, DRUGN/DRUGN, and DRUGN/DRUGN.
quinidine	drug	lidocaine	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGB, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGN, DRUGB/DRUGN, and DRUGN/DRUGN.
quinidine	drug	theophylline	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, DRUGA/DRUGN, DRUGN/DRUGB, and DRUGN/DRUGN.
quinidine	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGB, DRUGA/DRUGN, DRUGN/DRUGN, and DRUGB/DRUGN.
quinidine	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGA, DRUGB/DRUGN, DRUGB/DRUGN, DRUGA/DRUGN, DRUGN/DRUGN, and DRUGN/DRUGB.
quinidine	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGB, DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, DRUGB/DRUGN, and DRUGN/DRUGN.
lidocaine	drug	theophylline	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGN, DRUGA/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, and DRUGN/DRUGN.
lidocaine	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGA, DRUGN/DRUGN, and DRUGB/DRUGN.
lidocaine	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGA/DRUGN, DRUGB/DRUGN, DRUGB/DRUGN, DRUGN/DRUGA, DRUGN/DRUGN, and DRUGN/DRUGB.
lidocaine	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGB/DRUGA, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGN, DRUGA/DRUGB, and DRUGN/DRUGN.
theophylline	drug	acetaminophen	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, DRUGN/DRUGB, DRUGN/DRUGN, DRUGA/DRUGN, and DRUGB/DRUGN.
theophylline	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGA, DRUGN/DRUGN, DRUGB/DRUGN, DRUGB/DRUGN, DRUGN/DRUGN, DRUGA/DRUGN, and DRUGN/DRUGB.
theophylline	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, DRUGN/DRUGB, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGB/DRUGN.
acetaminophen	drug	valproic acid	drug
false

DDI-MedLine.d111.s5
DRUGA/DRUGN, DRUGN/DRUGN, DRUGB/DRUGA, DRUGB/DRUGN, DRUGN/DRUGN, DRUGN/DRUGA, and DRUGN/DRUGB.
acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d111.s5
DRUGN/DRUGN, DRUGN/DRUGN, DRUGB/DRUGN, DRUGB/DRUGA, DRUGN/DRUGN, DRUGN/DRUGN, and DRUGA/DRUGB.
valproic acid	drug	phenobarbital	drug
false

DDI-MedLine.d111.s7
Similarly dialyzed were DRUGA, DRUGB, and DRUGN, both alone at therapeutic concentrations in serum and with DRUGN at three different concentrations in serum.
phenobarbital	drug	quinidine	drug
false

DDI-MedLine.d111.s7
Similarly dialyzed were DRUGA, DRUGN, and DRUGB, both alone at therapeutic concentrations in serum and with DRUGN at three different concentrations in serum.
phenobarbital	drug	theophylline	drug
false

DDI-MedLine.d111.s7
Similarly dialyzed were DRUGA, DRUGN, and DRUGN, both alone at therapeutic concentrations in serum and with DRUGB at three different concentrations in serum.
phenobarbital	drug	ethanol	drug
false

DDI-MedLine.d111.s7
Similarly dialyzed were DRUGN, DRUGA, and DRUGB, both alone at therapeutic concentrations in serum and with DRUGN at three different concentrations in serum.
quinidine	drug	theophylline	drug
false

DDI-MedLine.d111.s7
Similarly dialyzed were DRUGN, DRUGA, and DRUGN, both alone at therapeutic concentrations in serum and with DRUGB at three different concentrations in serum.
quinidine	drug	ethanol	drug
false

DDI-MedLine.d111.s7
Similarly dialyzed were DRUGN, DRUGN, and DRUGA, both alone at therapeutic concentrations in serum and with DRUGB at three different concentrations in serum.
theophylline	drug	ethanol	drug
false

DDI-MedLine.d111.s14
Coingestion of DRUGA with DRUGN, DRUGB with DRUGA, and DRUGN with DRUGB at high to toxic concentrations decreases the binding of the target drug.
acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d111.s14
Coingestion of DRUGA with DRUGN, DRUGN with DRUGA, and DRUGB with DRUGN at high to toxic concentrations decreases the binding of the target drug.
acetaminophen	drug	valproic acid	drug
false

DDI-MedLine.d111.s14
Coingestion of DRUGA with DRUGN, DRUGB with DRUGA, and DRUGN with DRUGB at high to toxic concentrations decreases the binding of the target drug.
acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d111.s14
Coingestion of DRUGN with DRUGA, DRUGB with DRUGN, and DRUGN with DRUGB at high to toxic concentrations decreases the binding of the target drug.
theophylline	drug	phenobarbital	drug
false

DDI-MedLine.d111.s14
Coingestion of DRUGB with DRUGA, DRUGN with DRUGB, and DRUGN with DRUGN at high to toxic concentrations decreases the binding of the target drug.
theophylline	drug	acetaminophen	drug
false

DDI-MedLine.d111.s14
Coingestion of DRUGN with DRUGA, DRUGN with DRUGN, and DRUGB with DRUGN at high to toxic concentrations decreases the binding of the target drug.
theophylline	drug	valproic acid	drug
false

DDI-MedLine.d111.s14
Coingestion of DRUGN with DRUGA, DRUGB with DRUGN, and DRUGN with DRUGB at high to toxic concentrations decreases the binding of the target drug.
theophylline	drug	phenobarbital	drug
false

DDI-MedLine.d111.s14
Coingestion of DRUGN with DRUGN, DRUGA with DRUGN, and DRUGB with DRUGA at high to toxic concentrations decreases the binding of the target drug.
phenobarbital	drug	valproic acid	drug
false

DDI-MedLine.d111.s14
Coingestion of DRUGA with DRUGN, DRUGN with DRUGA, and DRUGB with DRUGN at high to toxic concentrations decreases the binding of the target drug.
acetaminophen	drug	valproic acid	drug
false

DDI-MedLine.d111.s14
Coingestion of DRUGA with DRUGN, DRUGB with DRUGA, and DRUGN with DRUGB at high to toxic concentrations decreases the binding of the target drug.
acetaminophen	drug	phenobarbital	drug
false

DDI-MedLine.d60.s2
The serum concentration of DRUGA increased dramatically from 16.6 to 49.1 microg/mL when DRUGB was coadministered, although the daily dosage of DRUGA and other DRUGN had not changed.
phenytoin	drug	fluvoxamine	drug
false

DDI-MedLine.d60.s2
The serum concentration of DRUGA increased dramatically from 16.6 to 49.1 microg/mL when DRUGN was coadministered, although the daily dosage of DRUGA and other DRUGB had not changed.
phenytoin	drug	drugs	drug
false

DDI-MedLine.d60.s2
The serum concentration of DRUGB increased dramatically from 16.6 to 49.1 microg/mL when DRUGA was coadministered, although the daily dosage of DRUGB and other DRUGN had not changed.
fluvoxamine	drug	phenytoin	drug
false

DDI-MedLine.d60.s2
The serum concentration of DRUGN increased dramatically from 16.6 to 49.1 microg/mL when DRUGA was coadministered, although the daily dosage of DRUGN and other DRUGB had not changed.
fluvoxamine	drug	drugs	drug
false

DDI-MedLine.d60.s2
The serum concentration of DRUGA increased dramatically from 16.6 to 49.1 microg/mL when DRUGN was coadministered, although the daily dosage of DRUGA and other DRUGB had not changed.
phenytoin	drug	drugs	drug
false

DDI-MedLine.d60.s5
The interaction may be a result of inhibition of both DRUGA and 2C19 by DRUGB.
CYP2C9	drug	fluvoxamine	drug
false

DDI-MedLine.d123.s2
Here we show that a combination of DRUGA or 3,7-dihydroxyflavone with DRUGB may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of DRUGB-sensitive strains.
galangin	drug	vancomycin	drug
false

DDI-MedLine.d137.s0
DRUGA and DRUGB exert additive ocular and renal vasodilator effects on healthy humans.
Glucose	drug	insulin	drug
false

DDI-MedLine.d137.s1
AIMS/HYPOTHESIS: There is evidence that DRUGA and DRUGB cause renal and ocular vasodilation.
insulin	drug	glucose	drug
false

DDI-MedLine.d137.s9
Haemodynamic effects of DRUGA and DRUGB were additive when DRUGN was co-administered but not under basal conditions.
glucose	drug	insulin	drug
false

DDI-MedLine.d137.s9
Haemodynamic effects of DRUGA and DRUGN were additive when DRUGB was co-administered but not under basal conditions.
glucose	drug	somatostatin	drug
false

DDI-MedLine.d137.s9
Haemodynamic effects of DRUGN and DRUGA were additive when DRUGB was co-administered but not under basal conditions.
insulin	drug	somatostatin	drug
false

DDI-MedLine.d137.s10
CONCLUSIONS/INTERPRETATION: DRUGA and DRUGB can exert additive vasodilator properties on renal and ocular circulation.
Glucose	drug	insulin	drug
false

DDI-MedLine.d124.s0
Lack of interaction between DRUGA and DRUGB: pharmacokinetics and drug disposition.
levofloxacin	drug	oxycodone	drug
false

DDI-MedLine.d124.s1
Previous studies have demonstrated a significant reduction in the oral bioavailability of DRUGA and DRUGB when administered concomitantly with an intravenous DRUGN such as DRUGN.
trovafloxacin	drug	ciprofloxacin	drug
false

DDI-MedLine.d124.s1
Previous studies have demonstrated a significant reduction in the oral bioavailability of DRUGN and DRUGN when administered concomitantly with an intravenous DRUGA such as DRUGB.
opiate	group	morphine	drug
false

DDI-MedLine.d124.s2
This decrease in absorption results in a 36% and 50% lower AUC for DRUGA and DRUGB, respectively, which could cause clinical failures.
trovafloxacin	drug	ciprofloxacin	drug
false

DDI-MedLine.d124.s3
The authors investigated the possibility of a similar interaction between DRUGA and DRUGB.
oxycodone	drug	levofloxacin	drug
false

DDI-MedLine.d124.s6
1 hour after starting the DRUGA or DRUGB 500 mg p.o.
oxycodone	drug	levofloxacin	drug
false

DDI-MedLine.d124.s9
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for DRUGA versus DRUGA/DRUGB regimens.
levofloxacin	drug	oxycodone	drug
false

DDI-MedLine.d124.s9
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for DRUGA versus DRUGA/DRUGB regimens.
levofloxacin	drug	oxycodone	drug
false

DDI-MedLine.d124.s10
It was concluded that oral DRUGA and DRUGB can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.
oxycodone	drug	levofloxacin	drug
false

DDI-MedLine.d105.s0
Lack of an effect of DRUGA on the disposition of DRUGB and DRUGN in HIV-infected patients.
azithromycin	drug	zidovudine	drug
false

DDI-MedLine.d105.s0
Lack of an effect of DRUGA on the disposition of DRUGN and DRUGB in HIV-infected patients.
azithromycin	drug	dideoxyinosine	drug
false

DDI-MedLine.d105.s0
Lack of an effect of DRUGN on the disposition of DRUGA and DRUGB in HIV-infected patients.
zidovudine	drug	dideoxyinosine	drug
false

DDI-MedLine.d105.s1
Two studies were conducted in HIV-infected subjects to assess the potential for DRUGA to interact with DRUGB and DRUGN.
azithromycin	drug	zidovudine	drug
false

DDI-MedLine.d105.s1
Two studies were conducted in HIV-infected subjects to assess the potential for DRUGA to interact with DRUGN and DRUGB.
azithromycin	drug	dideoxyinosine	drug
false

DDI-MedLine.d105.s1
Two studies were conducted in HIV-infected subjects to assess the potential for DRUGN to interact with DRUGA and DRUGB.
zidovudine	drug	dideoxyinosine	drug
false

DDI-MedLine.d105.s3
The DRUGA study dosed subjects with 1200 mg/day of DRUGB (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of DRUGA.
zidovudine	drug	azithromycin	drug
false

DDI-MedLine.d105.s3
The DRUGB study dosed subjects with 1200 mg/day of DRUGA (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of DRUGB.
azithromycin	drug	zidovudine	drug
false

DDI-MedLine.d105.s4
Subjects treated with 200 mg of DRUGA twice daily for 21 days received 1200 mg of DRUGB or an equivalent amount of placebo/day for Days 8 to 21.
dideoxyinosine	drug	azithromycin	drug
false

DDI-MedLine.d105.s7
DRUGA had no significant impact on the Cmax and AUC of DRUGB, although it significantly decreased the DRUGB tmax by 44% and increased the intracellular exposure to phosphorylated DRUGB by 110%.
Azithromycin	drug	zidovudine	drug
false

DDI-MedLine.d105.s8
DRUGA had no significant effect on DRUGB pharmacokinetics.
Azithromycin	drug	dideoxyinosine	drug
false

DDI-MedLine.d105.s9
Based on the results of these studies, it is concluded that DRUGA may be safely coadministered with both DRUGB and DRUGN.
azithromycin	drug	zidovudine	drug
false

DDI-MedLine.d105.s9
Based on the results of these studies, it is concluded that DRUGA may be safely coadministered with both DRUGN and DRUGB.
azithromycin	drug	dideoxyinosine	drug
false

DDI-MedLine.d105.s9
Based on the results of these studies, it is concluded that DRUGN may be safely coadministered with both DRUGA and DRUGB.
zidovudine	drug	dideoxyinosine	drug
false

DDI-MedLine.d67.s0
Effect of DRUGA and DRUGB on the antinociceptive effect of DRUGN, DRUGN and DRUGN in mice.
diazepam	drug	midazolam	drug
false

DDI-MedLine.d67.s0
Effect of DRUGA and DRUGN on the antinociceptive effect of DRUGB, DRUGN and DRUGN in mice.
diazepam	drug	morphine	drug
false

DDI-MedLine.d67.s0
Effect of DRUGA and DRUGN on the antinociceptive effect of DRUGN, DRUGB and DRUGN in mice.
diazepam	drug	metamizol	drug
false

DDI-MedLine.d67.s0
Effect of DRUGA and DRUGN on the antinociceptive effect of DRUGN, DRUGN and DRUGB in mice.
diazepam	drug	indomethacin	drug
false

DDI-MedLine.d67.s0
Effect of DRUGN and DRUGA on the antinociceptive effect of DRUGB, DRUGN and DRUGN in mice.
midazolam	drug	morphine	drug
false

DDI-MedLine.d67.s0
Effect of DRUGN and DRUGA on the antinociceptive effect of DRUGN, DRUGB and DRUGN in mice.
midazolam	drug	metamizol	drug
false

DDI-MedLine.d67.s0
Effect of DRUGN and DRUGA on the antinociceptive effect of DRUGN, DRUGN and DRUGB in mice.
midazolam	drug	indomethacin	drug
false

DDI-MedLine.d67.s0
Effect of DRUGN and DRUGN on the antinociceptive effect of DRUGA, DRUGB and DRUGN in mice.
morphine	drug	metamizol	drug
false

DDI-MedLine.d67.s0
Effect of DRUGN and DRUGN on the antinociceptive effect of DRUGA, DRUGN and DRUGB in mice.
morphine	drug	indomethacin	drug
false

DDI-MedLine.d67.s0
Effect of DRUGN and DRUGN on the antinociceptive effect of DRUGN, DRUGA and DRUGB in mice.
metamizol	drug	indomethacin	drug
false

DDI-MedLine.d67.s1
The influence of DRUGA and DRUGB on antinociceptive effect of DRUGN (10 mg/kg), DRUGN (500 mg/kg) and DRUGN (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
midazolam	drug	diazepam	drug
false

DDI-MedLine.d67.s1
The influence of DRUGA and DRUGN on antinociceptive effect of DRUGB (10 mg/kg), DRUGN (500 mg/kg) and DRUGN (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
midazolam	drug	morphine	drug
false

DDI-MedLine.d67.s1
The influence of DRUGA and DRUGN on antinociceptive effect of DRUGN (10 mg/kg), DRUGB (500 mg/kg) and DRUGN (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
midazolam	drug	metamizol	drug
false

DDI-MedLine.d67.s1
The influence of DRUGA and DRUGN on antinociceptive effect of DRUGN (10 mg/kg), DRUGN (500 mg/kg) and DRUGB (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
midazolam	drug	indomethacin	drug
false

DDI-MedLine.d67.s1
The influence of DRUGN and DRUGA on antinociceptive effect of DRUGB (10 mg/kg), DRUGN (500 mg/kg) and DRUGN (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
diazepam	drug	morphine	drug
false

DDI-MedLine.d67.s1
The influence of DRUGN and DRUGA on antinociceptive effect of DRUGN (10 mg/kg), DRUGB (500 mg/kg) and DRUGN (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
diazepam	drug	metamizol	drug
false

DDI-MedLine.d67.s1
The influence of DRUGN and DRUGA on antinociceptive effect of DRUGN (10 mg/kg), DRUGN (500 mg/kg) and DRUGB (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
diazepam	drug	indomethacin	drug
false

DDI-MedLine.d67.s1
The influence of DRUGN and DRUGN on antinociceptive effect of DRUGA (10 mg/kg), DRUGB (500 mg/kg) and DRUGN (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
morphine	drug	metamizol	drug
false

DDI-MedLine.d67.s1
The influence of DRUGN and DRUGN on antinociceptive effect of DRUGA (10 mg/kg), DRUGN (500 mg/kg) and DRUGB (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
morphine	drug	indomethacin	drug
false

DDI-MedLine.d67.s1
The influence of DRUGN and DRUGN on antinociceptive effect of DRUGN (10 mg/kg), DRUGA (500 mg/kg) and DRUGB (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
metamizol	drug	indomethacin	drug
false

DDI-MedLine.d67.s3
DRUGA were administered to mice 30 min before applying the DRUGB.
Benzodiazepines	group	analgesic drugs	group
false

DDI-MedLine.d67.s5
DRUGA at doses of 0.25 mg/kg and 2.5 mg/kg injected with DRUGB was found to decrease the antinociceptive effect of DRUGB.
Diazepam	drug	morphine	drug
false

DDI-MedLine.d67.s6
Similarly, DRUGN decreased the antinociceptive effect of DRUGA (only in the tail-flick test) and DRUGB.
metamizol	drug	indomethacin	drug
false

DDI-MedLine.d67.s7
DRUGN used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of DRUGA, DRUGB (only in the tail-flick test) and DRUGN.
morphine	drug	metamizol	drug
false

DDI-MedLine.d67.s7
DRUGN used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of DRUGA, DRUGN (only in the tail-flick test) and DRUGB.
morphine	drug	indomethacin	drug
false

DDI-MedLine.d67.s7
DRUGN used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of DRUGN, DRUGA (only in the tail-flick test) and DRUGB.
metamizol	drug	indomethacin	drug
false

DDI-MedLine.d102.s0
Influence of DRUGA and DRUGB on the sensitivity of rat thoracic aorta to DRUGN.
estradiol	drug	progesterone	drug
false

DDI-MedLine.d102.s0
Influence of DRUGA and DRUGN on the sensitivity of rat thoracic aorta to DRUGB.
estradiol	drug	noradrenaline	drug
false

DDI-MedLine.d102.s0
Influence of DRUGN and DRUGA on the sensitivity of rat thoracic aorta to DRUGB.
progesterone	drug	noradrenaline	drug
false

DDI-MedLine.d102.s1
The aim of this study was to investigate the effects of low and high doses of DRUGA, and of DRUGB on the response to DRUGN in rat thoracic aorta.
estradiol	drug	progesterone	drug
false

DDI-MedLine.d102.s1
The aim of this study was to investigate the effects of low and high doses of DRUGA, and of DRUGN on the response to DRUGB in rat thoracic aorta.
estradiol	drug	noradrenaline	drug
false

DDI-MedLine.d102.s1
The aim of this study was to investigate the effects of low and high doses of DRUGN, and of DRUGA on the response to DRUGB in rat thoracic aorta.
progesterone	drug	noradrenaline	drug
false

DDI-MedLine.d102.s3
injection of vehicle (corn oil, 0.1 mL/day), DRUGA (10 microg/kg/day or 4 mg/kg/day) and/or DRUGB (20 mg/kg/day), for eight days.
estradiol	drug	progesterone	drug
false

DDI-MedLine.d102.s6
Endothelium-intact aortic rings from high-DRUGA rats were supersensitive to DRUGN when compared to vehicle-, DRUGB- and DRUGB + high-DRUGA-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
estradiol	drug	progesterone	drug
false

DDI-MedLine.d102.s6
Endothelium-intact aortic rings from high-DRUGA rats were supersensitive to DRUGN when compared to vehicle-, DRUGB- and DRUGB + high-DRUGA-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
estradiol	drug	progesterone	drug
false

DDI-MedLine.d102.s6
Endothelium-intact aortic rings from high-DRUGN rats were supersensitive to DRUGA when compared to vehicle-, DRUGB- and DRUGB + high-DRUGN-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
noradrenaline	drug	progesterone	drug
false

DDI-MedLine.d102.s6
Endothelium-intact aortic rings from high-DRUGN rats were supersensitive to DRUGA when compared to vehicle-, DRUGB- and DRUGB + high-DRUGN-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
noradrenaline	drug	progesterone	drug
false

DDI-MedLine.d102.s6
Endothelium-intact aortic rings from high-DRUGB rats were supersensitive to DRUGA when compared to vehicle-, DRUGN- and DRUGN + high-DRUGB-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
noradrenaline	drug	estradiol	drug
false

DDI-MedLine.d102.s6
Endothelium-intact aortic rings from high-DRUGB rats were supersensitive to DRUGN when compared to vehicle-, DRUGA- and DRUGA + high-DRUGB-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
progesterone	drug	estradiol	drug
false

DDI-MedLine.d102.s6
Endothelium-intact aortic rings from high-DRUGB rats were supersensitive to DRUGN when compared to vehicle-, DRUGA- and DRUGA + high-DRUGB-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
progesterone	drug	estradiol	drug
false

DDI-MedLine.d1.s5
DRUGN is contraindicated in patients using DRUGA or who may need to use DRUGB, because the combination may cause a sharp fall of the blood pressure.
long-acting nitrates	group	short-acting nitrates	group
false

DDI-MedLine.d1.s6
No interactions have been observed with DRUGA, DRUGB, DRUGN and DRUGN and DRUGN.
beta-receptor blockers	group	calcium antagonists	group
false

DDI-MedLine.d1.s6
No interactions have been observed with DRUGA, DRUGN, DRUGB and DRUGN and DRUGN.
beta-receptor blockers	group	thiazide diuretics	group
false

DDI-MedLine.d1.s6
No interactions have been observed with DRUGA, DRUGN, DRUGN and DRUGB and DRUGN.
beta-receptor blockers	group	loop diuretics	group
false

DDI-MedLine.d1.s6
No interactions have been observed with DRUGA, DRUGN, DRUGN and DRUGN and DRUGB.
beta-receptor blockers	group	ACE inhibitors	group
false

DDI-MedLine.d1.s6
No interactions have been observed with DRUGN, DRUGA, DRUGB and DRUGN and DRUGN.
calcium antagonists	group	thiazide diuretics	group
false

DDI-MedLine.d1.s6
No interactions have been observed with DRUGN, DRUGA, DRUGN and DRUGB and DRUGN.
calcium antagonists	group	loop diuretics	group
false

DDI-MedLine.d1.s6
No interactions have been observed with DRUGN, DRUGA, DRUGN and DRUGN and DRUGB.
calcium antagonists	group	ACE inhibitors	group
false

DDI-MedLine.d1.s6
No interactions have been observed with DRUGN, DRUGN, DRUGA and DRUGB and DRUGN.
thiazide diuretics	group	loop diuretics	group
false

DDI-MedLine.d1.s6
No interactions have been observed with DRUGN, DRUGN, DRUGA and DRUGN and DRUGB.
thiazide diuretics	group	ACE inhibitors	group
false

DDI-MedLine.d1.s6
No interactions have been observed with DRUGN, DRUGN, DRUGN and DRUGA and DRUGB.
loop diuretics	group	ACE inhibitors	group
false

DDI-MedLine.d46.s0
Influence of coadministration of DRUGA on DRUGB pharmacokinetics and QTc intervals in healthy volunteers.
fluoxetine	drug	cisapride	drug
false

DDI-MedLine.d46.s1
STUDY OBJECTIVE: To evaluate the effect of DRUGA on the pharmacokinetics and cardiovascular safety of DRUGB at steady state in healthy men.
fluoxetine	drug	cisapride	drug
false

DDI-MedLine.d46.s9
and phase 3 (days 45-52): DRUGA 10 mg 4 times/day (days 45-51) plus DRUGB 20 mg/day (days 45-52).
cisapride	drug	fluoxetine	drug
false

DDI-MedLine.d46.s14
There were no clinically significant changes in corrected QT intervals during administration of DRUGA alone or with DRUGB.
cisapride	drug	fluoxetine	drug
false

DDI-MedLine.d46.s15
DRUGA was well tolerated when administered alone or with DRUGB.
Cisapride	drug	fluoxetine	drug
false

DDI-MedLine.d46.s16
CONCLUSION: DRUGA can be administered safely to patients receiving low therapeutic dosages of DRUGB.
Cisapride	drug	fluoxetine	drug
false

DDI-MedLine.d83.s1
DRUGA, a DRUGB, is a DRUGN which has proven efficacy against the positive and negative symptoms of schizophrenia.
Olanzapine	drug	thienobenzodiazepine derivative	group
false

DDI-MedLine.d83.s1
DRUGA, a DRUGN, is a DRUGB which has proven efficacy against the positive and negative symptoms of schizophrenia.
Olanzapine	drug	second generation (atypical) antipsychotic agent	group
false

DDI-MedLine.d83.s1
DRUGN, a DRUGA, is a DRUGB which has proven efficacy against the positive and negative symptoms of schizophrenia.
thienobenzodiazepine derivative	group	second generation (atypical) antipsychotic agent	group
false

DDI-MedLine.d83.s3
In large, well controlled trials in patients with schizophrenia or related psychoses, DRUGA 5 to 20 mg/day was significantly superior to DRUGB 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms.
olanzapine	drug	haloperidol	drug
false

DDI-MedLine.d83.s4
The 1-year risk of relapse (rehospitalisation) was significantly lower with DRUGA than with DRUGB treatment.
olanzapine	drug	haloperidol	drug
false

DDI-MedLine.d83.s5
In the first double-blind comparative study (28-week) of DRUGA and DRUGB, DRUGA 10 to 20 mg/day proved to be significantly more effective than DRUGB 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.
olanzapine	drug	risperidone	drug
false

DDI-MedLine.d83.s5
In the first double-blind comparative study (28-week) of DRUGA and DRUGB, DRUGA 10 to 20 mg/day proved to be significantly more effective than DRUGB 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.
olanzapine	drug	risperidone	drug
false

DDI-MedLine.d83.s5
In the first double-blind comparative study (28-week) of DRUGB and DRUGA, DRUGB 10 to 20 mg/day proved to be significantly more effective than DRUGA 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.
risperidone	drug	olanzapine	drug
false

DDI-MedLine.d83.s5
In the first double-blind comparative study (28-week) of DRUGA and DRUGB, DRUGA 10 to 20 mg/day proved to be significantly more effective than DRUGB 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.
olanzapine	drug	risperidone	drug
false

DDI-MedLine.d83.s6
In contrast, preliminary results from an 8-week controlled study suggested DRUGA 2 to 6 mg/day was superior to DRUGB 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology.
risperidone	drug	olanzapine	drug
false

DDI-MedLine.d83.s7
Improvements in general cognitive function seen with DRUGA treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either DRUGB or DRUGN.
olanzapine	drug	risperidone	drug
false

DDI-MedLine.d83.s7
Improvements in general cognitive function seen with DRUGA treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either DRUGN or DRUGB.
olanzapine	drug	haloperidol	drug
false

DDI-MedLine.d83.s7
Improvements in general cognitive function seen with DRUGN treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either DRUGA or DRUGB.
risperidone	drug	haloperidol	drug
false

DDI-MedLine.d83.s8
However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of DRUGA and DRUGB treatment in patients with schizophrenia or schizoaffective disorder.
olanzapine	drug	risperidone	drug
false

DDI-MedLine.d83.s10
DRUGA is associated with significantly fewer extrapyramidal symptoms than DRUGB and DRUGN.
Olanzapine	drug	haloperidol	drug
false

DDI-MedLine.d83.s10
DRUGA is associated with significantly fewer extrapyramidal symptoms than DRUGN and DRUGB.
Olanzapine	drug	risperidone	drug
false

DDI-MedLine.d83.s10
DRUGN is associated with significantly fewer extrapyramidal symptoms than DRUGA and DRUGB.
haloperidol	drug	risperidone	drug
false

DDI-MedLine.d83.s11
In addition, DRUGA is not associated with a risk of agranulocytosis as seen with DRUGB or clinically significant hyperprolactinaemia as seen with DRUGN or prolongation of the QT interval.
olanzapine	drug	clozapine	drug
false

DDI-MedLine.d83.s11
In addition, DRUGA is not associated with a risk of agranulocytosis as seen with DRUGN or clinically significant hyperprolactinaemia as seen with DRUGB or prolongation of the QT interval.
olanzapine	drug	risperidone	drug
false

DDI-MedLine.d83.s11
In addition, DRUGN is not associated with a risk of agranulocytosis as seen with DRUGA or clinically significant hyperprolactinaemia as seen with DRUGB or prolongation of the QT interval.
clozapine	drug	risperidone	drug
false

DDI-MedLine.d83.s13
In comparison with DRUGA, the adverse events reported significantly more frequently with DRUGB in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with DRUGN, only bodyweight gain occurred significantly more frequently with DRUGB.
haloperidol	drug	olanzapine	drug
false

DDI-MedLine.d83.s13
In comparison with DRUGA, the adverse events reported significantly more frequently with DRUGN in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with DRUGB, only bodyweight gain occurred significantly more frequently with DRUGN.
haloperidol	drug	risperidone	drug
false

DDI-MedLine.d83.s13
In comparison with DRUGA, the adverse events reported significantly more frequently with DRUGB in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with DRUGN, only bodyweight gain occurred significantly more frequently with DRUGB.
haloperidol	drug	olanzapine	drug
false

DDI-MedLine.d83.s13
In comparison with DRUGN, the adverse events reported significantly more frequently with DRUGA in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with DRUGB, only bodyweight gain occurred significantly more frequently with DRUGA.
olanzapine	drug	risperidone	drug
false

DDI-MedLine.d83.s13
In comparison with DRUGN, the adverse events reported significantly more frequently with DRUGB in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with DRUGA, only bodyweight gain occurred significantly more frequently with DRUGB.
risperidone	drug	olanzapine	drug
false

DDI-MedLine.d83.s15
Pharmacoeconomic analyses indicate that DRUGA does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with DRUGB.
olanzapine	drug	haloperidol	drug
false

DDI-MedLine.d83.s16
Compared with DRUGA, DRUGB has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug.
risperidone	drug	olanzapine	drug
false

DDI-MedLine.d83.s17
DRUGA treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than DRUGB, and to broadly the same extent as DRUGN.
Olanzapine	drug	haloperidol	drug
false

DDI-MedLine.d83.s17
DRUGA treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than DRUGN, and to broadly the same extent as DRUGB.
Olanzapine	drug	risperidone	drug
false

DDI-MedLine.d83.s17
DRUGN treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than DRUGA, and to broadly the same extent as DRUGB.
haloperidol	drug	risperidone	drug
false

DDI-MedLine.d83.s18
CONCLUSIONS: DRUGA demonstrated superior antipsychotic efficacy compared with DRUGB in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia.
Olanzapine	drug	haloperidol	drug
false

DDI-MedLine.d83.s19
The reduced risk of adverse events and therapeutic superiority compared with DRUGA and DRUGB in the treatment of negative and depressive symptoms support the choice of DRUGN as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
haloperidol	drug	risperidone	drug
false

DDI-MedLine.d83.s19
The reduced risk of adverse events and therapeutic superiority compared with DRUGA and DRUGN in the treatment of negative and depressive symptoms support the choice of DRUGB as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
haloperidol	drug	olanzapine	drug
false

DDI-MedLine.d83.s19
The reduced risk of adverse events and therapeutic superiority compared with DRUGN and DRUGA in the treatment of negative and depressive symptoms support the choice of DRUGB as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
risperidone	drug	olanzapine	drug
false

DDI-MedLine.d132.s0
The emerging roles of DRUGA in DRUGB therapy.
non-nucleoside reverse transcriptase inhibitors	group	antiretroviral	group
false

DDI-MedLine.d132.s1
The availability of potent DRUGA (DRUGB)-based regimens for DRUGN therapy and concerns regarding DRUGN (DRUGN)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
non-nucleoside reverse transcriptase inhibitor	group	NNRTI	group
false

DDI-MedLine.d132.s1
The availability of potent DRUGA (DRUGN)-based regimens for DRUGB therapy and concerns regarding DRUGN (DRUGN)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
non-nucleoside reverse transcriptase inhibitor	group	antiretroviral	group
false

DDI-MedLine.d132.s1
The availability of potent DRUGA (DRUGN)-based regimens for DRUGN therapy and concerns regarding DRUGB (DRUGN)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
non-nucleoside reverse transcriptase inhibitor	group	protease inhibitor	group
false

DDI-MedLine.d132.s1
The availability of potent DRUGA (DRUGN)-based regimens for DRUGN therapy and concerns regarding DRUGN (DRUGB)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
non-nucleoside reverse transcriptase inhibitor	group	PI	group
false

DDI-MedLine.d132.s1
The availability of potent DRUGN (DRUGA)-based regimens for DRUGB therapy and concerns regarding DRUGN (DRUGN)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
NNRTI	group	antiretroviral	group
false

DDI-MedLine.d132.s1
The availability of potent DRUGN (DRUGA)-based regimens for DRUGN therapy and concerns regarding DRUGB (DRUGN)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
NNRTI	group	protease inhibitor	group
false

DDI-MedLine.d132.s1
The availability of potent DRUGN (DRUGA)-based regimens for DRUGN therapy and concerns regarding DRUGN (DRUGB)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
NNRTI	group	PI	group
false

DDI-MedLine.d132.s1
The availability of potent DRUGN (DRUGN)-based regimens for DRUGA therapy and concerns regarding DRUGB (DRUGN)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
antiretroviral	group	protease inhibitor	group
false

DDI-MedLine.d132.s1
The availability of potent DRUGN (DRUGN)-based regimens for DRUGA therapy and concerns regarding DRUGN (DRUGB)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
antiretroviral	group	PI	group
false

DDI-MedLine.d132.s1
The availability of potent DRUGN (DRUGN)-based regimens for DRUGN therapy and concerns regarding DRUGA (DRUGB)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
protease inhibitor	group	PI	group
false

DDI-MedLine.d132.s2
DRUGA-based regimens may have several advantages over DRUGB-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration.
NNRTI	group	PI	group
false

DDI-MedLine.d132.s3
No data from prospective clinical trials currently exist comparing the 3 approved agents (DRUGA, DRUGB or DRUGN).
efavirenz	drug	nevirapine	drug
false

DDI-MedLine.d132.s3
No data from prospective clinical trials currently exist comparing the 3 approved agents (DRUGA, DRUGN or DRUGB).
efavirenz	drug	delavirdine	drug
false

DDI-MedLine.d132.s3
No data from prospective clinical trials currently exist comparing the 3 approved agents (DRUGN, DRUGA or DRUGB).
nevirapine	drug	delavirdine	drug
false

DDI-MedLine.d132.s4
Both DRUGA and DRUGB have been compared to triple therapy with the DRUGN DRUGN over 48 weeks as initial therapy, with similar responses being observed with DRUGB regimens and superiority observed with DRUGA.
efavirenz	drug	nevirapine	drug
false

DDI-MedLine.d132.s4
Both DRUGA and DRUGN have been compared to triple therapy with the DRUGB DRUGN over 48 weeks as initial therapy, with similar responses being observed with DRUGN regimens and superiority observed with DRUGA.
efavirenz	drug	PI	group
false

DDI-MedLine.d132.s4
Both DRUGA and DRUGN have been compared to triple therapy with the DRUGN DRUGB over 48 weeks as initial therapy, with similar responses being observed with DRUGN regimens and superiority observed with DRUGA.
efavirenz	drug	indinavir	drug
false

DDI-MedLine.d132.s4
Both DRUGA and DRUGB have been compared to triple therapy with the DRUGN DRUGN over 48 weeks as initial therapy, with similar responses being observed with DRUGB regimens and superiority observed with DRUGA.
efavirenz	drug	nevirapine	drug
false

DDI-MedLine.d132.s4
Both DRUGN and DRUGA have been compared to triple therapy with the DRUGB DRUGN over 48 weeks as initial therapy, with similar responses being observed with DRUGA regimens and superiority observed with DRUGN.
nevirapine	drug	PI	group
false

DDI-MedLine.d132.s4
Both DRUGN and DRUGA have been compared to triple therapy with the DRUGN DRUGB over 48 weeks as initial therapy, with similar responses being observed with DRUGA regimens and superiority observed with DRUGN.
nevirapine	drug	indinavir	drug
false

DDI-MedLine.d132.s4
Both DRUGB and DRUGA have been compared to triple therapy with the DRUGN DRUGN over 48 weeks as initial therapy, with similar responses being observed with DRUGA regimens and superiority observed with DRUGB.
nevirapine	drug	efavirenz	drug
false

DDI-MedLine.d132.s4
Both DRUGN and DRUGN have been compared to triple therapy with the DRUGA DRUGB over 48 weeks as initial therapy, with similar responses being observed with DRUGN regimens and superiority observed with DRUGN.
PI	group	indinavir	drug
false

DDI-MedLine.d132.s4
Both DRUGN and DRUGB have been compared to triple therapy with the DRUGA DRUGN over 48 weeks as initial therapy, with similar responses being observed with DRUGB regimens and superiority observed with DRUGN.
PI	group	nevirapine	drug
false

DDI-MedLine.d132.s4
Both DRUGB and DRUGN have been compared to triple therapy with the DRUGA DRUGN over 48 weeks as initial therapy, with similar responses being observed with DRUGN regimens and superiority observed with DRUGB.
PI	group	efavirenz	drug
false

DDI-MedLine.d132.s4
Both DRUGN and DRUGB have been compared to triple therapy with the DRUGN DRUGA over 48 weeks as initial therapy, with similar responses being observed with DRUGB regimens and superiority observed with DRUGN.
indinavir	drug	nevirapine	drug
false

DDI-MedLine.d132.s4
Both DRUGB and DRUGN have been compared to triple therapy with the DRUGN DRUGA over 48 weeks as initial therapy, with similar responses being observed with DRUGN regimens and superiority observed with DRUGB.
indinavir	drug	efavirenz	drug
false

DDI-MedLine.d132.s4
Both DRUGB and DRUGA have been compared to triple therapy with the DRUGN DRUGN over 48 weeks as initial therapy, with similar responses being observed with DRUGA regimens and superiority observed with DRUGB.
nevirapine	drug	efavirenz	drug
false

DDI-MedLine.d132.s5
A smaller 24-week study has suggested DRUGA may be superior to the DRUGB DRUGN.
nevirapine	drug	PI	group
false

DDI-MedLine.d132.s5
A smaller 24-week study has suggested DRUGA may be superior to the DRUGN DRUGB.
nevirapine	drug	nelfinavir	drug
false

DDI-MedLine.d132.s5
A smaller 24-week study has suggested DRUGN may be superior to the DRUGA DRUGB.
PI	group	nelfinavir	drug
false

DDI-MedLine.d132.s6
Limited comparative data in patients with high viral loads treated with DRUGA- or DRUGB-based regimens currently exist.
nevirapine	drug	delavirdine	drug
false

DDI-MedLine.d132.s8
The superiority of DRUGA over DRUGB-based regimens has been observed in comparative data in a subset of patients with high viral loads.
efavirenz	drug	indinavir	drug
false

DDI-MedLine.d132.s10
DRUGA has demonstrated superiority over DRUGB in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances.
Efavirenz	drug	nelfinavir	drug
false

DDI-MedLine.d42.s4
METHODS: Clinical studies, case reports, and commentaries and editorials concerning DRUGA published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms DRUGA, DRUGB, and erectile dysfunction.
sildenafil	drug	Viagra	brand
false

DDI-MedLine.d42.s4
METHODS: Clinical studies, case reports, and commentaries and editorials concerning DRUGA published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms DRUGA, DRUGB, and erectile dysfunction.
sildenafil	drug	Viagra	brand
false

DDI-MedLine.d42.s5
RESULTS: DRUGA has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, DRUGB [DRUGN]).
Sildenafil	drug	selective serotonin reuptake inhibitors	group
false

DDI-MedLine.d42.s5
RESULTS: DRUGA has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, DRUGN [DRUGB]).
Sildenafil	drug	SSRIs	group
false

DDI-MedLine.d42.s5
RESULTS: DRUGN has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, DRUGA [DRUGB]).
selective serotonin reuptake inhibitors	group	SSRIs	group
false

DDI-MedLine.d38.s0
Acute DRUGA administration does not affect subjective responses to DRUGB in humans.
hydrocortisone	drug	d-amphetamine	drug
false

DDI-MedLine.d38.s2
However, the effects of stress and DRUGA on the subjective and behavioral effects of DRUGB have not been well studied in humans.
glucocorticoids	group	psychostimulants	group
false

DDI-MedLine.d38.s3
OBJECTIVES: To examine the effects of acute DRUGA pretreatment on the subjective and behavioral effects of DRUGB.
hydrocortisone	drug	d-amphetamine	drug
false

DDI-MedLine.d38.s4
METHODS: DRUGA (100 mg) and DRUGB (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design.
Hydrocortisone	drug	d-amphetamine	drug
false

DDI-MedLine.d38.s8
However, DRUGA pretreatment did not affect any of the physiological, behavioral, or subjective effects of DRUGB.
hydrocortisone	drug	d-amphetamine	drug
false

DDI-MedLine.d38.s9
CONCLUSIONS: In contrast to the effects of DRUGA in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of DRUGB in humans.
glucocorticoids	group	d-amphetamine	drug
false

DDI-MedLine.d23.s0
The effects of DRUGA and of DRUGB anesthesia on DRUGN tolerance in dogs.
ketamine	drug	Innovar	brand
false

DDI-MedLine.d23.s0
The effects of DRUGA and of DRUGN anesthesia on DRUGB tolerance in dogs.
ketamine	drug	digitalis	group
false

DDI-MedLine.d23.s0
The effects of DRUGN and of DRUGA anesthesia on DRUGB tolerance in dogs.
Innovar	brand	digitalis	group
false

DDI-MedLine.d23.s1
In a comparison of DRUGA tolerance in dogs anesthetized with DRUGB, DRUGN Vet, or DRUGN, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGB or DRUGN than with DRUGN.
digitalis	group	ketamine	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGA tolerance in dogs anesthetized with DRUGN, DRUGB, or DRUGN, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGN or DRUGN than with DRUGN.
digitalis	group	Innovar Vet	brand
false

DDI-MedLine.d23.s1
In a comparison of DRUGA tolerance in dogs anesthetized with DRUGN, DRUGN Vet, or DRUGB, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGN or DRUGN than with DRUGB.
digitalis	group	pentobarbital	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGA tolerance in dogs anesthetized with DRUGN, DRUGN Vet, or DRUGN, the dosage of DRUGB needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGB, with DRUGN or DRUGN than with DRUGN.
digitalis	group	ouabain	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGA tolerance in dogs anesthetized with DRUGN, DRUGN Vet, or DRUGN, the dosage of DRUGB needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGB, with DRUGN or DRUGN than with DRUGN.
digitalis	group	ouabain	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGA tolerance in dogs anesthetized with DRUGB, DRUGN Vet, or DRUGN, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGB or DRUGN than with DRUGN.
digitalis	group	ketamine	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGA tolerance in dogs anesthetized with DRUGN, DRUGB Vet, or DRUGN, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGN or DRUGB than with DRUGN.
digitalis	group	Innovar	brand
false

DDI-MedLine.d23.s1
In a comparison of DRUGA tolerance in dogs anesthetized with DRUGN, DRUGN Vet, or DRUGB, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGN or DRUGN than with DRUGB.
digitalis	group	pentobarbital	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGA, DRUGB, or DRUGN, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGA or DRUGN than with DRUGN.
ketamine	drug	Innovar Vet	brand
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGA, DRUGN Vet, or DRUGB, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGA or DRUGN than with DRUGB.
ketamine	drug	pentobarbital	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGA, DRUGN Vet, or DRUGN, the dosage of DRUGB needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGB, with DRUGA or DRUGN than with DRUGN.
ketamine	drug	ouabain	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGA, DRUGB Vet, or DRUGN, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGA or DRUGB than with DRUGN.
ketamine	drug	Innovar	brand
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGA, DRUGN Vet, or DRUGB, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGA or DRUGN than with DRUGB.
ketamine	drug	pentobarbital	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGA, or DRUGB, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGN or DRUGN than with DRUGB.
Innovar Vet	brand	pentobarbital	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGA, or DRUGN, the dosage of DRUGB needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGB, with DRUGN or DRUGN than with DRUGN.
Innovar Vet	brand	ouabain	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGB, DRUGA, or DRUGN, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGB or DRUGN than with DRUGN.
Innovar Vet	brand	ketamine	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGA, or DRUGN, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGN or DRUGB than with DRUGN.
Innovar Vet	brand	Innovar	brand
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGA, or DRUGB, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGN or DRUGN than with DRUGB.
Innovar Vet	brand	pentobarbital	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGN Vet, or DRUGA, the dosage of DRUGB needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGB, with DRUGN or DRUGN than with DRUGA.
pentobarbital	drug	ouabain	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGB, DRUGN Vet, or DRUGA, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGB or DRUGN than with DRUGA.
pentobarbital	drug	ketamine	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGB Vet, or DRUGA, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGN or DRUGB than with DRUGA.
pentobarbital	drug	Innovar	brand
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGB, DRUGN Vet, or DRUGN, the dosage of DRUGA needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGA, with DRUGB or DRUGN than with DRUGN.
ouabain	drug	ketamine	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGB Vet, or DRUGN, the dosage of DRUGA needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGA, with DRUGN or DRUGB than with DRUGN.
ouabain	drug	Innovar	brand
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGN Vet, or DRUGB, the dosage of DRUGA needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGA, with DRUGN or DRUGN than with DRUGB.
ouabain	drug	pentobarbital	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGB, DRUGN Vet, or DRUGN, the dosage of DRUGA needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGA, with DRUGB or DRUGN than with DRUGN.
ouabain	drug	ketamine	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGB Vet, or DRUGN, the dosage of DRUGA needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGA, with DRUGN or DRUGB than with DRUGN.
ouabain	drug	Innovar	brand
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGN Vet, or DRUGB, the dosage of DRUGA needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGA, with DRUGN or DRUGN than with DRUGB.
ouabain	drug	pentobarbital	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGA, DRUGB Vet, or DRUGN, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGA or DRUGB than with DRUGN.
ketamine	drug	Innovar	brand
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGA, DRUGN Vet, or DRUGB, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGA or DRUGN than with DRUGB.
ketamine	drug	pentobarbital	drug
false

DDI-MedLine.d23.s1
In a comparison of DRUGN tolerance in dogs anesthetized with DRUGN, DRUGA Vet, or DRUGB, the dosage of DRUGN needed to cause ventricular tachycardia was significantly higher, as was the LD50 of DRUGN, with DRUGN or DRUGA than with DRUGB.
Innovar	brand	pentobarbital	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGA was generally converted to sinus rhythm following administration of DRUGN, DRUGN, or DRUGN but not after administration of DRUGB alone or after DRUGN.
ouabain	drug	fentayl	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGA was generally converted to sinus rhythm following administration of DRUGN, DRUGN, or DRUGN but not after administration of DRUGN alone or after DRUGB.
ouabain	drug	pentobarbital	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGN was generally converted to sinus rhythm following administration of DRUGA, DRUGB, or DRUGN but not after administration of DRUGN alone or after DRUGN.
Innovar	brand	ketamine	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGN was generally converted to sinus rhythm following administration of DRUGA, DRUGN, or DRUGB but not after administration of DRUGN alone or after DRUGN.
Innovar	brand	droperidol	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGN was generally converted to sinus rhythm following administration of DRUGA, DRUGN, or DRUGN but not after administration of DRUGB alone or after DRUGN.
Innovar	brand	fentayl	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGN was generally converted to sinus rhythm following administration of DRUGA, DRUGN, or DRUGN but not after administration of DRUGN alone or after DRUGB.
Innovar	brand	pentobarbital	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGN was generally converted to sinus rhythm following administration of DRUGN, DRUGA, or DRUGB but not after administration of DRUGN alone or after DRUGN.
ketamine	drug	droperidol	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGN was generally converted to sinus rhythm following administration of DRUGN, DRUGA, or DRUGN but not after administration of DRUGB alone or after DRUGN.
ketamine	drug	fentayl	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGN was generally converted to sinus rhythm following administration of DRUGN, DRUGA, or DRUGN but not after administration of DRUGN alone or after DRUGB.
ketamine	drug	pentobarbital	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGN was generally converted to sinus rhythm following administration of DRUGN, DRUGN, or DRUGA but not after administration of DRUGB alone or after DRUGN.
droperidol	drug	fentayl	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGN was generally converted to sinus rhythm following administration of DRUGN, DRUGN, or DRUGA but not after administration of DRUGN alone or after DRUGB.
droperidol	drug	pentobarbital	drug
false

DDI-MedLine.d23.s2
Ventricular tachycardia induced by DRUGN was generally converted to sinus rhythm following administration of DRUGN, DRUGN, or DRUGN but not after administration of DRUGA alone or after DRUGB.
fentayl	drug	pentobarbital	drug
false

DDI-MedLine.d49.s1
The minimal inhibitory concentrations of DRUGA and DRUGB alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates.
clindamycin	drug	gentamicin	drug
false

DDI-MedLine.d49.s3
DRUGA did not interfere with the activity of DRUGB within the range of concentrations tested (0.1 to 100 mug/ml);
Gentamicin	drug	clindamycin	drug
false

DDI-MedLine.d49.s7
All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both DRUGA (minimal inhibitory concentration greater than 3.1 mug/ml) and DRUGB (minimal inhibitory concentration greater than 6.2 mug/ml).
clindamycin	drug	gentamicin	drug
false

DDI-MedLine.d120.s0
Molecular basis for the selective toxicity of DRUGA for yeast and DRUGB for animal cells.
amphotericin B	drug	filipin	drug_n
false

DDI-MedLine.d120.s1
Among the DRUGA, many, like DRUGB, cannot be used clinically because they are toxic;
polyene antibiotics	group	filipin	drug_n
false

DDI-MedLine.d120.s3
Both the toxicity of DRUGA and the therapeutic value of DRUGB can be rationalized at the cellular and molecular level by the following observations: (i) these DRUGN showed differential effects on cells;
filipin	drug_n	amphotericin B	drug
false

DDI-MedLine.d120.s3
Both the toxicity of DRUGA and the therapeutic value of DRUGN can be rationalized at the cellular and molecular level by the following observations: (i) these DRUGB showed differential effects on cells;
filipin	drug_n	polyene antibiotics	group
false

DDI-MedLine.d120.s3
Both the toxicity of DRUGN and the therapeutic value of DRUGA can be rationalized at the cellular and molecular level by the following observations: (i) these DRUGB showed differential effects on cells;
amphotericin B	drug	polyene antibiotics	group
false

DDI-MedLine.d120.s4
DRUGA was more potent in lysing human red blood cells, whereas DRUGB was more potent in inhibiting yeast cell growth;
filipin	drug_n	amphotericin B	drug
false

DDI-MedLine.d120.s5
and (ii) the effects of DRUGA were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of DRUGB were more efficiently inhibited by ergosterol, the major membrane sterol in yeast.
filipin	drug_n	amphotericin B	drug
false

DDI-MedLine.d40.s1
The DRUGA, DRUGB, inhibits the growth of several species of Candida.
antifungal drug	group	miconazole nitrate	drug
false

DDI-MedLine.d29.s0
Effect of DRUGA on the apparent volume of distribution and elimination of DRUGB.
probenecid	drug	cloxacillin	drug
false

DDI-MedLine.d29.s2
(1968, 1970), the higher serum concentrations of DRUGA and DRUGB reached after administration of DRUGN are due not only to slower renal elimination but also to an altered distribution in the body.
penicillins	group	cephaloridine	drug
false

DDI-MedLine.d29.s3
To determine whether DRUGA has a direct effect on the distribution of DRUGB, the elimination and distribution of DRUGB was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of DRUGA.
probenecid	drug	cloxacillin	drug
false

DDI-MedLine.d29.s3
To determine whether DRUGA has a direct effect on the distribution of DRUGB, the elimination and distribution of DRUGB was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of DRUGA.
probenecid	drug	cloxacillin	drug
false

DDI-MedLine.d29.s3
To determine whether DRUGB has a direct effect on the distribution of DRUGA, the elimination and distribution of DRUGA was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of DRUGB.
cloxacillin	drug	probenecid	drug
false

DDI-MedLine.d29.s3
To determine whether DRUGB has a direct effect on the distribution of DRUGA, the elimination and distribution of DRUGA was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of DRUGB.
cloxacillin	drug	probenecid	drug
false

DDI-MedLine.d29.s4
No significant difference was found between the mean values of the volume of distribution of DRUGA with and without DRUGB (13.0 and 12.6 liters, respectively).
cloxacillin	drug	probenecid	drug
false

DDI-MedLine.d122.s1
Many people use both DRUGA and DRUGB (i.e., cigarettes and other tobacco products).
alcohol	drug	nicotine	drug
false

DDI-MedLine.d122.s3
The initiation of DRUGA or DRUGB use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking.
alcohol	drug	nicotine	drug
false

DDI-MedLine.d122.s4
Moreover, the mechanisms underlying the development of dependence may be similar for DRUGA and DRUGB.
alcohol	drug	nicotine	drug
false

DDI-MedLine.d134.s0
[Dose-time effects of competitive displacement of DRUGA by DRUGB following oral and intravenous administration]
The effect of various doses of DRUGB in several dose fractions on the extent and the time scale of displacement of DRUGA, in dependence on application mode, was studied.
radiopertechnetate	drug	sodium perchlorate	drug_n
false

DDI-MedLine.d134.s0
[Dose-time effects of competitive displacement of DRUGA by DRUGB following oral and intravenous administration]
The effect of various doses of DRUGB in several dose fractions on the extent and the time scale of displacement of DRUGA, in dependence on application mode, was studied.
radiopertechnetate	drug	sodium perchlorate	drug_n
false

DDI-MedLine.d134.s0
[Dose-time effects of competitive displacement of DRUGB by DRUGA following oral and intravenous administration]
The effect of various doses of DRUGA in several dose fractions on the extent and the time scale of displacement of DRUGB, in dependence on application mode, was studied.
sodium perchlorate	drug_n	radiopertechnetate	drug
false

DDI-MedLine.d134.s0
[Dose-time effects of competitive displacement of DRUGB by DRUGA following oral and intravenous administration]
The effect of various doses of DRUGA in several dose fractions on the extent and the time scale of displacement of DRUGB, in dependence on application mode, was studied.
sodium perchlorate	drug_n	radiopertechnetate	drug
false

DDI-MedLine.d134.s1
An intravenous dose of 50 mg DRUGA was in respect of competitive suppression of organs actively concentrating DRUGB as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radioDRUGB.
perchlorate	drug_n	pertechnetate	drug
false

DDI-MedLine.d134.s1
An intravenous dose of 50 mg DRUGA was in respect of competitive suppression of organs actively concentrating DRUGN as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of DRUGB.
perchlorate	drug_n	radiopertechnetate	drug
false

DDI-MedLine.d134.s1
An intravenous dose of 50 mg DRUGN was in respect of competitive suppression of organs actively concentrating DRUGA as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radioDRUGA.
pertechnetate	drug	radiopertechnetate	drug
false

DDI-MedLine.d118.s0
DRUGA: mammalian target of DRUGB inhibitor to prevent kidney rejection.
Sirolimus	drug	rapamycin	drug
false

DDI-MedLine.d118.s2
DRUGA works differently from the DRUGB currently available, and except for increased lipid levels, the adverse reaction profile of DRUGN does not appear to overlap to any great extent with that associated with DRUGN or DRUGN.
Sirolimus	drug	immunosuppressants	group
false

DDI-MedLine.d118.s2
DRUGA works differently from the DRUGN currently available, and except for increased lipid levels, the adverse reaction profile of DRUGB does not appear to overlap to any great extent with that associated with DRUGN or DRUGN.
Sirolimus	drug	sirolimus	drug
false

DDI-MedLine.d118.s2
DRUGA works differently from the DRUGN currently available, and except for increased lipid levels, the adverse reaction profile of DRUGN does not appear to overlap to any great extent with that associated with DRUGB or DRUGN.
Sirolimus	drug	cyclosporine	drug
false

DDI-MedLine.d118.s2
DRUGA works differently from the DRUGN currently available, and except for increased lipid levels, the adverse reaction profile of DRUGN does not appear to overlap to any great extent with that associated with DRUGN or DRUGB.
Sirolimus	drug	tacrolimus	drug
false

DDI-MedLine.d118.s2
DRUGN works differently from the DRUGA currently available, and except for increased lipid levels, the adverse reaction profile of DRUGB does not appear to overlap to any great extent with that associated with DRUGN or DRUGN.
immunosuppressants	group	sirolimus	drug
false

DDI-MedLine.d118.s2
DRUGN works differently from the DRUGA currently available, and except for increased lipid levels, the adverse reaction profile of DRUGN does not appear to overlap to any great extent with that associated with DRUGB or DRUGN.
immunosuppressants	group	cyclosporine	drug
false

DDI-MedLine.d118.s2
DRUGN works differently from the DRUGA currently available, and except for increased lipid levels, the adverse reaction profile of DRUGN does not appear to overlap to any great extent with that associated with DRUGN or DRUGB.
immunosuppressants	group	tacrolimus	drug
false

DDI-MedLine.d118.s2
DRUGN works differently from the DRUGN currently available, and except for increased lipid levels, the adverse reaction profile of DRUGA does not appear to overlap to any great extent with that associated with DRUGB or DRUGN.
sirolimus	drug	cyclosporine	drug
false

DDI-MedLine.d118.s2
DRUGN works differently from the DRUGN currently available, and except for increased lipid levels, the adverse reaction profile of DRUGA does not appear to overlap to any great extent with that associated with DRUGN or DRUGB.
sirolimus	drug	tacrolimus	drug
false

DDI-MedLine.d118.s2
DRUGN works differently from the DRUGN currently available, and except for increased lipid levels, the adverse reaction profile of DRUGN does not appear to overlap to any great extent with that associated with DRUGA or DRUGB.
cyclosporine	drug	tacrolimus	drug
false

DDI-MedLine.d118.s3
While additional research is needed, the initial clinical data in kidney recipients suggest that DRUGA, in combination with DRUGB or DRUGN, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUGB or DRUGN dosage, and permit steroid withdrawal (Kelly, 1999).
sirolimus	drug	cyclosporine	drug
false

DDI-MedLine.d118.s3
While additional research is needed, the initial clinical data in kidney recipients suggest that DRUGA, in combination with DRUGN or DRUGB, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUGN or DRUGB dosage, and permit steroid withdrawal (Kelly, 1999).
sirolimus	drug	tacrolimus	drug
false

DDI-MedLine.d118.s3
While additional research is needed, the initial clinical data in kidney recipients suggest that DRUGA, in combination with DRUGB or DRUGN, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUGB or DRUGN dosage, and permit steroid withdrawal (Kelly, 1999).
sirolimus	drug	cyclosporine	drug
false

DDI-MedLine.d118.s3
While additional research is needed, the initial clinical data in kidney recipients suggest that DRUGA, in combination with DRUGN or DRUGB, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUGN or DRUGB dosage, and permit steroid withdrawal (Kelly, 1999).
sirolimus	drug	tacrolimus	drug
false

DDI-MedLine.d118.s3
While additional research is needed, the initial clinical data in kidney recipients suggest that DRUGN, in combination with DRUGA or DRUGB, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUGA or DRUGB dosage, and permit steroid withdrawal (Kelly, 1999).
cyclosporine	drug	tacrolimus	drug
false

DDI-MedLine.d118.s3
While additional research is needed, the initial clinical data in kidney recipients suggest that DRUGN, in combination with DRUGA or DRUGB, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUGA or DRUGB dosage, and permit steroid withdrawal (Kelly, 1999).
cyclosporine	drug	tacrolimus	drug
false

DDI-MedLine.d118.s3
While additional research is needed, the initial clinical data in kidney recipients suggest that DRUGN, in combination with DRUGB or DRUGA, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUGB or DRUGA dosage, and permit steroid withdrawal (Kelly, 1999).
tacrolimus	drug	cyclosporine	drug
false

DDI-MedLine.d118.s3
While additional research is needed, the initial clinical data in kidney recipients suggest that DRUGN, in combination with DRUGA or DRUGB, might have the potential to reduce the frequency of rejection episodes, permit reductions in DRUGA or DRUGB dosage, and permit steroid withdrawal (Kelly, 1999).
cyclosporine	drug	tacrolimus	drug
false

DDI-MedLine.d88.s0
The effects of DRUGA, DRUGB and DRUGN on bar-press behavior in normal and genetically nervous dogs.
chlordiazepoxide	drug	amphetamine	drug
false

DDI-MedLine.d88.s0
The effects of DRUGA, DRUGN and DRUGB on bar-press behavior in normal and genetically nervous dogs.
chlordiazepoxide	drug	cocaine	drug
false

DDI-MedLine.d88.s0
The effects of DRUGN, DRUGA and DRUGB on bar-press behavior in normal and genetically nervous dogs.
amphetamine	drug	cocaine	drug
false

DDI-MedLine.d88.s1
Studies on two strains of pointer dogs have demonstrated that administration of a DRUGA (DRUGB) facilitates acquisition of goal-directed behavior in "genetically nervous"
benzodiazepine	group	chlordiazepoxide	drug
false

DDI-MedLine.d88.s4
The concomitant administration of either DRUGA or DRUGB, compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects.
cocaine	drug	amphetamine	drug
false

DDI-MedLine.d119.s1
DRUGA is the first DRUGB to be approved for clinical use, and has been studied extensively in humans since 1986.
Fluvastatin	drug	synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor	group
false

DDI-MedLine.d119.s2
It is structurally distinct from the other currently available DRUGA (DRUGB, DRUGN, and DRUGN), leading to unique biopharmaceutical properties relative to the other agents of this class.
HMGCoA reductase inhibitors	group	lovastatin	drug
false

DDI-MedLine.d119.s2
It is structurally distinct from the other currently available DRUGA (DRUGN, DRUGB, and DRUGN), leading to unique biopharmaceutical properties relative to the other agents of this class.
HMGCoA reductase inhibitors	group	simvastatin	drug
false

DDI-MedLine.d119.s2
It is structurally distinct from the other currently available DRUGA (DRUGN, DRUGN, and DRUGB), leading to unique biopharmaceutical properties relative to the other agents of this class.
HMGCoA reductase inhibitors	group	pravastatin	drug
false

DDI-MedLine.d119.s2
It is structurally distinct from the other currently available DRUGN (DRUGA, DRUGB, and DRUGN), leading to unique biopharmaceutical properties relative to the other agents of this class.
lovastatin	drug	simvastatin	drug
false

DDI-MedLine.d119.s2
It is structurally distinct from the other currently available DRUGN (DRUGA, DRUGN, and DRUGB), leading to unique biopharmaceutical properties relative to the other agents of this class.
lovastatin	drug	pravastatin	drug
false

DDI-MedLine.d119.s2
It is structurally distinct from the other currently available DRUGN (DRUGN, DRUGA, and DRUGB), leading to unique biopharmaceutical properties relative to the other agents of this class.
simvastatin	drug	pravastatin	drug
false

DDI-MedLine.d119.s17
Further, no effects on either DRUGA levels or prothrombin times were observed in a study involving concomitant administration of DRUGA and DRUGB.
warfarin	drug	fluvastatin	drug
false

DDI-MedLine.d119.s17
Further, no effects on either DRUGA levels or prothrombin times were observed in a study involving concomitant administration of DRUGA and DRUGB.
warfarin	drug	fluvastatin	drug
false

DDI-MedLine.d119.s18
Moreover, additional interaction studies with DRUGA and DRUGB have not demonstrated any effect on DRUGN plasma levels, and administration to a patient population chronically receiving DRUGN resulted in no difference in the extent of bioavailability of DRUGN relative to control data.
niacin	drug	propranolol	drug
false

DDI-MedLine.d119.s18
Moreover, additional interaction studies with DRUGA and DRUGN have not demonstrated any effect on DRUGB plasma levels, and administration to a patient population chronically receiving DRUGN resulted in no difference in the extent of bioavailability of DRUGN relative to control data.
niacin	drug	fluvastatin	drug
false

DDI-MedLine.d119.s18
Moreover, additional interaction studies with DRUGA and DRUGN have not demonstrated any effect on DRUGN plasma levels, and administration to a patient population chronically receiving DRUGB resulted in no difference in the extent of bioavailability of DRUGB relative to control data.
niacin	drug	digoxin	drug
false

DDI-MedLine.d119.s18
Moreover, additional interaction studies with DRUGA and DRUGN have not demonstrated any effect on DRUGN plasma levels, and administration to a patient population chronically receiving DRUGB resulted in no difference in the extent of bioavailability of DRUGB relative to control data.
niacin	drug	digoxin	drug
false

DDI-MedLine.d119.s18
Moreover, additional interaction studies with DRUGN and DRUGA have not demonstrated any effect on DRUGB plasma levels, and administration to a patient population chronically receiving DRUGN resulted in no difference in the extent of bioavailability of DRUGN relative to control data.
propranolol	drug	fluvastatin	drug
false

DDI-MedLine.d119.s18
Moreover, additional interaction studies with DRUGN and DRUGA have not demonstrated any effect on DRUGN plasma levels, and administration to a patient population chronically receiving DRUGB resulted in no difference in the extent of bioavailability of DRUGB relative to control data.
propranolol	drug	digoxin	drug
false

DDI-MedLine.d119.s18
Moreover, additional interaction studies with DRUGN and DRUGA have not demonstrated any effect on DRUGN plasma levels, and administration to a patient population chronically receiving DRUGB resulted in no difference in the extent of bioavailability of DRUGB relative to control data.
propranolol	drug	digoxin	drug
false

DDI-MedLine.d119.s18
Moreover, additional interaction studies with DRUGN and DRUGN have not demonstrated any effect on DRUGA plasma levels, and administration to a patient population chronically receiving DRUGB resulted in no difference in the extent of bioavailability of DRUGB relative to control data.
fluvastatin	drug	digoxin	drug
false

DDI-MedLine.d119.s18
Moreover, additional interaction studies with DRUGN and DRUGN have not demonstrated any effect on DRUGA plasma levels, and administration to a patient population chronically receiving DRUGB resulted in no difference in the extent of bioavailability of DRUGB relative to control data.
fluvastatin	drug	digoxin	drug
false

DDI-MedLine.d57.s1
The literature provides considerable evidence indicating that several, but not all DRUGA, are indeed DRUGB and some are DRUGN as well.
antihistaminics	group	analgesic agents	group
false

DDI-MedLine.d57.s1
The literature provides considerable evidence indicating that several, but not all DRUGA, are indeed DRUGN and some are DRUGB as well.
antihistaminics	group	analgesic adjuvants	group
false

DDI-MedLine.d57.s1
The literature provides considerable evidence indicating that several, but not all DRUGN, are indeed DRUGA and some are DRUGB as well.
analgesic agents	group	analgesic adjuvants	group
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGA, DRUGB, DRUGN, DRUGN, DRUGN, DRUGN, DRUGN, and DRUGN.
diphenhydramine	drug	hydroxyzine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGA, DRUGN, DRUGB, DRUGN, DRUGN, DRUGN, DRUGN, and DRUGN.
diphenhydramine	drug	orphenadrine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGA, DRUGN, DRUGN, DRUGB, DRUGN, DRUGN, DRUGN, and DRUGN.
diphenhydramine	drug	pyrilamine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGA, DRUGN, DRUGN, DRUGN, DRUGB, DRUGN, DRUGN, and DRUGN.
diphenhydramine	drug	phenyltoloxamine	drug_n
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGA, DRUGN, DRUGN, DRUGN, DRUGN, DRUGB, DRUGN, and DRUGN.
diphenhydramine	drug	promethazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGA, DRUGN, DRUGN, DRUGN, DRUGN, DRUGN, DRUGB, and DRUGN.
diphenhydramine	drug	methdilazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGA, DRUGN, DRUGN, DRUGN, DRUGN, DRUGN, DRUGN, and DRUGB.
diphenhydramine	drug	tripelennamine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGA, DRUGB, DRUGN, DRUGN, DRUGN, DRUGN, and DRUGN.
hydroxyzine	drug	orphenadrine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGA, DRUGN, DRUGB, DRUGN, DRUGN, DRUGN, and DRUGN.
hydroxyzine	drug	pyrilamine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGA, DRUGN, DRUGN, DRUGB, DRUGN, DRUGN, and DRUGN.
hydroxyzine	drug	phenyltoloxamine	drug_n
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGA, DRUGN, DRUGN, DRUGN, DRUGB, DRUGN, and DRUGN.
hydroxyzine	drug	promethazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGA, DRUGN, DRUGN, DRUGN, DRUGN, DRUGB, and DRUGN.
hydroxyzine	drug	methdilazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGA, DRUGN, DRUGN, DRUGN, DRUGN, DRUGN, and DRUGB.
hydroxyzine	drug	tripelennamine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGA, DRUGB, DRUGN, DRUGN, DRUGN, and DRUGN.
orphenadrine	drug	pyrilamine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGA, DRUGN, DRUGB, DRUGN, DRUGN, and DRUGN.
orphenadrine	drug	phenyltoloxamine	drug_n
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGA, DRUGN, DRUGN, DRUGB, DRUGN, and DRUGN.
orphenadrine	drug	promethazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGA, DRUGN, DRUGN, DRUGN, DRUGB, and DRUGN.
orphenadrine	drug	methdilazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGA, DRUGN, DRUGN, DRUGN, DRUGN, and DRUGB.
orphenadrine	drug	tripelennamine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGN, DRUGA, DRUGB, DRUGN, DRUGN, and DRUGN.
pyrilamine	drug	phenyltoloxamine	drug_n
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGN, DRUGA, DRUGN, DRUGB, DRUGN, and DRUGN.
pyrilamine	drug	promethazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGN, DRUGA, DRUGN, DRUGN, DRUGB, and DRUGN.
pyrilamine	drug	methdilazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGN, DRUGA, DRUGN, DRUGN, DRUGN, and DRUGB.
pyrilamine	drug	tripelennamine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGN, DRUGN, DRUGA, DRUGB, DRUGN, and DRUGN.
phenyltoloxamine	drug_n	promethazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGN, DRUGN, DRUGA, DRUGN, DRUGB, and DRUGN.
phenyltoloxamine	drug_n	methdilazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGN, DRUGN, DRUGA, DRUGN, DRUGN, and DRUGB.
phenyltoloxamine	drug_n	tripelennamine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGN, DRUGN, DRUGN, DRUGA, DRUGB, and DRUGN.
promethazine	drug	methdilazine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGN, DRUGN, DRUGN, DRUGA, DRUGN, and DRUGB.
promethazine	drug	tripelennamine	drug
false

DDI-MedLine.d57.s2
Those for which effectiveness is reported includes DRUGN, DRUGN, DRUGN, DRUGN, DRUGN, DRUGN, DRUGA, and DRUGB.
methdilazine	drug	tripelennamine	drug
false

DDI-MedLine.d27.s0
[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that DRUGN (1 mg/kg) removes the antiedematous action of DRUGA, DRUGB, DRUGN and DRUGN and reduces the action of DRUGN.
diazepam	drug	phenazepam	drug_n
false

DDI-MedLine.d27.s0
[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that DRUGN (1 mg/kg) removes the antiedematous action of DRUGA, DRUGN, DRUGB and DRUGN and reduces the action of DRUGN.
diazepam	drug	phenibut	drug_n
false

DDI-MedLine.d27.s0
[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that DRUGN (1 mg/kg) removes the antiedematous action of DRUGA, DRUGN, DRUGN and DRUGB and reduces the action of DRUGN.
diazepam	drug	amizyl	drug_n
false

DDI-MedLine.d27.s0
[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that DRUGN (1 mg/kg) removes the antiedematous action of DRUGA, DRUGN, DRUGN and DRUGN and reduces the action of DRUGB.
diazepam	drug	phentolamine	drug
false

DDI-MedLine.d27.s0
[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that DRUGN (1 mg/kg) removes the antiedematous action of DRUGN, DRUGA, DRUGB and DRUGN and reduces the action of DRUGN.
phenazepam	drug_n	phenibut	drug_n
false

DDI-MedLine.d27.s0
[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that DRUGN (1 mg/kg) removes the antiedematous action of DRUGN, DRUGA, DRUGN and DRUGB and reduces the action of DRUGN.
phenazepam	drug_n	amizyl	drug_n
false

DDI-MedLine.d27.s0
[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that DRUGN (1 mg/kg) removes the antiedematous action of DRUGN, DRUGA, DRUGN and DRUGN and reduces the action of DRUGB.
phenazepam	drug_n	phentolamine	drug
false

DDI-MedLine.d27.s0
[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that DRUGN (1 mg/kg) removes the antiedematous action of DRUGN, DRUGN, DRUGA and DRUGB and reduces the action of DRUGN.
phenibut	drug_n	amizyl	drug_n
false

DDI-MedLine.d27.s0
[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that DRUGN (1 mg/kg) removes the antiedematous action of DRUGN, DRUGN, DRUGA and DRUGN and reduces the action of DRUGB.
phenibut	drug_n	phentolamine	drug
false

DDI-MedLine.d27.s0
[The GABA-ergic system and brain edema]
It has been shown in rats with experimental toxic and traumatic edemas that DRUGN (1 mg/kg) removes the antiedematous action of DRUGN, DRUGN, DRUGN and DRUGA and reduces the action of DRUGB.
amizyl	drug_n	phentolamine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGA--an analog of the octapeptide cholecystokinin--of DRUGB binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGB and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGB binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGA--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGB]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	neuroleptics	group
false

DDI-MedLine.d15.s0
[Stimulation by DRUGA--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGB (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	haloperidol	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGA--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGB (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	pyreneperone	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGA--an analog of the octapeptide cholecystokinin--of DRUGB binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGB and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGB binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGA--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGA--an analog of the octapeptide cholecystokinin--of DRUGB binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGB and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGB binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGA--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGA binding after the long-term administration of DRUGB]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGA and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGA binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
3H-spiroperidol	drug_n	neuroleptics	group
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGA binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGB (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGA and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGA binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
3H-spiroperidol	drug_n	haloperidol	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGA binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGB (0.25 mg/kg) resulted in the reduced interaction between DRUGA and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGA binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
3H-spiroperidol	drug_n	pyreneperone	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGA binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGA and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGA binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
3H-spiroperidol	drug_n	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGA binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGA and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGA binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
3H-spiroperidol	drug_n	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGA]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGB (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
neuroleptics	group	haloperidol	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGA]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGB (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
neuroleptics	group	pyreneperone	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGB binding after the long-term administration of DRUGA]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGB and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGB binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
neuroleptics	group	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGA]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
neuroleptics	group	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGB binding after the long-term administration of DRUGA]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGB and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGB binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
neuroleptics	group	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGA]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
neuroleptics	group	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGA (0.25 mg/kg) and DRUGB (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
haloperidol	drug	pyreneperone	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGB binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGA (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGB and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGB binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
haloperidol	drug	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGA (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
haloperidol	drug	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGB binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGA (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGB and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGB binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
haloperidol	drug	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGA (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
haloperidol	drug	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGB binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGA (0.25 mg/kg) resulted in the reduced interaction between DRUGB and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGB binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
pyreneperone	drug_n	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGA (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
pyreneperone	drug_n	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGB binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGA (0.25 mg/kg) resulted in the reduced interaction between DRUGB and low affinity binding sites for DRUGN in subcortical structures, whereas DRUGB binding with high affinity binding sites for DRUGN increased both in the frontal cortex and subcortical structures of the forebrain.
pyreneperone	drug_n	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGN binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGA (0.25 mg/kg) resulted in the reduced interaction between DRUGN and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGN binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
pyreneperone	drug_n	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGA binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGA and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGA binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
3H-spiroperidol	drug_n	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGA binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGA and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGA binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
3H-spiroperidol	drug_n	apomorphine	drug
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGB binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGB and low affinity binding sites for DRUGA in subcortical structures, whereas DRUGB binding with high affinity binding sites for DRUGA increased both in the frontal cortex and subcortical structures of the forebrain.
apomorphine	drug	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s0
[Stimulation by DRUGN--an analog of the octapeptide cholecystokinin--of DRUGA binding after the long-term administration of DRUGN]
It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of DRUGN (0.25 mg/kg) and DRUGN (0.25 mg/kg) resulted in the reduced interaction between DRUGA and low affinity binding sites for DRUGB in subcortical structures, whereas DRUGA binding with high affinity binding sites for DRUGB increased both in the frontal cortex and subcortical structures of the forebrain.
3H-spiroperidol	drug_n	apomorphine	drug
false

DDI-MedLine.d15.s1
After prolonged administration of DRUGA the displacing effect of DRUGB, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on DRUGN binding.
neuroleptics	group	cerulein	drug_n
false

DDI-MedLine.d15.s1
After prolonged administration of DRUGA the displacing effect of DRUGN, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on DRUGB binding.
neuroleptics	group	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s1
After prolonged administration of DRUGN the displacing effect of DRUGA, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on DRUGB binding.
cerulein	drug_n	3H-spiroperidol	drug_n
false

DDI-MedLine.d15.s2
It is assumed that increased interaction between DRUGA and high affinity binding sites for DRUGB on dopamine2- and serotonin2-receptors underlies the antipsychotic action of DRUGN after their prolonged administration.
3H-spiroperidol	drug_n	apomorphine	drug
false

DDI-MedLine.d15.s2
It is assumed that increased interaction between DRUGA and high affinity binding sites for DRUGN on dopamine2- and serotonin2-receptors underlies the antipsychotic action of DRUGB after their prolonged administration.
3H-spiroperidol	drug_n	neuroleptics	group
false

DDI-MedLine.d15.s2
It is assumed that increased interaction between DRUGN and high affinity binding sites for DRUGA on dopamine2- and serotonin2-receptors underlies the antipsychotic action of DRUGB after their prolonged administration.
apomorphine	drug	neuroleptics	group
false

DDI-MedLine.d56.s0
Dual effect of DRUGA on the DRUGB-induced contraction and norepinephrine release in the guinea-pig vas deferens.
ouabain	drug	palytoxin	drug_n
false

DDI-MedLine.d56.s1
DRUGA (DRUGB), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens.
Palytoxin	drug_n	PTX	drug_n
false

DDI-MedLine.d56.s5
When DRUGA was applied to the muscle in the presence of DRUGN, both first and second contractile responses to DRUGB were abolished.
ouabain	drug	PTX	drug_n
false

DDI-MedLine.d56.s5
When DRUGN was applied to the muscle in the presence of DRUGA, both first and second contractile responses to DRUGB were abolished.
phentolamine	drug	PTX	drug_n
false

DDI-MedLine.d82.s1
The intestinal absorption of DRUGA(DRUGB) has been investigated in the chick by means of the in situ ligated duodenal loop technique.
arsenate	drug_n	As(V)	drug_n
false

DDI-MedLine.d82.s2
By this procedure, it was observed that DRUGA is rapidly and essentially completely absorbed (80-95%) from the lumen at DRUGB concentrations up to 5 mM, declining to about 50% absorption at 50 mM.
arsenate	drug_n	As(V)	drug_n
false

DDI-MedLine.d82.s7
Furthermore, DRUGA and DRUGB do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level.
arsenate	drug_n	phosphate	drug
false

DDI-MedLine.d22.s2
By contrast, DRUGA (1 mM) and DRUGB (1 mM) had no significant effect on the translocation when added alone.
spermidine	drug_n	putrescine	drug_n
false

DDI-MedLine.d22.s3
DRUGA, and to a lesser extent, DRUGB, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction.
Spermine	drug	spermidine	drug_n
false

DDI-MedLine.d100.s5
DRUGA, such as DRUGB, DRUGN and DRUGN, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
Slow-channel calcium blockers	group	verapamil	drug
false

DDI-MedLine.d100.s5
DRUGA, such as DRUGN, DRUGB and DRUGN, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
Slow-channel calcium blockers	group	diltiazem	drug
false

DDI-MedLine.d100.s5
DRUGA, such as DRUGN, DRUGN and DRUGB, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
Slow-channel calcium blockers	group	nifedipine	drug
false

DDI-MedLine.d100.s5
DRUGN, such as DRUGA, DRUGB and DRUGN, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
verapamil	drug	diltiazem	drug
false

DDI-MedLine.d100.s5
DRUGN, such as DRUGA, DRUGN and DRUGB, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
verapamil	drug	nifedipine	drug
false

DDI-MedLine.d100.s5
DRUGN, such as DRUGN, DRUGA and DRUGB, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
diltiazem	drug	nifedipine	drug
false

DDI-MedLine.d63.s0
Differential actions of intrathecal DRUGA on blocking the tail-flick inhibition induced by intraventricular DRUGB and DRUGN in rats.
naloxone	drug	beta-endorphin	drug_n
false

DDI-MedLine.d63.s0
Differential actions of intrathecal DRUGA on blocking the tail-flick inhibition induced by intraventricular DRUGN and DRUGB in rats.
naloxone	drug	morphine	drug
false

DDI-MedLine.d63.s0
Differential actions of intrathecal DRUGN on blocking the tail-flick inhibition induced by intraventricular DRUGA and DRUGB in rats.
beta-endorphin	drug_n	morphine	drug
false

DDI-MedLine.d63.s2
The blockade of the spinal endorphinergic system by intrathecal DRUGA on the production of tail-flick inhibition induced by intraventricular DRUGB and DRUGN was then studied.
naloxone	drug	beta-endorphin	drug_n
false

DDI-MedLine.d63.s2
The blockade of the spinal endorphinergic system by intrathecal DRUGA on the production of tail-flick inhibition induced by intraventricular DRUGN and DRUGB was then studied.
naloxone	drug	morphine	drug
false

DDI-MedLine.d63.s2
The blockade of the spinal endorphinergic system by intrathecal DRUGN on the production of tail-flick inhibition induced by intraventricular DRUGA and DRUGB was then studied.
beta-endorphin	drug_n	morphine	drug
false

DDI-MedLine.d63.s3
Intraventricular injection of DRUGA and DRUGB produced an inhibition of the tail-flick response to the heat stimulus in rats.
beta-endorphin	drug_n	morphine	drug
false

DDI-MedLine.d63.s4
Intrathecal injection of DRUGA at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of DRUGB, and a high dose of DRUGA (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular DRUGB (16 micrograms).
naloxone	drug	beta-endorphin	drug_n
false

DDI-MedLine.d63.s4
Intrathecal injection of DRUGB at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of DRUGA, and a high dose of DRUGB (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular DRUGA (16 micrograms).
beta-endorphin	drug_n	naloxone	drug
false

DDI-MedLine.d63.s6
Intraventricular injection of DRUGN at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular DRUGA and DRUGB.
beta-endorphin	drug_n	morphine	drug
false

DDI-MedLine.d63.s7
The results indicate that a spinal DRUGA-sensitive endorphinergic system is involved in the production of DRUGB but not DRUGN-induced tail-flick inhibition, and suggest that intraventricular DRUGB and DRUGN elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
naloxone	drug	beta-endorphin	drug_n
false

DDI-MedLine.d63.s7
The results indicate that a spinal DRUGA-sensitive endorphinergic system is involved in the production of DRUGN but not DRUGB-induced tail-flick inhibition, and suggest that intraventricular DRUGN and DRUGB elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
naloxone	drug	morphine	drug
false

DDI-MedLine.d63.s7
The results indicate that a spinal DRUGA-sensitive endorphinergic system is involved in the production of DRUGB but not DRUGN-induced tail-flick inhibition, and suggest that intraventricular DRUGB and DRUGN elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
naloxone	drug	beta-endorphin	drug_n
false

DDI-MedLine.d63.s7
The results indicate that a spinal DRUGA-sensitive endorphinergic system is involved in the production of DRUGN but not DRUGB-induced tail-flick inhibition, and suggest that intraventricular DRUGN and DRUGB elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
naloxone	drug	morphine	drug
false

DDI-MedLine.d63.s7
The results indicate that a spinal DRUGN-sensitive endorphinergic system is involved in the production of DRUGA but not DRUGB-induced tail-flick inhibition, and suggest that intraventricular DRUGA and DRUGB elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
beta-endorphin	drug_n	morphine	drug
false

DDI-MedLine.d63.s7
The results indicate that a spinal DRUGN-sensitive endorphinergic system is involved in the production of DRUGA but not DRUGB-induced tail-flick inhibition, and suggest that intraventricular DRUGA and DRUGB elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
beta-endorphin	drug_n	morphine	drug
false

DDI-MedLine.d63.s7
The results indicate that a spinal DRUGN-sensitive endorphinergic system is involved in the production of DRUGB but not DRUGA-induced tail-flick inhibition, and suggest that intraventricular DRUGB and DRUGA elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
morphine	drug	beta-endorphin	drug_n
false

DDI-MedLine.d63.s7
The results indicate that a spinal DRUGN-sensitive endorphinergic system is involved in the production of DRUGA but not DRUGB-induced tail-flick inhibition, and suggest that intraventricular DRUGA and DRUGB elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
beta-endorphin	drug_n	morphine	drug
false

DDI-MedLine.d63.s8
descending epsilon and mu systems for DRUGA and DRUGB, respectively, are proposed.
beta-endorphin	drug_n	morphine	drug
false

DDI-MedLine.d73.s0
Neurochemical and functional consequences following DRUGA (DRUGB) and DRUGN.
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	drug_n	MPTP	drug_n
false

DDI-MedLine.d73.s0
Neurochemical and functional consequences following DRUGA (DRUGN) and DRUGB.
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	drug_n	methamphetamine	drug
false

DDI-MedLine.d73.s0
Neurochemical and functional consequences following DRUGN (DRUGA) and DRUGB.
MPTP	drug_n	methamphetamine	drug
false

DDI-MedLine.d73.s1
The neurochemical and functional consequences following DRUGA administration to the rat were evaluated and compared to similar effects following DRUGB administration.
MPTP	drug_n	methamphetamine	drug
false

DDI-MedLine.d73.s3
The DRUGN-induced neuronal damage produced a tolerance to the disruptive effects of DRUGA and a supersensitivity to the disruptive effects of DRUGB in rats responding in a schedule controlled paradigm.
amphetamine	drug	apomorphine	drug
false

DDI-MedLine.d73.s4
DRUGA, like DRUGB, produced depletions of striatal dopamine but these actions were potentiated by DRUGN pretreatment.
Methamphetamine	drug	MPTP	drug_n
false

DDI-MedLine.d73.s4
DRUGN, like DRUGA, produced depletions of striatal dopamine but these actions were potentiated by DRUGB pretreatment.
MPTP	drug_n	pargyline	drug
false

DDI-MedLine.d12.s0
DRUGA and DRUGB similarly inhibit and stimulate DRUGN- or DRUGN-induced proliferation of prostatic epithelium.
Dexamethasone	drug	retinyl acetate	drug
false

DDI-MedLine.d12.s0
DRUGN and DRUGN similarly inhibit and stimulate DRUGA- or DRUGB-induced proliferation of prostatic epithelium.
EGF	drug_n	insulin	drug
false

DDI-MedLine.d12.s1
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing DRUGA (1 microgram/ml), DRUGB (10 ng/ml), and DRUGN (3.7 micrograms/ml or 0.1 IU/ml).
transferrin	drug_n	EGF	drug_n
false

DDI-MedLine.d12.s1
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing DRUGA (1 microgram/ml), DRUGN (10 ng/ml), and DRUGB (3.7 micrograms/ml or 0.1 IU/ml).
transferrin	drug_n	insulin	drug
false

DDI-MedLine.d12.s1
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing DRUGN (1 microgram/ml), DRUGA (10 ng/ml), and DRUGB (3.7 micrograms/ml or 0.1 IU/ml).
EGF	drug_n	insulin	drug
false

DDI-MedLine.d12.s2
Although neither DRUGA nor DRUGB affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGN alone, they modify the mitogenic effect of DRUGN and DRUGN.
dexamethasone	drug	retinyl acetate	drug
false

DDI-MedLine.d12.s2
Although neither DRUGA nor DRUGN affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGB alone, they modify the mitogenic effect of DRUGN and DRUGN.
dexamethasone	drug	transferrin	drug_n
false

DDI-MedLine.d12.s2
Although neither DRUGN nor DRUGA affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGB alone, they modify the mitogenic effect of DRUGN and DRUGN.
retinyl acetate	drug	transferrin	drug_n
false

DDI-MedLine.d12.s2
Although neither DRUGN nor DRUGN affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGA alone, they modify the mitogenic effect of DRUGB and DRUGN.
transferrin	drug_n	EGF	drug_n
false

DDI-MedLine.d12.s2
Although neither DRUGN nor DRUGN affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGA alone, they modify the mitogenic effect of DRUGN and DRUGB.
transferrin	drug_n	insulin	drug
false

DDI-MedLine.d12.s2
Although neither DRUGN nor DRUGN affected the proliferation of prostatic epithelium in RPMI1640 containing DRUGN alone, they modify the mitogenic effect of DRUGA and DRUGB.
EGF	drug_n	insulin	drug
false

DDI-MedLine.d12.s3
DRUGA at 10(-10) M or DRUGB at about 3 X 10(-9) M inhibits proliferation stimulated by DRUGN.
Dexamethasone	drug	retinyl acetate	drug
false

DDI-MedLine.d12.s4
Higher concentrations of DRUGA (10(-8) - 10(-6) M) or DRUGB (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of DRUGN.
dexamethasone	drug	retinyl acetate	drug
false

DDI-MedLine.d12.s5
DRUGA had a similar effect in the presence of DRUGB.
Dexamethasone	drug	insulin	drug
false

DDI-MedLine.d12.s7
These results suggest that both DRUGA and DRUGB, and possibly other DRUGN and DRUGN, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of DRUGN and DRUGN.
dexamethasone	drug	retinyl acetate	drug
false

DDI-MedLine.d12.s7
These results suggest that both DRUGA and DRUGN, and possibly other DRUGB and DRUGN, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of DRUGN and DRUGN.
dexamethasone	drug	glucocorticoids	group
false

DDI-MedLine.d12.s7
These results suggest that both DRUGA and DRUGN, and possibly other DRUGN and DRUGB, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of DRUGN and DRUGN.
dexamethasone	drug	retinoids	group
false

DDI-MedLine.d12.s7
These results suggest that both DRUGN and DRUGA, and possibly other DRUGB and DRUGN, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of DRUGN and DRUGN.
retinyl acetate	drug	glucocorticoids	group
false

DDI-MedLine.d12.s7
These results suggest that both DRUGN and DRUGA, and possibly other DRUGN and DRUGB, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of DRUGN and DRUGN.
retinyl acetate	drug	retinoids	group
false

DDI-MedLine.d12.s7
These results suggest that both DRUGN and DRUGN, and possibly other DRUGA and DRUGB, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of DRUGN and DRUGN.
glucocorticoids	group	retinoids	group
false

DDI-MedLine.d12.s7
These results suggest that both DRUGN and DRUGN, and possibly other DRUGN and DRUGN, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of DRUGA and DRUGB.
insulin	drug	EGF	drug_n
false

DDI-MedLine.d9.s3
For the DRUGA now available in the United States (DRUGB, DRUGN and DRUGN), these data appeared well after clinical patterns of use evolved.
calcium-entry blocking agents	group	verapamil	drug
false

DDI-MedLine.d9.s3
For the DRUGA now available in the United States (DRUGN, DRUGB and DRUGN), these data appeared well after clinical patterns of use evolved.
calcium-entry blocking agents	group	nifedipine	drug
false

DDI-MedLine.d9.s3
For the DRUGA now available in the United States (DRUGN, DRUGN and DRUGB), these data appeared well after clinical patterns of use evolved.
calcium-entry blocking agents	group	diltiazem	drug
false

DDI-MedLine.d9.s3
For the DRUGN now available in the United States (DRUGA, DRUGB and DRUGN), these data appeared well after clinical patterns of use evolved.
verapamil	drug	nifedipine	drug
false

DDI-MedLine.d9.s3
For the DRUGN now available in the United States (DRUGA, DRUGN and DRUGB), these data appeared well after clinical patterns of use evolved.
verapamil	drug	diltiazem	drug
false

DDI-MedLine.d9.s3
For the DRUGN now available in the United States (DRUGN, DRUGA and DRUGB), these data appeared well after clinical patterns of use evolved.
nifedipine	drug	diltiazem	drug
false

DDI-MedLine.d9.s5
by the nonlinear kinetic characteristics for DRUGA and DRUGB (and probably for DRUGN, as well) and the derivative implications for decreased dosing frequency requirements;
verapamil	drug	diltiazem	drug
false

DDI-MedLine.d9.s5
by the nonlinear kinetic characteristics for DRUGA and DRUGN (and probably for DRUGB, as well) and the derivative implications for decreased dosing frequency requirements;
verapamil	drug	nifedipine	drug
false

DDI-MedLine.d9.s5
by the nonlinear kinetic characteristics for DRUGN and DRUGA (and probably for DRUGB, as well) and the derivative implications for decreased dosing frequency requirements;
diltiazem	drug	nifedipine	drug
false

DDI-MedLine.d45.s0
Selective survival in DRUGA and DRUGB of Pseudomonas aeruginosa serotype O11 from drug addicts.
pentazocine	drug	tripelennamine	drug
false

DDI-MedLine.d45.s1
The growth of Pseudomonas aeruginosa, particularly serotype O11, in DRUGA and DRUGB
pentazocine	drug	tripelennamine	drug
false

DDI-MedLine.d45.s5
Twelve strains of Staphylococcus aureus (a frequent cause of infection in DRUGA, but not in DRUGB and DRUGN, addicts) were completely inhibited by the drug combination.
heroin	drug_n	pentazocine	drug
false

DDI-MedLine.d45.s5
Twelve strains of Staphylococcus aureus (a frequent cause of infection in DRUGA, but not in DRUGN and DRUGB, addicts) were completely inhibited by the drug combination.
heroin	drug_n	tripelennamine	drug
false

DDI-MedLine.d45.s9
aureus, to survive in DRUGA and DRUGB may explain in part a shift from S.
pentazocine	drug	tripelennamine	drug
false

DDI-MedLine.d61.s0
Pharmacokinetic evaluation of the DRUGA-DRUGB interaction.
digoxin	drug	amiodarone	drug
false

DDI-MedLine.d61.s3
The pharmacokinetic variables for DRUGA were determined after a 1.0 mg intravenous dose of DRUGA in each subject, before and after oral DRUGB, 400 mg daily for 3 weeks.
digoxin	drug	amiodarone	drug
false

DDI-MedLine.d61.s3
The pharmacokinetic variables for DRUGA were determined after a 1.0 mg intravenous dose of DRUGA in each subject, before and after oral DRUGB, 400 mg daily for 3 weeks.
digoxin	drug	amiodarone	drug
false

DDI-MedLine.d61.s8
DRUGA caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in DRUGB pharmacokinetics.
Amiodarone	drug	digoxin	drug
false

DDI-MedLine.d61.s9
These alterations in DRUGB pharmacokinetics produced by DRUGA explain the increase in serum DRUGB level that has been observed when this drug combination has been used clinically.
amiodarone	drug	digoxin	drug
false

DDI-MedLine.d85.s1
Because the DRUGA DRUGB is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral DRUGB, either alone or in combination with the chemosensitizer DRUGN.
nitrosourea	group	CCNU	drug
false

DDI-MedLine.d85.s1
Because the DRUGA DRUGB is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral DRUGB, either alone or in combination with the chemosensitizer DRUGN.
nitrosourea	group	CCNU	drug
false

DDI-MedLine.d85.s1
Because the DRUGA DRUGN is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral DRUGN, either alone or in combination with the chemosensitizer DRUGB.
nitrosourea	group	misonidazole	drug_n
false

DDI-MedLine.d85.s1
Because the DRUGN DRUGA is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral DRUGA, either alone or in combination with the chemosensitizer DRUGB.
CCNU	drug	misonidazole	drug_n
false

DDI-MedLine.d85.s1
Because the DRUGN DRUGA is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral DRUGA, either alone or in combination with the chemosensitizer DRUGB.
CCNU	drug	misonidazole	drug_n
false

DDI-MedLine.d30.s1
The behavioral effects of the stereoisomers of DRUGA (DRUGB) were compared with those of DRUGN (DRUGN) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
N-allylnormetazocine	drug_n	NANM	drug_n
false

DDI-MedLine.d30.s1
The behavioral effects of the stereoisomers of DRUGA (DRUGN) were compared with those of DRUGB (DRUGN) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
N-allylnormetazocine	drug_n	phencyclidine	drug_n
false

DDI-MedLine.d30.s1
The behavioral effects of the stereoisomers of DRUGA (DRUGN) were compared with those of DRUGN (DRUGB) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
N-allylnormetazocine	drug_n	PCP	drug_n
false

DDI-MedLine.d30.s1
The behavioral effects of the stereoisomers of DRUGN (DRUGA) were compared with those of DRUGB (DRUGN) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
NANM	drug_n	phencyclidine	drug_n
false

DDI-MedLine.d30.s1
The behavioral effects of the stereoisomers of DRUGN (DRUGA) were compared with those of DRUGN (DRUGB) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
NANM	drug_n	PCP	drug_n
false

DDI-MedLine.d30.s1
The behavioral effects of the stereoisomers of DRUGN (DRUGN) were compared with those of DRUGA (DRUGB) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
phencyclidine	drug_n	PCP	drug_n
false

DDI-MedLine.d30.s2
Intermediate doses of DRUGA or DRUGB produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons;
(+)-NANM	drug_n	PCP	drug_n
false

DDI-MedLine.d30.s6
In monkeys, DRUGA was about 10 times more potent than DRUGB in decreasing responding, whereas in pigeons DRUGA was about equipotent with DRUGB.
(-)-NANM	drug_n	(+)-NANM	drug_n
false

DDI-MedLine.d30.s6
In monkeys, DRUGA was about 10 times more potent than DRUGB in decreasing responding, whereas in pigeons DRUGA was about equipotent with DRUGB.
(-)-NANM	drug_n	(+)-NANM	drug_n
false

DDI-MedLine.d30.s6
In monkeys, DRUGB was about 10 times more potent than DRUGA in decreasing responding, whereas in pigeons DRUGB was about equipotent with DRUGA.
(+)-NANM	drug_n	(-)-NANM	drug_n
false

DDI-MedLine.d30.s6
In monkeys, DRUGA was about 10 times more potent than DRUGB in decreasing responding, whereas in pigeons DRUGA was about equipotent with DRUGB.
(-)-NANM	drug_n	(+)-NANM	drug_n
false

DDI-MedLine.d30.s7
In both species, DRUGA, but not DRUGB, antagonized the rate-decreasing effects of DRUGN on FI and FR responding.
(-)-NANM	drug_n	(+)-NANM	drug_n
false

DDI-MedLine.d30.s7
In both species, DRUGN, but not DRUGA, antagonized the rate-decreasing effects of DRUGB on FI and FR responding.
(+)-NANM	drug_n	morphine	drug
false

DDI-MedLine.d30.s8
In monkeys, the effects of DRUGA, but not DRUGB or DRUGN, were antagonized by DRUGN;
(-)-NANM	drug_n	(+)-NANM	drug_n
false

DDI-MedLine.d30.s8
In monkeys, the effects of DRUGA, but not DRUGN or DRUGB, were antagonized by DRUGN;
(-)-NANM	drug_n	PCP	drug_n
false

DDI-MedLine.d30.s8
In monkeys, the effects of DRUGN, but not DRUGA or DRUGB, were antagonized by DRUGN;
(+)-NANM	drug_n	PCP	drug_n
false

DDI-MedLine.d30.s8
In monkeys, the effects of DRUGN, but not DRUGA or DRUGN, were antagonized by DRUGB;
(+)-NANM	drug_n	naloxone	drug
false

DDI-MedLine.d30.s8
In monkeys, the effects of DRUGN, but not DRUGN or DRUGA, were antagonized by DRUGB;
PCP	drug_n	naloxone	drug
false

DDI-MedLine.d30.s9
the doses of DRUGN required to antagonize the effects of DRUGA were more than 100 times higher than those required to antagonize the effects of DRUGB.
(-)-NANM	drug_n	morphine	drug
false

DDI-MedLine.d30.s10
In pigeons, DRUGA did not systematically alter the effects of DRUGB, DRUGN or DRUGN.
naloxone	drug	(-)-NANM	drug_n
false

DDI-MedLine.d30.s10
In pigeons, DRUGA did not systematically alter the effects of DRUGN, DRUGB or DRUGN.
naloxone	drug	(+)-NANM	drug_n
false

DDI-MedLine.d30.s10
In pigeons, DRUGA did not systematically alter the effects of DRUGN, DRUGN or DRUGB.
naloxone	drug	PCP	drug_n
false

DDI-MedLine.d30.s10
In pigeons, DRUGN did not systematically alter the effects of DRUGA, DRUGB or DRUGN.
(-)-NANM	drug_n	(+)-NANM	drug_n
false

DDI-MedLine.d30.s10
In pigeons, DRUGN did not systematically alter the effects of DRUGA, DRUGN or DRUGB.
(-)-NANM	drug_n	PCP	drug_n
false

DDI-MedLine.d30.s10
In pigeons, DRUGN did not systematically alter the effects of DRUGN, DRUGA or DRUGB.
(+)-NANM	drug_n	PCP	drug_n
false

DDI-MedLine.d30.s11
DRUGA reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-DRUGB or DRUGN in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of DRUGN or either stereoisomer of DRUGB.
Haloperidol	drug	NANM	drug_n
false

DDI-MedLine.d30.s11
DRUGN reduced or eliminated the increases in FI responding produced by intermediate doses of either DRUGA or DRUGB in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of DRUGB or either stereoisomer of DRUGN.
(+)-NANM	drug_n	PCP	drug_n
false

DDI-MedLine.d30.s11
DRUGN reduced or eliminated the increases in FI responding produced by intermediate doses of either DRUGA or DRUGN in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of DRUGN or either stereoisomer of DRUGB.
(+)-NANM	drug_n	NANM	drug_n
false

DDI-MedLine.d30.s11
DRUGN reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-DRUGB or DRUGA in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of DRUGA or either stereoisomer of DRUGB.
PCP	drug_n	NANM	drug_n
false

DDI-MedLine.d55.s1
Since DRUGA is frequently co-administered with DRUGB, it is of clinical interest to study the effect of DRUGA on the hepatotoxicity of DRUGB.
caffeine	drug	acetaminophen	drug
false

DDI-MedLine.d55.s1
Since DRUGA is frequently co-administered with DRUGB, it is of clinical interest to study the effect of DRUGA on the hepatotoxicity of DRUGB.
caffeine	drug	acetaminophen	drug
false

DDI-MedLine.d55.s1
Since DRUGB is frequently co-administered with DRUGA, it is of clinical interest to study the effect of DRUGB on the hepatotoxicity of DRUGA.
acetaminophen	drug	caffeine	drug
false

DDI-MedLine.d55.s1
Since DRUGA is frequently co-administered with DRUGB, it is of clinical interest to study the effect of DRUGA on the hepatotoxicity of DRUGB.
caffeine	drug	acetaminophen	drug
false

DDI-MedLine.d130.s3
To determine whether injection of DRUGA would permit larger doses of DRUGB to be administered, a fixed 9.9-g/m2 dose of DRUGA was given intravenously over three hours concurrently with escalating doses of DRUGB.
thiosulfate	drug	cisplatin	drug
false

DDI-MedLine.d130.s3
To determine whether injection of DRUGA would permit larger doses of DRUGB to be administered, a fixed 9.9-g/m2 dose of DRUGA was given intravenously over three hours concurrently with escalating doses of DRUGB.
thiosulfate	drug	cisplatin	drug
false

DDI-MedLine.d130.s3
To determine whether injection of DRUGB would permit larger doses of DRUGA to be administered, a fixed 9.9-g/m2 dose of DRUGB was given intravenously over three hours concurrently with escalating doses of DRUGA.
cisplatin	drug	thiosulfate	drug
false

DDI-MedLine.d130.s3
To determine whether injection of DRUGA would permit larger doses of DRUGB to be administered, a fixed 9.9-g/m2 dose of DRUGA was given intravenously over three hours concurrently with escalating doses of DRUGB.
thiosulfate	drug	cisplatin	drug
false

DDI-MedLine.d130.s4
DRUGA was administered over the last two hours of the DRUGB infusion.
Cisplatin	drug	thiosulfate	drug
false

DDI-MedLine.d130.s6
Comparison of DRUGA pharmacokinetics in patients treated with 202.5 mg/m2 plus DRUGB to those in patients treated with 100 mg/m2 without DRUGB indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of DRUGA.
cisplatin	drug	thiosulfate	drug
false

DDI-MedLine.d130.s6
Comparison of DRUGA pharmacokinetics in patients treated with 202.5 mg/m2 plus DRUGB to those in patients treated with 100 mg/m2 without DRUGB indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of DRUGA.
cisplatin	drug	thiosulfate	drug
false

DDI-MedLine.d130.s6
Comparison of DRUGB pharmacokinetics in patients treated with 202.5 mg/m2 plus DRUGA to those in patients treated with 100 mg/m2 without DRUGA indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of DRUGB.
thiosulfate	drug	cisplatin	drug
false

DDI-MedLine.d130.s6
Comparison of DRUGB pharmacokinetics in patients treated with 202.5 mg/m2 plus DRUGA to those in patients treated with 100 mg/m2 without DRUGA indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of DRUGB.
thiosulfate	drug	cisplatin	drug
false

DDI-MedLine.d5.s0
Repeated oral administration of DRUGA in sheep: interactions of DRUGA with DRUGB, DRUGN, and DRUGN.
coumaphos	drug_n	bishydroxycoumarin	drug
false

DDI-MedLine.d5.s0
Repeated oral administration of DRUGA in sheep: interactions of DRUGA with DRUGN, DRUGB, and DRUGN.
coumaphos	drug_n	trichlorfon	drug_n
false

DDI-MedLine.d5.s0
Repeated oral administration of DRUGA in sheep: interactions of DRUGA with DRUGN, DRUGN, and DRUGB.
coumaphos	drug_n	phenobarbital sodium	drug
false

DDI-MedLine.d5.s0
Repeated oral administration of DRUGA in sheep: interactions of DRUGA with DRUGB, DRUGN, and DRUGN.
coumaphos	drug_n	bishydroxycoumarin	drug
false

DDI-MedLine.d5.s0
Repeated oral administration of DRUGA in sheep: interactions of DRUGA with DRUGN, DRUGB, and DRUGN.
coumaphos	drug_n	trichlorfon	drug_n
false

DDI-MedLine.d5.s0
Repeated oral administration of DRUGA in sheep: interactions of DRUGA with DRUGN, DRUGN, and DRUGB.
coumaphos	drug_n	phenobarbital sodium	drug
false

DDI-MedLine.d5.s0
Repeated oral administration of DRUGN in sheep: interactions of DRUGN with DRUGA, DRUGB, and DRUGN.
bishydroxycoumarin	drug	trichlorfon	drug_n
false

DDI-MedLine.d5.s0
Repeated oral administration of DRUGN in sheep: interactions of DRUGN with DRUGA, DRUGN, and DRUGB.
bishydroxycoumarin	drug	phenobarbital sodium	drug
false

DDI-MedLine.d5.s0
Repeated oral administration of DRUGN in sheep: interactions of DRUGN with DRUGN, DRUGA, and DRUGB.
trichlorfon	drug_n	phenobarbital sodium	drug
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGA, DRUGB (an DRUGN), DRUGN (an DRUGN), and DRUGN (an inducer of microsomal enzymes) were investigated in sheep.
coumaphos	drug_n	bishydroxycoumarin	drug
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGA, DRUGN (an DRUGB), DRUGN (an DRUGN), and DRUGN (an inducer of microsomal enzymes) were investigated in sheep.
coumaphos	drug_n	anticoagulant	group
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGA, DRUGN (an DRUGN), DRUGB (an DRUGN), and DRUGN (an inducer of microsomal enzymes) were investigated in sheep.
coumaphos	drug_n	trichlorfon	drug_n
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGA, DRUGN (an DRUGN), DRUGN (an DRUGB), and DRUGN (an inducer of microsomal enzymes) were investigated in sheep.
coumaphos	drug_n	organophosphorous compound	group
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGA, DRUGN (an DRUGN), DRUGN (an DRUGN), and DRUGB (an inducer of microsomal enzymes) were investigated in sheep.
coumaphos	drug_n	phenobarbital sodium	drug
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGN, DRUGA (an DRUGB), DRUGN (an DRUGN), and DRUGN (an inducer of microsomal enzymes) were investigated in sheep.
bishydroxycoumarin	drug	anticoagulant	group
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGN, DRUGA (an DRUGN), DRUGB (an DRUGN), and DRUGN (an inducer of microsomal enzymes) were investigated in sheep.
bishydroxycoumarin	drug	trichlorfon	drug_n
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGN, DRUGA (an DRUGN), DRUGN (an DRUGB), and DRUGN (an inducer of microsomal enzymes) were investigated in sheep.
bishydroxycoumarin	drug	organophosphorous compound	group
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGN, DRUGA (an DRUGN), DRUGN (an DRUGN), and DRUGB (an inducer of microsomal enzymes) were investigated in sheep.
bishydroxycoumarin	drug	phenobarbital sodium	drug
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGN, DRUGN (an DRUGA), DRUGB (an DRUGN), and DRUGN (an inducer of microsomal enzymes) were investigated in sheep.
anticoagulant	group	trichlorfon	drug_n
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGN, DRUGN (an DRUGA), DRUGN (an DRUGB), and DRUGN (an inducer of microsomal enzymes) were investigated in sheep.
anticoagulant	group	organophosphorous compound	group
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGN, DRUGN (an DRUGA), DRUGN (an DRUGN), and DRUGB (an inducer of microsomal enzymes) were investigated in sheep.
anticoagulant	group	phenobarbital sodium	drug
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGN, DRUGN (an DRUGN), DRUGA (an DRUGB), and DRUGN (an inducer of microsomal enzymes) were investigated in sheep.
trichlorfon	drug_n	organophosphorous compound	group
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGN, DRUGN (an DRUGN), DRUGA (an DRUGN), and DRUGB (an inducer of microsomal enzymes) were investigated in sheep.
trichlorfon	drug_n	phenobarbital sodium	drug
false

DDI-MedLine.d5.s1
Interactions between treatments with DRUGN, DRUGN (an DRUGN), DRUGN (an DRUGA), and DRUGB (an inducer of microsomal enzymes) were investigated in sheep.
organophosphorous compound	group	phenobarbital sodium	drug
false

DDI-MedLine.d5.s2
A daily dose of 2 mg of DRUGA/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of DRUGB in wethers.
coumaphos	drug_n	bishydroxy-coumarin	drug
false

DDI-MedLine.d2.s0
Failure of DRUGA to modify DRUGB induced hypertension in sheep.
neomycin	drug	ACTH	group
false

DDI-MedLine.d2.s1
Studies in rats have shown that DRUGA administration attenuates certain types of DRUGB dependent hypertension, including DRUGN hypertension.
neomycin	drug	adrenocortical steroid	group
false

DDI-MedLine.d2.s1
Studies in rats have shown that DRUGN administration attenuates certain types of DRUGA dependent hypertension, including DRUGB hypertension.
adrenocortical steroid	group	ACTH	drug
false

DDI-MedLine.d2.s2
The effects of oral DRUGA on DRUGB induced hypertension were examined in conscious sheep.
neomycin	drug	ACTH	group
false

DDI-MedLine.d2.s3
DRUGA has no effect on the blood pressure or metabolic responses to DRUGB in sheep.
Neomycin	drug	ACTH	group
false

DDI-MedLine.d66.s0
Changes in urinary homocysteine following DRUGA and DRUGB administration to rats.
synthetic steroidal estrogen	group	synthetic steroidal progestogen	group
false

DDI-MedLine.d66.s1
The present work involved the administration of both DRUGA and DRUGB to groups of rats, followed by determination of the homocysteine excretion rate in urine.
ethynyl estradiol	drug	levonorgestrel	drug
false

DDI-MedLine.d66.s2
The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and DRUGA-treated rats and the levels shown by rats treated with DRUGB.
levonorgestrel	drug	ethynyl estradiol	drug
false

DDI-MedLine.d93.s4
Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of DRUGA (DRUGB) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle.
trimethyl lead	drug_n	TML	drug_n
false

DDI-MedLine.d93.s6
The 20% v/v solution of DRUGA was prepared in water from a stock solution of 95% DRUGB.
alcohol	drug	ethanol	drug
false

DDI-MedLine.d54.s3
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, DRUGA (2.0 g/kg), DRUGB (0.6 mg/kg) or DRUGN (15.0 mg/kg) on separate days.
ethanol	drug	physostigmine	drug
false

DDI-MedLine.d54.s3
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, DRUGA (2.0 g/kg), DRUGN (0.6 mg/kg) or DRUGB (15.0 mg/kg) on separate days.
ethanol	drug	atropine	drug
false

DDI-MedLine.d54.s3
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, DRUGN (2.0 g/kg), DRUGA (0.6 mg/kg) or DRUGB (15.0 mg/kg) on separate days.
physostigmine	drug	atropine	drug
false

DDI-MedLine.d54.s10
DRUGA, either alone or in combination with DRUGB, produced approximately the same degree of enhancement of component P2.
Atropine	drug	alcohol	drug
false

DDI-MedLine.d81.s0
Hypothermia as an index of the DRUGA-DRUGB reaction in the rat.
disulfiram	drug	ethanol	drug
false

DDI-MedLine.d81.s1
Decreased core temperature in female rats was investigated as one possible index of the DRUGA-DRUGB reaction (DER).
disulfiram	drug	ethanol	drug
false

DDI-MedLine.d81.s2
Core temperature was decreased in rats in a dose-dependent manner when DRUGB was administered to rats treated with DRUGA 8 hours before the DRUGB challenge.
disulfiram	drug	ethanol	drug
false

DDI-MedLine.d131.s0
Interaction on the antinociceptive effect between DRUGN and DRUGA or DRUGB.
enkephalins	drug_n	tuftsin	drug_n
false

DDI-MedLine.d131.s1
The aim of this paper was to study the interaction between DRUGA and both DRUGB or its synthetic analogue DRUGN, or DRUGN, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
neurotensin	drug_n	enkephalins	drug_n
false

DDI-MedLine.d131.s1
The aim of this paper was to study the interaction between DRUGA and both DRUGN or its synthetic analogue DRUGB, or DRUGN, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
neurotensin	drug_n	D-Ala2-metenkephalinamide	drug_n
false

DDI-MedLine.d131.s1
The aim of this paper was to study the interaction between DRUGA and both DRUGN or its synthetic analogue DRUGN, or DRUGB, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
neurotensin	drug_n	tuftsin	drug_n
false

DDI-MedLine.d131.s1
The aim of this paper was to study the interaction between DRUGN and both DRUGA or its synthetic analogue DRUGB, or DRUGN, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
enkephalins	drug_n	D-Ala2-metenkephalinamide	drug_n
false

DDI-MedLine.d131.s1
The aim of this paper was to study the interaction between DRUGN and both DRUGA or its synthetic analogue DRUGN, or DRUGB, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
enkephalins	drug_n	tuftsin	drug_n
false

DDI-MedLine.d131.s1
The aim of this paper was to study the interaction between DRUGN and both DRUGN or its synthetic analogue DRUGA, or DRUGB, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
D-Ala2-metenkephalinamide	drug_n	tuftsin	drug_n
false

DDI-MedLine.d97.s10
Recommendations were to avoid administration of diffusible DRUGA treatment during the cure, and to improve the general conditions of patients before the cure of DRUGB.
anti-helminthic	group	melarsoprol	drug
false

DDI-MedLine.d34.s1
The effects of supplementary oral DRUGA and DRUGB, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of DRUGN and 48 or 446 mg/kg of DRUGN over a period of 19 days in a total of 24 rats.
cobalt	drug	iron	drug
false

DDI-MedLine.d34.s1
The effects of supplementary oral DRUGA and DRUGN, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of DRUGB and 48 or 446 mg/kg of DRUGN over a period of 19 days in a total of 24 rats.
cobalt	drug	Co	drug
false

DDI-MedLine.d34.s1
The effects of supplementary oral DRUGA and DRUGN, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of DRUGN and 48 or 446 mg/kg of DRUGB over a period of 19 days in a total of 24 rats.
cobalt	drug	Fe	drug
false

DDI-MedLine.d34.s1
The effects of supplementary oral DRUGN and DRUGA, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of DRUGB and 48 or 446 mg/kg of DRUGN over a period of 19 days in a total of 24 rats.
iron	drug	Co	drug
false

DDI-MedLine.d34.s1
The effects of supplementary oral DRUGN and DRUGA, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of DRUGN and 48 or 446 mg/kg of DRUGB over a period of 19 days in a total of 24 rats.
iron	drug	Fe	drug
false

DDI-MedLine.d34.s1
The effects of supplementary oral DRUGN and DRUGN, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of DRUGA and 48 or 446 mg/kg of DRUGB over a period of 19 days in a total of 24 rats.
Co	drug	Fe	drug
false

DDI-MedLine.d34.s4
DRUGA excretion was enhanced by supplementary DRUGB;
Cobalt	drug	cobalt	drug
false

DDI-MedLine.d34.s8
The lower rate of absorption in the groups receiving 446 mg DRUGA instead of 48 mg of DRUGA per kg diet resulted in a decreased renal excretion of DRUGB.
Fe	drug	cobalt	drug
false

DDI-MedLine.d34.s11
Because of the low dietary DRUGA concentration as compared to the DRUGB contents of the diets, no effect of DRUGA on DRUGB absorption and excretion occurred.
cobalt	drug	iron	drug
false

DDI-MedLine.d34.s11
Because of the low dietary DRUGA concentration as compared to the DRUGB contents of the diets, no effect of DRUGA on DRUGB absorption and excretion occurred.
cobalt	drug	iron	drug
false

DDI-MedLine.d34.s11
Because of the low dietary DRUGB concentration as compared to the DRUGA contents of the diets, no effect of DRUGB on DRUGA absorption and excretion occurred.
iron	drug	cobalt	drug
false

DDI-MedLine.d34.s11
Because of the low dietary DRUGA concentration as compared to the DRUGB contents of the diets, no effect of DRUGA on DRUGB absorption and excretion occurred.
cobalt	drug	iron	drug
false

DDI-MedLine.d34.s12
Differences in DRUGA balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further DRUGB.(ABSTRACT TRUNCATED AT 250 WORDS)
iron	drug	Fe	drug
false

DDI-MedLine.d39.s0
Effect of DRUGA on DRUGB-induced changes in steroid hormone levels and lethality in male rats.
estradiol	drug	endotoxin	drug_n
false

DDI-MedLine.d39.s1
We examined the effect of exogenous DRUGA on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli DRUGB in male rats and the deaths due to nonlethal and lethal doses of DRUGB.
estradiol	drug	endotoxin	drug_n
false

DDI-MedLine.d39.s1
We examined the effect of exogenous DRUGA on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli DRUGB in male rats and the deaths due to nonlethal and lethal doses of DRUGB.
estradiol	drug	endotoxin	drug_n
false

DDI-MedLine.d39.s2
Injection of DRUGA 5 min before a nonlethal dose of DRUGB changed the serum sex steroid hormone response of male rats to DRUGB.
estradiol	drug	endotoxin	drug_n
false

DDI-MedLine.d39.s3
The serum estrogen concentrations of DRUGA + DRUGB-treated rats decreased by 50%, while those of the DRUGB-treated rats increased (2- to 5-fold).
estradiol	drug	endotoxin	drug_n
false

DDI-MedLine.d39.s4
The serum androgen concentrations of DRUGA + DRUGB-treated rats did not change significantly, while those of DRUGB-treated rats dropped to 30-40%
estradiol	drug	endotoxin	drug_n
false

DDI-MedLine.d39.s4
The serum androgen concentrations of DRUGA + DRUGB-treated rats did not change significantly, while those of DRUGB-treated rats dropped to 30-40%
estradiol	drug	endotoxin	drug_n
false

DDI-MedLine.d39.s8
These results, together with the known relationships between DRUGA and the immune response, suggest that DRUGAs affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.
estrogen	group	estrogens	group
false

DDI-MedLine.d128.s1
The DRUGA (DRUGB)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction.
16,16-dimethylprostaglandin E2	drug_n	dmPGE2	drug_n
false

DDI-MedLine.d128.s12
DRUGA and DRUGB (0.1 and 1.0 mg/kg, s.c.)
Loperamide	drug	morphine	drug
false

DDI-MedLine.d128.s13
DRUGA and DRUGB (0.1 and 1.0 mg/kg, s.c.) inhibited the DRUGN (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
Loperamide	drug	morphine	drug
false

DDI-MedLine.d128.s15
DRUGN (5 mg/kg, s.c.) completely antagonized the inhibitory effect of DRUGA and partly antagonized the effect of DRUGB.
loperamide	drug	morphine	drug
false

DDI-MedLine.d89.s1
DRUGA is an DRUGB used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys.
Gentamicin	drug	aminoglycoside antibiotic	group
false

DDI-MedLine.d89.s7
Therapeutic drug monitoring (TDM) of DRUGA therapy, and bone scintigraphy employing DRUGB as the DRUGN was carried out in 22 patients.
gentamicin	drug	99mTc-MDP	drug
false

DDI-MedLine.d89.s7
Therapeutic drug monitoring (TDM) of DRUGA therapy, and bone scintigraphy employing DRUGN as the DRUGB was carried out in 22 patients.
gentamicin	drug	radiopharmaceutical	group
false

DDI-MedLine.d89.s7
Therapeutic drug monitoring (TDM) of DRUGN therapy, and bone scintigraphy employing DRUGA as the DRUGB was carried out in 22 patients.
99mTc-MDP	drug	radiopharmaceutical	group
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGA in turn (DRUGB, DRUGN, DRUGN, DRUGN, DRUGN), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
immunosuppressive drugs	group	corticosteroids	group
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGA in turn (DRUGN, DRUGB, DRUGN, DRUGN, DRUGN), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
immunosuppressive drugs	group	cyclosporin	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGA in turn (DRUGN, DRUGN, DRUGB, DRUGN, DRUGN), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
immunosuppressive drugs	group	azathioprine	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGA in turn (DRUGN, DRUGN, DRUGN, DRUGB, DRUGN), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
immunosuppressive drugs	group	methotrexate	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGA in turn (DRUGN, DRUGN, DRUGN, DRUGN, DRUGB), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
immunosuppressive drugs	group	cyclophosphamide	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGN in turn (DRUGA, DRUGB, DRUGN, DRUGN, DRUGN), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
corticosteroids	group	cyclosporin	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGN in turn (DRUGA, DRUGN, DRUGB, DRUGN, DRUGN), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
corticosteroids	group	azathioprine	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGN in turn (DRUGA, DRUGN, DRUGN, DRUGB, DRUGN), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
corticosteroids	group	methotrexate	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGN in turn (DRUGA, DRUGN, DRUGN, DRUGN, DRUGB), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
corticosteroids	group	cyclophosphamide	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGN in turn (DRUGN, DRUGA, DRUGB, DRUGN, DRUGN), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
cyclosporin	drug	azathioprine	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGN in turn (DRUGN, DRUGA, DRUGN, DRUGB, DRUGN), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
cyclosporin	drug	methotrexate	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGN in turn (DRUGN, DRUGA, DRUGN, DRUGN, DRUGB), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
cyclosporin	drug	cyclophosphamide	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGN in turn (DRUGN, DRUGN, DRUGA, DRUGB, DRUGN), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
azathioprine	drug	methotrexate	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGN in turn (DRUGN, DRUGN, DRUGA, DRUGN, DRUGB), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
azathioprine	drug	cyclophosphamide	drug
false

DDI-MedLine.d11.s4
This article looks at five commonly used DRUGN in turn (DRUGN, DRUGN, DRUGN, DRUGA, DRUGB), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
methotrexate	drug	cyclophosphamide	drug
false

DDI-MedLine.d107.s1
Little has been studied of the adverse effects of the exposure of the liver to the interaction of DRUGA with its congeners and DRUGB, coexisting in the contents of alcoholic beverages.
ethanol	drug	acetaldehyde	drug_n
false

DDI-MedLine.d107.s3
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUGA, mDRUGA, higher DRUGN and DRUGN in the same proportions as those found in most common distilled and fermented alcoholic beverages;
ethanol	drug	methanol	drug_n
false

DDI-MedLine.d107.s3
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUGA, mDRUGA, higher DRUGB and DRUGN in the same proportions as those found in most common distilled and fermented alcoholic beverages;
ethanol	drug	alcohols	drug_n
false

DDI-MedLine.d107.s3
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUGA, mDRUGA, higher DRUGN and DRUGB in the same proportions as those found in most common distilled and fermented alcoholic beverages;
ethanol	drug	acetaldehyde	drug_n
false

DDI-MedLine.d107.s3
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUGN, DRUGA, higher DRUGB and DRUGN in the same proportions as those found in most common distilled and fermented alcoholic beverages;
methanol	drug_n	alcohols	drug_n
false

DDI-MedLine.d107.s3
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUGN, DRUGA, higher DRUGN and DRUGB in the same proportions as those found in most common distilled and fermented alcoholic beverages;
methanol	drug_n	acetaldehyde	drug_n
false

DDI-MedLine.d107.s3
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing DRUGN, DRUGN, higher DRUGA and DRUGB in the same proportions as those found in most common distilled and fermented alcoholic beverages;
alcohols	drug_n	acetaldehyde	drug_n
false

DDI-MedLine.d53.s0
Induction of apoptosis in breast cancer cells in response to DRUGA and DRUGB.
vitamin D	group	antiestrogens	group
false

DDI-MedLine.d53.s1
1,DRUGA (DRUGB), the active metabolite of DRUGN, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro.
25-Dihydroxycholecalciferol D3	drug	1,25(OH)2D3	drug
false

DDI-MedLine.d53.s1
1,DRUGA (DRUGN), the active metabolite of DRUGB, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro.
25-Dihydroxycholecalciferol D3	drug	vitamin D	group
false

DDI-MedLine.d53.s1
1,DRUGN (DRUGA), the active metabolite of DRUGB, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro.
1,25(OH)2D3	drug	vitamin D	group
false

DDI-MedLine.d53.s3
In the experiments reported here, we examined the interactions between DRUGA and the DRUGB DRUGN (DRUGN), which also induces apoptosis in MCF-7 cells.
1,25(OH)2D3	drug	antiestrogen	group
false

DDI-MedLine.d53.s3
In the experiments reported here, we examined the interactions between DRUGA and the DRUGN DRUGB (DRUGN), which also induces apoptosis in MCF-7 cells.
1,25(OH)2D3	drug	4-hydroxytamoxifen	drug_n
false

DDI-MedLine.d53.s3
In the experiments reported here, we examined the interactions between DRUGA and the DRUGN DRUGN (DRUGB), which also induces apoptosis in MCF-7 cells.
1,25(OH)2D3	drug	TAM	drug_n
false

DDI-MedLine.d53.s3
In the experiments reported here, we examined the interactions between DRUGN and the DRUGA DRUGB (DRUGN), which also induces apoptosis in MCF-7 cells.
antiestrogen	group	4-hydroxytamoxifen	drug_n
false

DDI-MedLine.d53.s3
In the experiments reported here, we examined the interactions between DRUGN and the DRUGA DRUGN (DRUGB), which also induces apoptosis in MCF-7 cells.
antiestrogen	group	TAM	drug_n
false

DDI-MedLine.d53.s3
In the experiments reported here, we examined the interactions between DRUGN and the DRUGN DRUGA (DRUGB), which also induces apoptosis in MCF-7 cells.
4-hydroxytamoxifen	drug_n	TAM	drug_n
false

DDI-MedLine.d53.s9
These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of DRUGA-mediated signalling or disruption of DRUGB-dependent signalling.
vitamin-D	group	estrogen	group
false

DDI-MedLine.d51.s1
We investigated the effects of adenosine receptor antagonists, DRUGA, DRUGB, 8-phenylDRUGB, and DRUGN (DRUGN), in a light/dark test in mice.
caffeine	drug	theophylline	drug
false

DDI-MedLine.d51.s1
We investigated the effects of adenosine receptor antagonists, DRUGA, DRUGN, DRUGB, and DRUGN (DRUGN), in a light/dark test in mice.
caffeine	drug	8-phenyltheophylline	drug_n
false

DDI-MedLine.d51.s1
We investigated the effects of adenosine receptor antagonists, DRUGA, DRUGN, 8-phenylDRUGN, and DRUGB (DRUGN), in a light/dark test in mice.
caffeine	drug	8-cyclopentyl-1,3-dipropylxanthine	drug_n
false

DDI-MedLine.d51.s1
We investigated the effects of adenosine receptor antagonists, DRUGA, DRUGN, 8-phenylDRUGN, and DRUGN (DRUGB), in a light/dark test in mice.
caffeine	drug	DPCPX	drug_n
false

DDI-MedLine.d51.s1
We investigated the effects of adenosine receptor antagonists, DRUGN, DRUGA, 8-phenylDRUGA, and DRUGN (DRUGN), in a light/dark test in mice.
theophylline	drug	8-phenyltheophylline	drug_n
false

DDI-MedLine.d51.s1
We investigated the effects of adenosine receptor antagonists, DRUGN, DRUGA, 8-phenylDRUGA, and DRUGB (DRUGN), in a light/dark test in mice.
theophylline	drug	8-cyclopentyl-1,3-dipropylxanthine	drug_n
false

DDI-MedLine.d51.s1
We investigated the effects of adenosine receptor antagonists, DRUGN, DRUGA, 8-phenylDRUGA, and DRUGN (DRUGB), in a light/dark test in mice.
theophylline	drug	DPCPX	drug_n
false

DDI-MedLine.d51.s1
We investigated the effects of adenosine receptor antagonists, DRUGN, DRUGN, DRUGA, and DRUGB (DRUGN), in a light/dark test in mice.
8-phenyltheophylline	drug_n	8-cyclopentyl-1,3-dipropylxanthine	drug_n
false

DDI-MedLine.d51.s1
We investigated the effects of adenosine receptor antagonists, DRUGN, DRUGN, DRUGA, and DRUGN (DRUGB), in a light/dark test in mice.
8-phenyltheophylline	drug_n	DPCPX	drug_n
false

DDI-MedLine.d51.s1
We investigated the effects of adenosine receptor antagonists, DRUGN, DRUGN, 8-phenylDRUGN, and DRUGA (DRUGB), in a light/dark test in mice.
8-cyclopentyl-1,3-dipropylxanthine	drug_n	DPCPX	drug_n
false

DDI-MedLine.d51.s3
The anxiogenic effects of DRUGA were reduced by pretreatment with DRUGN, an A2-selective agonist, but not by DRUGB (DRUGN), an A1-selective agonist.
theophylline	drug	N6-cyclopentyladenosine	drug_n
false

DDI-MedLine.d51.s3
The anxiogenic effects of DRUGA were reduced by pretreatment with DRUGN, an A2-selective agonist, but not by DRUGN (DRUGB), an A1-selective agonist.
theophylline	drug	CPA	drug_n
false

DDI-MedLine.d51.s3
The anxiogenic effects of DRUGN were reduced by pretreatment with DRUGA, an A2-selective agonist, but not by DRUGB (DRUGN), an A1-selective agonist.
CGS 21680	drug_n	N6-cyclopentyladenosine	drug_n
false

DDI-MedLine.d51.s3
The anxiogenic effects of DRUGN were reduced by pretreatment with DRUGA, an A2-selective agonist, but not by DRUGN (DRUGB), an A1-selective agonist.
CGS 21680	drug_n	CPA	drug_n
false

DDI-MedLine.d51.s3
The anxiogenic effects of DRUGN were reduced by pretreatment with DRUGN, an A2-selective agonist, but not by DRUGA (DRUGB), an A1-selective agonist.
N6-cyclopentyladenosine	drug_n	CPA	drug_n
false

DDI-MedLine.d51.s4
However, the antagonism of the DRUGA-induced anxiogenic effects by DRUGN was only observed in the time spent in the light zone, and DRUGB-induced anxiogenic effects were neither reversed by DRUGN nor by DRUGN.
theophylline	drug	DPCPX	drug_n
false

DDI-MedLine.d51.s4
However, the antagonism of the DRUGA-induced anxiogenic effects by DRUGN was only observed in the time spent in the light zone, and DRUGN-induced anxiogenic effects were neither reversed by DRUGB nor by DRUGN.
theophylline	drug	CGS 21680	drug
false

DDI-MedLine.d51.s4
However, the antagonism of the DRUGA-induced anxiogenic effects by DRUGN was only observed in the time spent in the light zone, and DRUGN-induced anxiogenic effects were neither reversed by DRUGN nor by DRUGB.
theophylline	drug	CPA	drug_n
false

DDI-MedLine.d51.s4
However, the antagonism of the DRUGN-induced anxiogenic effects by DRUGA was only observed in the time spent in the light zone, and DRUGB-induced anxiogenic effects were neither reversed by DRUGN nor by DRUGN.
CGS21680	drug_n	DPCPX	drug_n
false

DDI-MedLine.d51.s4
However, the antagonism of the DRUGN-induced anxiogenic effects by DRUGA was only observed in the time spent in the light zone, and DRUGN-induced anxiogenic effects were neither reversed by DRUGB nor by DRUGN.
CGS21680	drug_n	CGS 21680	drug
false

DDI-MedLine.d51.s4
However, the antagonism of the DRUGN-induced anxiogenic effects by DRUGA was only observed in the time spent in the light zone, and DRUGN-induced anxiogenic effects were neither reversed by DRUGN nor by DRUGB.
CGS21680	drug_n	CPA	drug_n
false

DDI-MedLine.d51.s4
However, the antagonism of the DRUGN-induced anxiogenic effects by DRUGN was only observed in the time spent in the light zone, and DRUGA-induced anxiogenic effects were neither reversed by DRUGB nor by DRUGN.
DPCPX	drug_n	CGS 21680	drug
false

DDI-MedLine.d51.s4
However, the antagonism of the DRUGN-induced anxiogenic effects by DRUGN was only observed in the time spent in the light zone, and DRUGA-induced anxiogenic effects were neither reversed by DRUGN nor by DRUGB.
DPCPX	drug_n	CPA	drug_n
false

DDI-MedLine.d51.s4
However, the antagonism of the DRUGN-induced anxiogenic effects by DRUGN was only observed in the time spent in the light zone, and DRUGN-induced anxiogenic effects were neither reversed by DRUGA nor by DRUGB.
CGS 21680	drug	CPA	drug_n
false

DDI-MedLine.d4.s0
[The effect of DRUGA on the activity of mixed-function mono-oxidases in the liver microsomes]
The effects of the DRUGB--the drug DRUGA--on hepatic microsomal monooxygenase activities were studied.
sandimmune	brand	immunodepressant	group
false

DDI-MedLine.d4.s0
[The effect of DRUGB on the activity of mixed-function mono-oxidases in the liver microsomes]
The effects of the DRUGA--the drug DRUGB--on hepatic microsomal monooxygenase activities were studied.
immunodepressant	group	sandimmune	brand
false

DDI-MedLine.d68.s0
[The effect of DRUGA on the renal excretion of DRUGB and DRUGN in dogs]
The intravenous injection of DRUGA in a dose of 20 mg/kg enhanced DRUGBe and DRUGN excretion in chronic canine experiments.
cimetidine	drug	verografin	drug
false

DDI-MedLine.d68.s0
[The effect of DRUGA on the renal excretion of DRUGN and DRUGB in dogs]
The intravenous injection of DRUGA in a dose of 20 mg/kg enhanced DRUGNe and DRUGB excretion in chronic canine experiments.
cimetidine	drug	iodamide	drug
false

DDI-MedLine.d68.s0
[The effect of DRUGA on the renal excretion of DRUGN and DRUGN in dogs]
The intravenous injection of DRUGA in a dose of 20 mg/kg enhanced DRUGB and DRUGN excretion in chronic canine experiments.
cimetidine	drug	verografine	drug
false

DDI-MedLine.d68.s0
[The effect of DRUGA on the renal excretion of DRUGN and DRUGB in dogs]
The intravenous injection of DRUGA in a dose of 20 mg/kg enhanced DRUGNe and DRUGB excretion in chronic canine experiments.
cimetidine	drug	iodamide	drug
false

DDI-MedLine.d68.s0
[The effect of DRUGN on the renal excretion of DRUGA and DRUGB in dogs]
The intravenous injection of DRUGN in a dose of 20 mg/kg enhanced DRUGAe and DRUGB excretion in chronic canine experiments.
verografin	drug	iodamide	drug
false

DDI-MedLine.d68.s0
[The effect of DRUGB on the renal excretion of DRUGA and DRUGN in dogs]
The intravenous injection of DRUGB in a dose of 20 mg/kg enhanced DRUGAe and DRUGN excretion in chronic canine experiments.
verografin	drug	cimetidine	drug
false

DDI-MedLine.d68.s0
[The effect of DRUGN on the renal excretion of DRUGA and DRUGN in dogs]
The intravenous injection of DRUGN in a dose of 20 mg/kg enhanced DRUGAe and DRUGN excretion in chronic canine experiments.
verografin	drug	verografine	drug
false

DDI-MedLine.d68.s0
[The effect of DRUGN on the renal excretion of DRUGA and DRUGB in dogs]
The intravenous injection of DRUGN in a dose of 20 mg/kg enhanced DRUGAe and DRUGB excretion in chronic canine experiments.
verografin	drug	iodamide	drug
false

DDI-MedLine.d68.s0
[The effect of DRUGB on the renal excretion of DRUGN and DRUGA in dogs]
The intravenous injection of DRUGB in a dose of 20 mg/kg enhanced DRUGNe and DRUGA excretion in chronic canine experiments.
iodamide	drug	cimetidine	drug
false

DDI-MedLine.d68.s0
[The effect of DRUGN on the renal excretion of DRUGN and DRUGA in dogs]
The intravenous injection of DRUGN in a dose of 20 mg/kg enhanced DRUGB and DRUGA excretion in chronic canine experiments.
iodamide	drug	verografine	drug
false

DDI-MedLine.d68.s0
[The effect of DRUGN on the renal excretion of DRUGN and DRUGB in dogs]
The intravenous injection of DRUGN in a dose of 20 mg/kg enhanced DRUGA and DRUGB excretion in chronic canine experiments.
verografine	drug	iodamide	drug
false

DDI-MedLine.d68.s1
The higher DRUGA and DRUGB excretion was due to their increased renal tubular secretion.
verografine	drug	iodamide	drug
false

DDI-MedLine.d68.s2
In dogs, DRUGA unchanged the secretion of DRUGB, a test agent for anionic transport.
cimetidine	drug	cardiotrast	drug
false

DDI-MedLine.d68.s3
Possible extrarenal mechanisms of action of DRUGA on DRUGB and DRUGN transport were also examined.
cimetidine	drug	verografine	drug
false

DDI-MedLine.d68.s3
Possible extrarenal mechanisms of action of DRUGA on DRUGN and DRUGB transport were also examined.
cimetidine	drug	iodamide	drug
false

DDI-MedLine.d68.s3
Possible extrarenal mechanisms of action of DRUGN on DRUGA and DRUGB transport were also examined.
verografine	drug	iodamide	drug
false

DDI-MedLine.d103.s5
Physiological oral DRUGA supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with DRUGA salts, with practically only one contra-indication: overt renal failure.
magnesium	drug	magnesium salt	drug
false

DDI-MedLine.d103.s6
Specific and aspecific treatments of DRUGA depletion are tricky using for example DRUGA sparing diuretics, pharmacological doses of DRUGN, physiological doses of DRUGN and of DRUGN.
magnesium	drug	magnesium sparing diuretics	group
false

DDI-MedLine.d103.s6
Specific and aspecific treatments of DRUGA depletion are tricky using for example DRUGA sparing diuretics, pharmacological doses of DRUGB, physiological doses of DRUGN and of DRUGN.
magnesium	drug	vitamin B6	drug
false

DDI-MedLine.d103.s6
Specific and aspecific treatments of DRUGA depletion are tricky using for example DRUGA sparing diuretics, pharmacological doses of DRUGN, physiological doses of DRUGB and of DRUGN.
magnesium	drug	vitamin D	group
false

DDI-MedLine.d103.s6
Specific and aspecific treatments of DRUGA depletion are tricky using for example DRUGA sparing diuretics, pharmacological doses of DRUGN, physiological doses of DRUGN and of DRUGB.
magnesium	drug	selenium	drug
false

DDI-MedLine.d103.s6
Specific and aspecific treatments of DRUGN depletion are tricky using for example DRUGA, pharmacological doses of DRUGB, physiological doses of DRUGN and of DRUGN.
magnesium sparing diuretics	group	vitamin B6	drug
false

DDI-MedLine.d103.s6
Specific and aspecific treatments of DRUGN depletion are tricky using for example DRUGA, pharmacological doses of DRUGN, physiological doses of DRUGB and of DRUGN.
magnesium sparing diuretics	group	vitamin D	group
false

DDI-MedLine.d103.s6
Specific and aspecific treatments of DRUGN depletion are tricky using for example DRUGA, pharmacological doses of DRUGN, physiological doses of DRUGN and of DRUGB.
magnesium sparing diuretics	group	selenium	drug
false

DDI-MedLine.d103.s6
Specific and aspecific treatments of DRUGN depletion are tricky using for example DRUGN sparing diuretics, pharmacological doses of DRUGA, physiological doses of DRUGB and of DRUGN.
vitamin B6	drug	vitamin D	group
false

DDI-MedLine.d103.s6
Specific and aspecific treatments of DRUGN depletion are tricky using for example DRUGN sparing diuretics, pharmacological doses of DRUGA, physiological doses of DRUGN and of DRUGB.
vitamin B6	drug	selenium	drug
false

DDI-MedLine.d103.s6
Specific and aspecific treatments of DRUGN depletion are tricky using for example DRUGN sparing diuretics, pharmacological doses of DRUGN, physiological doses of DRUGA and of DRUGB.
vitamin D	group	selenium	drug
false

DDI-MedLine.d103.s15
Lastly local use of the mucocutaneous and cytoprotective properties of DRUGA is still valid, in DRUGB and for preservation of transplants particularly.
magnesium	drug	cardioplegic solutions	drug
false

DDI-MedLine.d20.s4
The successive application of DRUGA (5 or 10 mg/kg egg weight (e.w.) and DRUGB (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of DRUGB alone.
glycine	drug	glutamate	drug
false

DDI-MedLine.d94.s11
The EC50 values for DRUGA, which is not a substrate for DRUGB uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium.
isoproterenol	drug	norepinephrine	drug
false

DDI-MedLine.d94.s12
The uptake inhibitors DRUGA and DRUGB (3 mumol/liter) potentiated the positive inotropic effects of DRUGN in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
cocaine	drug	desipramine	drug
false

DDI-MedLine.d94.s13
Radioligand binding experiments using the uptake inhibitor hydrogen-3 DRUGA revealed a significant decrease by approximately 30% in DRUGB uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05).
mazindol	drug	norepinephrine	drug
false

DDI-MedLine.d94.s16
This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as DRUGA and DRUGB, in the nonfailing heart only.
cocaine	drug	desipramine	drug
false

DDI-MedLine.d94.s17
Compromised DRUGA uptake-1 in functional class IV cannot be further increased by DRUGB and DRUGN.
norepinephrine	drug	cocaine	drug
false

DDI-MedLine.d94.s17
Compromised DRUGA uptake-1 in functional class IV cannot be further increased by DRUGN and DRUGB.
norepinephrine	drug	desipramine	drug
false

DDI-MedLine.d94.s17
Compromised DRUGN uptake-1 in functional class IV cannot be further increased by DRUGA and DRUGB.
cocaine	drug	desipramine	drug
false

DDI-MedLine.d14.s0
[A pharmacological analysis of the effect of DRUGA on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGA 1 and DRUGA 2 on DRUGN- and DRUGN-induced gastric acid secretion.
angiotensin	drug_n	angiotensin 1	drug_n
false

DDI-MedLine.d14.s0
[A pharmacological analysis of the effect of DRUGA on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGA 1 and DRUGA 2 on DRUGN- and DRUGN-induced gastric acid secretion.
angiotensin	drug_n	angiotensin 2	drug_n
false

DDI-MedLine.d14.s0
[A pharmacological analysis of the effect of DRUGA on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGA 1 and DRUGA 2 on DRUGB- and DRUGN-induced gastric acid secretion.
angiotensin	drug_n	pentagastrin	drug
false

DDI-MedLine.d14.s0
[A pharmacological analysis of the effect of DRUGA on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGA 1 and DRUGA 2 on DRUGN- and DRUGB-induced gastric acid secretion.
angiotensin	drug_n	histamine	drug
false

DDI-MedLine.d14.s0
[A pharmacological analysis of the effect of DRUGN on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGA and DRUGB on DRUGN- and DRUGN-induced gastric acid secretion.
angiotensin 1	drug_n	angiotensin 2	drug_n
false

DDI-MedLine.d14.s0
[A pharmacological analysis of the effect of DRUGN on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGA and DRUGN 2 on DRUGB- and DRUGN-induced gastric acid secretion.
angiotensin 1	drug_n	pentagastrin	drug
false

DDI-MedLine.d14.s0
[A pharmacological analysis of the effect of DRUGN on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGA and DRUGN 2 on DRUGN- and DRUGB-induced gastric acid secretion.
angiotensin 1	drug_n	histamine	drug
false

DDI-MedLine.d14.s0
[A pharmacological analysis of the effect of DRUGN on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGN and DRUGA on DRUGB- and DRUGN-induced gastric acid secretion.
angiotensin 2	drug_n	pentagastrin	drug
false

DDI-MedLine.d14.s0
[A pharmacological analysis of the effect of DRUGN on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGN and DRUGA on DRUGN- and DRUGB-induced gastric acid secretion.
angiotensin 2	drug_n	histamine	drug
false

DDI-MedLine.d14.s0
[A pharmacological analysis of the effect of DRUGN on stimulated gastric secretion]
Chronic experiments on dogs with gastric fistulas were carried out to study the influence of DRUGN and DRUGN 2 on DRUGA- and DRUGB-induced gastric acid secretion.
pentagastrin	drug	histamine	drug
false

DDI-MedLine.d14.s1
It was established that both angiotensins inhibited gastric acid secretion stimulated by DRUGA but not by DRUGB.
pentagastrin	drug	histamine	drug
false

DDI-MedLine.d14.s2
Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of DRUGA suggested the mediation of DRUGB influence through the modulation of cholinergic reactions of parietal cells in the stomach.
angiotensins	drug_n	angiotensin	drug_n
false

DDI-MedLine.d90.s1
Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by DRUGA infusion in 7 horses anaesthetised with DRUGB.
atracurium	drug	halothane	drug
false

DDI-MedLine.d90.s3
DRUGA was again given by infusion to maintain 40% twitch for a second hour, then 2 mg DRUGB/kg bwt were given i.v.
Atracurium	drug	gentamycin	drug
false

DDI-MedLine.d90.s7
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for DRUGA alone and 11.5 +/- 2.7 min for DRUGA plus DRUGB (P = 0.03).
atracurium	drug	gentamycin	drug
false

DDI-MedLine.d90.s8
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for DRUGA alone and 13.7 +/- 1.2 min for DRUGA plus DRUGB.
atracurium	drug	gentamycin	drug
false

DDI-MedLine.d90.s9
At 75% recovery of fade, hoof twitch was 87 +/- 3% for DRUGA alone and 82 +/- 4% for DRUGA plus DRUGB.
atracurium	drug	gentamycin	drug
false

DDI-MedLine.d113.s1
The DRUGA are a family of DRUGB and DRUGN.
benzodiazepines	group	anxiolytic	group
false

DDI-MedLine.d113.s1
The DRUGA are a family of DRUGN and DRUGB.
benzodiazepines	group	hypnotic drugs	group
false

DDI-MedLine.d113.s1
The DRUGN are a family of DRUGA and DRUGB.
anxiolytic	group	hypnotic drugs	group
false

DDI-MedLine.d113.s3
In addition to this pharmacological interaction, this report describes a novel chemical reaction between DRUGA (a DRUGB) and DRUGN under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.
temazepam	drug	benzodiazepine	group
false

DDI-MedLine.d113.s3
In addition to this pharmacological interaction, this report describes a novel chemical reaction between DRUGN (a DRUGA) and DRUGB under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.
benzodiazepine	group	ethanol	drug
false

